,date,information,related
0,2022-09-22,"Headline: Analyst Favorites With Strong Buyback Activity: Biogen Ranks As a Top Pick, source:The Online Investor, summary: the online investor,BIIB,, Headline: Mizuho Securities Reaffirms Their Hold Rating on Biogen (BIIB), source:TipRanks, summary: In a report released today, Salim Syed from Mizuho Securities maintained a Hold rating on Biogen (BIIB &#8211; Research Report), with a price target of $207.00. The...",BIIB
1,2022-09-23,"Headline: Alzheimer’s drug trial brings pivotal test of maligned brain plaque theory, source:Yahoo, summary: A late-stage trial of an Alzheimer’s drug set to generate results within weeks is shaping up as a pivotal moment in a three-decade quest to prove that removing sticky amyloid plaques from the brain can slow down the disease.  The phase 3 trial is being led by Eisai, a Tokyo-based pharmaceutical company that has partnered US biotech Biogen to develop lecanemab.  Earlier studies suggested the monoclonal antibody treatment can clear plaques known as beta amyloid that are at the centre of an increasingly acrimonious scientific debate over what causes Alzheimer’s., Headline: Biogen Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. shed 1.42% to $197.78 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index..., Headline: IBD Stock Of The Day: Could 'The Biggest Drug Ever' Drive Eli Lilly Stock Even Higher?, source:Yahoo, summary: Eli Lilly is the IBD Stock Of The Day as investors watch the company's obesity and Alzheimer's drugs, which could help shares skyrocket.",BIIB
2,2022-09-24,"Headline: Biotech Valuations Remain In a Slump, source:Yahoo, summary: Biotech stocks continue to slump and have taken a beating for over 12 months, but some promising data could lead to a rebound.  The cheap valuations of the sector right now could be good entry points for investors, experts said.  One catalyst coming up in the fall is the pending decision from the FDA for the clinical trial of an Alzheimer drug, Eisai's  lecanemab that is being jointly developed with Biogen .",BIIB
3,2022-09-26,"Headline: Alkermes: Nothing Stands Out As Interesting, source:SeekingAlpha, summary: Alkermes is producing losses despite being in business this long, and thereâs very little coverage of the company. Read more here., Headline: Biogen agrees to $900 million drug kickback settlement, U.S. Justice Dept says, source:Finnhub, summary: The U.S. Justice Department said on Monday that Biogen Inc had agreed to pay $900 million to resolve allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs, leading to the... | September 26, 2022, Headline: Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs, source:CNBC, summary: A former Biogen employee, Michael Bawduniak, alleged Biogen paid kickbacks to doctors to encourage them to prescribe its multiple sclerosis drugs. , Headline: Biogen agrees to $900 mln drug kickback settlement, U.S. Justice Dept says, source:Reuters, summary: The U.S. Justice Department said on Monday that Biogen Inc had agreed to pay $900 million to resolve allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs, leading to the submission of false Medicare and Medicaid claims. (Reporting by Eric Beech and..., Headline: DOJ says Biogen agrees to $900 million settlement over allegations of false Medicare claims, source:Yahoo, summary: The Justice Department said Biogen Inc. agreed to pay $900 million to resolve allegations that it caused the submission of false claims to Medicare and Medicaid by allegedly paying kickbacks to doctors., Headline: UPDATE 2-Biogen finalizes $900 mln drug kickback settlement, U.S. says, source:Yahoo, summary: Biogen Inc has finalized a $900 million settlement resolving a whistleblower lawsuit accusing the biotech company of paying doctors kickbacks to prescribe multiple sclerosis drugs, the U.S. Department of Justice said on Monday.  The settlement resolves a long-running whistleblower lawsuit in Boston federal court that a former employee pursued on the government's behalf., Headline: Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments, source:Yahoo, summary: The pharmaceutical company allegedly used speaking and consulting fees to persuade doctors to prescribe its multiple sclerosis drugs., Headline: Biogen finalizes $900 million drug kickback settlement, U.S. says, source:Reuters, summary: Biogen Inc has finalized a $900 million settlement resolving a whistleblower lawsuit accusing the biotech company of paying doctors kickbacks to prescribe multiple sclerosis drugs, the U.S. Department of Justice said on Monday.",BIIB
4,2022-09-27,"Headline: PRESS DIGEST- Wall Street Journal - Sept 27, source:Yahoo, summary: The following are the top stories in the Wall Street Journal.  - Pfizer Inc and BioNTech SE asked U.S. health regulators to clear use of their updated Covid-19 booster in children 5 years to 11 years.  - Ford Motor Co is asking a Georgia court for a new trial, after a jury reached a $1.7 billion verdict against the auto maker last month involving a truck rollover accident that left two people dead., Headline: Wall Street Breakfast: Dollar Vs. Stocks, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Dollar vs. Stocks The U.S., Headline: Biogen Settles For $900M In Bribe Case For Prescribing Multiple Sclerosis Drugs, source:Yahoo, summary: Biogen Inc (NASDAQ: BIIB) has reached a $900 million settlement with a whistleblower who accused the firm of paying doctors bribes to encourage them to prescribe its multiple sclerosis drugs. The whistleblower behind the report, Michael Bawduniak, will receive about $250 million directly, according to a statement released Monday by the U.S. Justice Department. About $843 million will essentially go to the federal government and a smaller part-$56 million to 15 American states that had joined the, Headline: Hurricane Ian to intensify, Biogen settles lawsuit, Ford asks for new trial after $1.7 billion loss, source:Yahoo, summary: Notable business headlines include Hurricane Ian becoming a Category 4 hurricane before hitting Florida, Biogen settling a lawsuit that alleged the company paid doctors to prescribe drugs, and Ford asking for a new trial after rollover accident suit., Headline: Biden Medicare costs victory due mostly to Alzheimer's drug change, source:Yahoo, summary: U.S. President Joe Biden will claim victory on Tuesday for a drop in costs for tens of millions of Americans covered by the Medicare health program, though it is primarily due to a decision to severely limit coverage of an expensive, new Alzheimer's drug.  The White House said Biden would highlight a drop in premiums next year for the first time in over a decade for Medicare Part B, which among other things covers doctor and hospital visits as well as drugs they administer.  The government Medicare plan covers some 35 million Americans aged 65 and older or who are disabled., Headline: UPDATE 1-Biden Medicare costs victory due mostly to Alzheimer's drug change, source:Yahoo, summary: U.S. President Joe Biden claimed victory on Tuesday for a drop in costs for tens of millions of Americans covered by the Medicare health program, though it is primarily due to a decision to severely limit coverage of an expensive, new Alzheimer's drug.  Biden highlighted a drop in premiums next year for the first time in over a decade for Medicare Part B, which among other things covers doctor and hospital visits as well as drugs they administer.  ""It's going to be a godsend for many families,"" Biden told healthcare advocates in a White House Rose Garden event., Headline: Biogen Makes Big Payout to Settle DOJ Whistleblower Case, source:Yahoo, summary: Qui Tam is perhaps better known as ""whistleblower litigation"" and it is included in the False Claims Act, which President Abraham Lincoln signed into law in 1863.  The False Claims Reform Act of 1985 changed the so-called ""Lincoln Law"", making it easier for the government to investigate False Claims Act cases and lowering the required burden of proof, as well as increasing the potential whistleblower's share to 15-30%, among other items.  Today, Qui Tam can translate into an awful lot of money changing hands ., Headline: LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE, source:Yahoo, summary: Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, ""Biogen"") announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collective, Headline: Eisai says Alzheimer's drug succeeds in slowing cognitive decline, source:Yahoo, summary: An experimental Alzheimer's drug developed by Eisai Co Ltd and Biogen Inc significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, the companies said on Tuesday.  Eisai said the results from the 1,800-patient trial prove the longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer's can delay advance of the debilitating disease.  Lecanemab, like the companies' previous drug Aduhelm, is an antibody designed to remove those amyloid deposits., Headline: Drugmakers Eisai and Biogen claim success in Alzheimer’s drug study, source:Yahoo, summary: Eisai and Biogen said they would apply for regulatory approval for a new Alzheimer’s drug following the results of a late-stage clinical trial that showed it slowed the rate at which the disease progresses.  The companies said on Tuesday that the phase-three trial had demonstrated that giving lecanemab, a monoclonal antibody treatment, to patients in the early stages of the disease reduced the rate of cognitive decline by 27 per cent compared with participants who received a placebo.  The results from the clinical trial will provide hope to the roughly 50mn Alzheimer’s suffers worldwide that progress is being made in the search for treatments to slow the disease., Headline: Factbox-Eisai-Biogen Alzheimer's drug success follows many failures, source:Reuters, summary: Eisai Co Ltd and Biogen Inc reported late-stage data from their Alzheimer's disease drug lecanemab that showed it significantly slowed cognitive decline, a big win for patients after a long string of failures to find an effective treatment for the memory-robbing disease., Headline: UPDATE 3-Eisai, Biogen say Alzheimer's drug succeeds in slowing cognitive decline, source:Yahoo, summary: Eisai Co Ltd and Biogen Inc on Tuesday said their experimental Alzheimer's drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, marking a rare win in a field littered with failed drugs.  ""It's not a huge effect, but it's a positive effect,"" said Ronald Petersen, director of the Mayo Clinic Alzheimer’s Disease Research Center in Rochester, Minnesota.  Eisai, leader of the 50-50 partnership's lecanemab program, is seeking FDA approval under an accelerated pathway, with a decision expected in early January., Headline: Eisai, Biogen say Alzheimer's drug succeeds in slowing cognitive decline, source:Reuters, summary: Eisai Co Ltd and Biogen Inc on Tuesday said their experimental Alzheimer's drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, marking a rare win in a field littered with failed drugs.",BIIB
5,2022-09-28,"Headline: Dow Jones Futures Fall On Apple iPhone Report, Rising Treasury Yields; Biogen Alzheimer's Drug Slows Decline, source:Yahoo, summary: Futures fell as Apple reportedly curbs iPhone production plans while the 10-year yield is just below 4%. A Biogen Alzheimer's drug shows promise., Headline: Biogen upgraded to Buy from Neutral at Mizuho, source:Thefly.com, summary: Mizuho analyst Salim Syed... BIIB, Headline: Biogen shares jump 40% to $276.02 following positive Alzheimer's study, source:Thefly.com, summary:  BIIB, Headline: Biogen (BIIB) Gets a Buy from Needham, source:TipRanks, summary: Needham analyst Ami Fadia maintained a Buy rating on Biogen (BIIB &#8211; Research Report) today and set a price target of $250.00. The company&#8217;s shares close..., Headline: Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression, source:Yahoo, summary: Eisai and Biogen BIIB said Wednesday that their drug, lecanemab, reduced cognitive and functional decline by 27%, compared with a placebo, over 18 months in a Phase 3 study of 1,800 patients with early-stage Alzheimer's., Headline: MorphoSys up 20%, Eli Lilly up 7% after Biogen data for lecanemab in Alzheimer's, source:Thefly.com, summary: Shares of MorphoSys (MOR)... LLY, MOR, RPRX, BIIB, Headline: Biogen lecanemab data is 'major development' in Alzheimer's disease, says UBS, source:Thefly.com, summary: UBS analyst Colin Bristow... BIIB, ESALY, Headline: Alzheimer's trial success 'a major positive' for Biogen, says Morgan Stanley, source:Thefly.com, summary: After Biogen (BIIB) and E... BIIB, Headline: Mizuho says Biogen data will serve as catalyst for these stocks, source:Thefly.com, summary: Mizuho analyst Graig Suva... ALEC, BIIB, ATHA, AXSM, BTAI, CERE, Headline: Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday, source:InvestorPlace, summary: It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning., Headline: Biogen price target raised to $217 from $183 at Wedbush, source:Thefly.com, summary: Wedbush analyst Laura Chi... BIIB, Headline: Biogen's CLARITY AD trial data best case scenario, says Cowen, source:Thefly.com, summary: Cowen analyst Phil Nadeau... BIIB, Headline: Biogen price target raised to $350 from $265 at Wells Fargo, source:Thefly.com, summary: Wells Fargo analyst Mohit... BIIB, Headline: Lilly shares could move higher on Biogen trial results, says Cantor Fitzgerald, source:Thefly.com, summary: Cantor Fitzgerald analyst... LLY, BIIB, ESALY, Headline: Eli Lilly likely to trade up 5%-10% on Biogen success, says Morgan Stanley, source:Thefly.com, summary: After Biogen (BIIB) and E... LLY, BIIB, ESALY, Headline: TOP NEWS: Biogen shares rocket on Alzheimer's study success, source:Alliance News, summary: No summary, Headline: GLOBAL BROKER RATINGS: Berenberg likes Renault; Biogen raised, source:Alliance News, summary: No summary, Headline: Biogen's 'near best case' data should lead to lecanemab approval, says Jefferies, source:Thefly.com, summary: After Biogen (BIIB) and E... BIIB, ESALY, Headline: Lecanemab success has 'bullish readthrough' for Acumen, says Stifel, source:Thefly.com, summary: Stifel analyst Paul Matte... ABOS, BIIB, ESALY, Headline: 7 Growth Stocks to Buy to Tap Into a Hidden Bull Market, source:InvestorPlace, summary: It's become a bit easier for investors to find growth stocks to buy hidden amid the bear market., Headline: Prothena price target raised to $81 from $50 at JMP Securities, source:Thefly.com, summary: JMP Securities analyst Ja... PRTA, BIIB, ESALY, Headline: Prothena up 60% in premarket at $49.59 following Biogen/Eisai data on lecanemab, source:Thefly.com, summary:  PRTA, BIIB, Headline: Analystsâ Top Healthcare Picks: Biogen (BIIB), HCA Healthcare (HCA), source:TipRanks, summary: There&#8217;s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (<span class='tr-stock-ticker' style='color:blue; font-w..., Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: Biogen skyrockets following positive Alzheimer's study results, Eli Lilly and MorphoSys jump in concert BIIB, LLY, MOR, OCGN, THO, CGNT, BB, AAPL, MNMD, LYFT, LMT, Headline: Biogen price target raised to $321 from $251 at RBC Capital, source:Thefly.com, summary: RBC Capital analyst Brian... BIIB, Headline: Path for Biogen's lecanemab to be 'multi-step' process, says Needham, source:Thefly.com, summary: Needham analyst Ami Fadia... BIIB, Headline: Unusually active option classes on open September 28th, source:Thefly.com, summary: Unusual total active opti... NNOX, BIIB, OCGN, SHY, SH, LLY, SAVA, LI, AAPL, Headline: Prothena upgraded at BofA as Biogen data seen strengthening amyloid thesis, source:Thefly.com, summary: BofA analyst Tazeen Ahmad... PRTA, BIIB, ESALY, Headline: Early notable gainers among liquid option names on September 28th, source:Thefly.com, summary: Notable gainers among liq... BIIB, LLY, ILMN, NEM, EXPE, Headline: Alzheimer's drug succeeds in slowing cognitive decline, makers Eisai and Biogen say, source:Reuters, summary: Eisai Co Ltd and Biogen Inc on Tuesday said their experimental Alzheimer's drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, marking a rare win in a field littered with failed drugs., Headline: Alzheimer's drug shows promise in early results of study, source:Associated Press, The, summary: No summary, Headline: Biogen, Eisai stocks soar on Alzheimer's success, lifting rival shares, source:Reuters, summary: Shares in Biogen and Eisai soared on Wednesday reflecting the surprise trial success of their experimental Alzheimer's drug, which also lifted the stocks of rival drugmakers Roche and Eli Lilly., Headline: Eisai upgraded to Equal Weight at Morgan Stanley after lecanemab success, source:Thefly.com, summary: Morgan Stanley analyst Sh... ESALY, BIIB, Headline: EISAI - LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE, source:Finnhub, summary: TOKYO - Eisai Co., Ltd. and Biogen Inc. announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab, an investigational anti-amyloid... | September 28, 2022, Headline: Alzheimerâs Stock Prothena (NASDAQ:PRTA) Takes Wings, source:TipRanks, summary: Shares of clinical-stage company Prothena (NASDAQ:PRTA) are soaring today as Biogenâs (NASDAQ:BIIB) promising results for lecanemab put the spotlight on Alzheimerâs..., Headline: Why Is Biogen (BIIB) Stock Up 40% Today?, source:InvestorPlace, summary: Positive results from a clinical trial offer encouragement for the medical community, as well as for downtrodden BIIB stock investors., Headline: Why Is Cassava Sciences (SAVA) Stock Heating Up Today?, source:InvestorPlace, summary: SAVA stock rose 5% on the success of Biogen in slowing cognitive decline from Alzheimer's, but its Simufilam has a different target., Headline: Stocks Resume Slump, Apple, Biogen, Elon Musk And Hurricane Ian - Five Things To Know, source:Yahoo, summary: Stock futures resume slump on rate hike, recession concerns; Apple shares slide on report of waning iPhone demand; Biogen shares soar after positive results from Alzheimer's trial; Elon musk seeks to overturn sec rule on Twitter vetting and Hurricane Ian to slam Florida coast as category 4 storm., Headline: Biogen (NASDAQ:BIIB) Surges on Positive Phase 3 Trial Results, source:TipRanks, summary: Shares of Biogen (NASDAQ:BIIB) are trending about 50% higher in the pre-market trading session today. Last night, the biopharmaceutical company announced that its A..., Headline: Will Medicare cover Eisai and Biogen's promising new Alzheimer's therapy if it's approved?, source:MarketWatch, summary: Some analysts are tempering their expectations of lecanemab until they get a better idea if Medicare will pay for the drug., Headline: Synaptogenix 'welcomes' Lecanemab Phase 3 trial results, source:Thefly.com, summary: Synaptogenix (SNPX) comme... SNPX, BIIB, ESALY, Headline: Dow Jones Futures Volatile On Bank Of England Reversal; Apple Falls On iPhone Report, Biogen Soars On Alzheimer's Drug, source:Yahoo, summary: Apple is curbing iPhone production. The 10-year yield hit 4%, until the Bank of England stepped in. A Biogen Alzheimer's drug shows promise., Headline: Biogen stock explodes higher after potential 'mega blockbuster' Alzheimer's drug study, source:Yahoo, summary: Biogen stock rips higher on a promising new drug. Here's what Wall Street is saying., Headline: Alzheimer's drug study yields positive results, say makers Eisai and Biogen, source:Reuters, summary: An experimental Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs., Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. AAPL, BIIB, ESALY, BTRS, PATH, MSFT, MAN, NFLX, LMT, ILMN, ETRN, LYFT, TGI, BR, M, GM, FYBR, DOCU, ASTL, SAND, CTAS, BB, THO, VFC, PAYX, BCS, BAC, C, CS, DB, MS, UBS, JEF, NMR, CSX, NSC, Headline: Why Is Acumen (ABOS) Stock Up 95% Today?, source:InvestorPlace, summary: Acumen Pharmaceuticals (ABOS) stock is rocketing higher on Wednesday but it's not due to any recent news from the company., Headline: Why Is Prothena (PRTA) Stock Up 75% Today?, source:InvestorPlace, summary: Prothena (PRTA) stock is seeing massive gains on Wednesday despite a lack of recent news from the late-stage clinical company., Headline: Stock market today: 4 tickers trending on Yahoo Finance, source:Yahoo, summary: Here are 4 tickers trending on Yahoo Finance in premarket trading., Headline: Biotech Stocks LLY, ESALY Gain on Biogen's Positive Trial Results, source:InvestorPlace, summary: Biogen produced an outstanding Phase 3 result for its Alzheimer’s treatment, sending associated biotech stocks soaring., Headline: Which Alzheimer's stock may be next to jump after Biogen's 'clean’ win?, source:Thefly.com, summary: Mizuho views the data as a , Headline: Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: Netflix upgrade, Lockheed Martin downgrade and Sunrun initiation among today's top calls on Wall Street NFLX, BIIB, ILMN, SHOO, SSB, TFC, LMT, LHX, CSX, ETRN, AVNT, RUN, IE, GNRC, SABR, ENVX, Headline: Stocks making the biggest moves midday: Apple, Netflix, Biogen, Canopy Growth and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: A Biotech Breakthrough Means Big Gains for These 2 Stocks, source:Yahoo, summary: Investors on Wall Street continued to have doubts about when the stock market is likely to recover, as ongoing worries about inflation, interest rates, and the global financial system have everyone on edge.  Biotech stocks have been among those hit hardest by the bear market in 2022, but Biogen (NASDAQ: BIIB) announced good news in a key clinical trial that has huge implications for those suffering from a harsh and debilitating disease.  Biogen's favorable outcome also gave industry peer Eli Lilly (NYSE: LLY) a boost, on optimism that a new way of coming up with important treatments could spur further successes., Headline: As Biogen Surges on Alzheimer Trial Results, Here's How to Play It, source:Yahoo, summary: Biotechnology firm Biogen and their Japan-based partner Eisai Co. Ltd reported better-than-expected results from a late-stage study of their developing Alzheimer's treatment. A successful treatment for Alzheimer's could be worth tens of billions in sales for Biogen., Headline: Biogen stock soars on promising data from Alzheimer’s drug trial, source:Yahoo, summary: Yahoo Finance Live anchors discuss Biogen stock performance on promising Alzheimer’s drug trial data., Headline: Midday Movers: Biogen, Apple, DocuSign and More, source:Yahoo, summary: By Liz Moyer, Headline: Biogen Soars 40% on Alzheimer’s Drug Trial. Mizuho Raises the Stock to Buy., source:Yahoo, summary: Mizuho analyst Salim Syed says there are enough data on the drug ""that likely allows for regulatory approval., Headline: Is This the First Alzheimer's Drug to Actually Work?, source:Yahoo, summary: Biogen and Eisai announced a positive surprise for a closely-watched Alzheimer's drug candidate in a late-stage study., Headline: Drug Slows Progression of Alzheimer’s in Big Trial, source:Yahoo, summary: (Bloomberg) -- Biogen Inc. and partner Eisai Co. surged and led other drugmakers’ shares higher amid optimism about their breakthrough trial results on Alzheimer’s disease. Most Read from BloombergApple Ditches iPhone Production Increase After Demand FaltersGermany Suspects Sabotage Hit Russia’s Nord Stream PipelinesAlzheimer’s Progression Slowed by Drug in Major TrialPutin’s Mobilization Hits Russia’s Economy in Its Weak SpotsRussia Declares Victory in Sham Ukraine ‘Referendums’The two partners, Headline: Biogen shares soar on landmark Alzheimer's data, lift rivals, source:Reuters, summary: Biogen Inc was set to add more than $10 billion to its market capitalization on Wednesday, as a surprise trial success of the experimental Alzheimer's drug it developed with Eisai was hailed as an unequivocal win by analysts., Headline: Biogen and Lilly: How I'm Playing the Alzheimer's Drug Stocks Game, source:Yahoo, summary: Cambridge, Massachusetts-based biotech Biogen  and Japanese drug maker Eisai  reported on Wednesday morning that their experimental Alzheimer's disease treatment had met the main goal of a late-stage clinical trial.  The candidate, Lecanemab, reduced the pace of cognitive decline in patients diagnosed with early-stage disease by 27% over 18 months compared to those treated with a placebo.  This result could be a major accomplishment for researchers who have been trying for decades to find a way to treat Alzheimer's. The medicine, before Biogen and Eisai started trying to develop it, was licensed from Sweden's BioArctic., Headline: Analysis-Alzheimer's drug breakthrough big boost for Roche, Eli Lilly, source:Reuters, summary: The results of a key Alzheimer's drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly., Headline: Wall Street bounces back as Treasury yields dip, source:Finnhub, summary: Wall Street rebounded strongly onWednesday following its recent sell-off, helped by easingTreasury yields, while Apple dropped on concerns about demandfor iPhones. The gains came... | September 28, 2022, Headline: 4 Alzheimer’s Penny Stocks To Watch After Biogen Stock Explodes, source:PennyStocks, summary: Penny stocks to buy [or avoid] after Biogen Alzheimer's news., Headline: ANALYSIS-Alzheimer's drug trial breakthrough boost for Roche, Eli Lilly, source:Reuters, summary: Drugs from Roche and Eli Lilly target the same protein as Biogen, Eisai compound, Headline: New Alzheimer’s Drug Success Was a Shock. Now There Are 5 Big Questions., source:Yahoo, summary: Data from Eisai and its partner Biogen are startling because their drug lecanemab slowed cognitive decline, and suggest that a theory that seemed all but disproved still has legs., Headline: Cyclo Therapeutics Up 21%; Company 'Pleased' With Progress on Drug Programs, source:MarketWatch, summary: By Josh Beckerman Cyclo Therapeutics Inc. shares rose 21% to $2.09 as it provided a business update and several companies working on treatments for..., Headline: Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study, source:Yahoo, summary: Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo., Headline: Why Biogen, Lilly, and Prothena Stocks Are Skyrocketing Today, source:Yahoo, summary: Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday.  The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating Alzheimer's disease.  The news also propelled two stocks of other drugmakers developing Alzheimer's disease drugs significantly higher., Headline: Biogen's Lecanemab Data Blows Alzheimer's Race Open Again, source:SeekingAlpha, summary: Data from Biogen's Lecanemab is strong enough to suggest the drug could be approved. Read why this could deliver a mutli-billion revenue opportunity for BIIB., Headline: A Positive Amyloid Trial, Finally?, source:SeekingAlpha, summary: The big news last night was the announcement of a positive readout in Eisai and Biogen's trial of lecanemab, another attempt at an anti-amyloid antibody for Alzheimer's therapy., Headline: Biogen, Thor rise; Apple, Equitrans Midstream fall, source:Associated Press, The, summary: No summary, Headline: NEW YORK MARKET CLOSE: Wall Street moves green as BoE offers support, source:Alliance News, summary: No summary, Headline: DaVita: Solid Valuation And Cash Flow, Price Recovering After SCOTUS Ruling, source:SeekingAlpha, summary: Marietta vs. DaVita ruling by the SCOTUS in June sided with the health plan, which allowed self-insured plans to exclude certain dialysis providers. Read more here., Headline: Health Care Up as Biogen Surges -- Health Care Roundup, source:MarketWatch, summary: Health-care companies rose after a jump in the price of one bellwether. Shares of biotech giant Biogen surged by roughly 40% after lecanemab, an Alzheimer's..., Headline: Big win for Biogen: Alzheimer's drug results spark huge gains, source:CNBC, summary: Oppenheimer's Jared Holz on Biogen after the company's stock soared on positive Alzheimer trials. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Dan Nathan, Karen Finerman and Courtney Garcia., Headline: Call of the Day: Netflix jumps on Atlantic Equities upgrade, source:CNBC, summary: Atlantic Equities upgrades Netflix and the traders respond. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Dan Nathan, Karen Finerman and Courtney Garcia., Headline: Alzheimer's patient advocates hopeful — but cautious— on Biogen news, source:Yahoo, summary: Positive data on the Cambridge company's Alzheimer's drug released late Tuesday restored some investor and analyst confidence. But patient advocates are holding out for full study results., Headline: Biogen Stock Clings to Key Level After Explosive Rally, source:Yahoo, summary: Biogen stock is up almost 40% on Wednesday but is barely holding above a key level. Let's look at the chart., Headline: Biogen Explodes Higher After Potential Mega Blockbuster Alzheimer's Drug Succeeds, source:Yahoo, summary: Biogen stock catapulted Wednesday — bringing shares of other Alzheimer's plays with it — after its experimental treatment succeeded in a test., Headline: Biogen Rally Adds $11 Billion in Value on Alzheimer’s Win, source:Yahoo, summary: (Bloomberg) -- Biogen Inc. rose the most since November 2020 after a key clinical trial with its partner Eisai Co. showed the therapy lecanemab slowed the progression of Alzheimer’s disease.Most Read from BloombergApple Ditches iPhone Production Increase After Demand FaltersGermany Suspects Sabotage Hit Russia’s Nord Stream PipelinesS&P 500 Roars Back From Six-Day Slide; Bonds Surge: Markets WrapPutin’s Mobilization Hits Russia’s Economy in Its Weak SpotsRussia Declares Victory in Sham Ukraine ‘, Headline: Biogen Alzheimer's drug may be 'first effort of a clear win': Analyst, source:Yahoo, summary: Baird Senior Research Analyst Brian Skorney joins Yahoo Finance Live to discuss the breakthrough of Biogen's Alzheimer's drug, which is pushing the stock higher., Headline: Dow Jones Jumps 549 Points As Treasury Yields Tumble, But Now What? Eli Lilly Leads 7 Bullish Stocks, source:Yahoo, summary: The major indexes rebounded as Treasury yields tumbled from 4% as the Bank of England resumed bond buying. Eli Lilly led stocks showing bullish action. Here's what to do now., Headline: Biogen's Alzheimer's Drug Success Pops Stocks Across the Industry, source:Yahoo, summary: For the 55 million people around the world who suffer from Alzheimer's and related dementias -- not to mention their loved ones -- Biogen's..., Headline: Noteworthy Thursday Option Activity: BIIB, TREE, RAD, source:Stock Options Channel, summary: Staff article entitled Noteworthy Thursday Option Activity: BIIB, TREE, RAD, about stock options, from Stock Options Channel.",BIIB
6,2022-09-29,"Headline: BIIB Crosses Above Average Analyst Target, source:ETF Channel, summary: Staff article entitled BIIB Crosses Above Average Analyst Target, about ETFs, from ETF Channel., Headline: Prothena price target raised to $110 from $100 at Oppenheimer, source:Thefly.com, summary: Oppenheimer analyst Jay O... PRTA, BIIB, ESALY, Headline: Biogen price target raised to $300 from $230 at Oppenheimer, source:Thefly.com, summary: Oppenheimer analyst Jay O... BIIB, ESALY, Headline: Biogen's lecanemab could be positive revenue driver for Akumin, says Clarus, source:Thefly.com, summary: After Biogen (BIIB) and p... AKU, BIIB, RDNT, Headline: Unusually active option classes on open September 29th, source:Thefly.com, summary: Unusual total active opti... HOG, CS, CLNN, BIIB, GM, HD, RIVN, LVS, EWG, Headline: Is Biogen a Smart Biotech Stock to Buy Right Now?, source:Yahoo, summary: New clinical trial results are great, but this company's Alzheimer's disease program has deeply disappointed investors in the past., Headline: Five questions around Biogen in wake of the new Alzheimer's drug data, source:Yahoo, summary: Biogen has spent much of the year shedding assets following the disastrous rollout of its first Alzheimer's disease drug. Will its new Alzheimer's drug stop that decline?, Headline: Dow Jones Futures Fall As Treasury Yields Rebound; Eli Lilly Leads 7 Bullish Stocks, source:Yahoo, summary: Dow Jones futures fell as Treasury yields rebounded, signaling Wednesday's rally may be short-lived. Eli Lilly leads some bullish stocks., Headline: November 11th Options Now Available For Biogen (BIIB), source:Stock Options Channel, summary: Staff article entitled November 11th Options Now Available For Biogen (BIIB), about stock options, from Stock Options Channel., Headline: Are Investors Undervaluing Biogen Inc. (NASDAQ:BIIB) By 40%?, source:Yahoo, summary: In this article we are going to estimate the intrinsic value of Biogen Inc. ( NASDAQ:BIIB ) by taking the forecast..., Headline: Teamwork Pays: Biogen, Eisai Announce Positive Results For Alzheimer's Drug, source:SeekingAlpha, summary: Positive clinical results announced for lecanemab, a novel treatment for Alzheimerâs disease. BIIB and ESALY are up over 35% on the news, although final decision is not until next year., Headline: LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data, source:Yahoo, summary: The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well., Headline: Biogen's Alzheimer’s drug could generate ‘$8 billion in peak sales’: Analyst, source:Yahoo, summary: Mizuho Americas Senior Biotech Analyst Salim Syed joins Yahoo Finance Live to discuss encouraging Phase 3 data from Biogen’s Alzheimer’s treatment lecanemab, how many sales the drug could generate, and what this means for the pharmaceutical industry., Headline: Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates, source:Yahoo, summary: Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week., Headline: NEW YORK MARKET CLOSE: Stocks shelled as recession fears confirmed, source:Alliance News, summary: No summary",BIIB
7,2022-09-30,"Headline: Biogen announces EMA filing acceptance of BIIB800, source:Thefly.com, summary: Biogen announced that the... BIIB, Headline: Biogen price target raised to $275 from $221 at JPMorgan, source:Thefly.com, summary: JPMorgan analyst Chris Sc... BIIB, RHHBY, Headline: Biogen: EMA Accepts Application for RoActemra Biosimilar >BIIB, source:MarketWatch, summary: By Colin Kellaher Biogen Inc. on Friday said the European Medicines Agency has accepted its application seeking approval of BIIB800, a proposed biosimilar to..., Headline: GLOBAL BROKER RATINGS: Deutsche Post raised to 'outperform', source:Alliance News, summary: No summary, Headline: Analysis-Eisai's trial success raises hope for Alzheimer's prevention, source:Reuters, summary: Clear evidence this week that Eisai and Biogen's drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer's researchers toward a tantalizing goal - preventing dementia even before symptoms start., Headline: Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab), source:Yahoo, summary: CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing RoACTEMRA®1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody. RoACTEMRA® is indicated in Europe as an intravenous formulation for severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate, moderate to, Headline: Eisai, Biogen And Alzheimer's: Never Say Die, Lecanemab To The Rescue, source:SeekingAlpha, summary: Eisai and Biogen get another chance. Read why the latest from the two companies is a big step forward even though it's still just a glimmer of hope for Alzheimerâs sufferers., Headline: Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review, source:Yahoo, summary: The major indexes fell, with the S&P 500 breaking below bear market lows. Biogen soared on an Alzheimer's drug while Nike dived., Headline: Amylyx Shows FDA Can Be Flexible on Drugs for Diseases With Few Treatments, source:Yahoo, summary: Relvyrio, Amylyx's drug to treat ALS, a neurological disorder without a cure, was approved even though the treatment is very expensive., Headline: Why Biogen Stock Popped as Much as 37.1% This Week, source:Yahoo, summary: Shares of Biogen (NASDAQ: BIIB) shot up as much as 37.1% this week, according to data from S&P Global Market Intelligence.  The large-cap drugmaker with a market cap of $39 billion announced that its new Alzheimer's drug it developed in a partnership with Eisai showed tremendous promise in a clinical trial.  As of 12:42 p.m. ET on Friday, shares of Biogen were up 35.5% this week., Headline: 9 Stocks Turned $10,000 Into $130,465 In 9 Months, source:Yahoo, summary: It's a tough S&P 500 stock market to make money on. But some investors are still finding a way to do it., Headline: The 5 Best—and 5 Worst—Stocks in the S&P 500 This Quarter, source:Yahoo, summary: The market has had a terrible run. Barron's takes a look at the winners and losers this quarter., Headline: The 5 Best—and 5 Worst—Stocks in the Nasdaq This Quarter, source:Yahoo, summary: Constellation Energy was the best performer in the Nasdaq 100 for the third quarter. Okta was the worst., Headline: Stocks moving in after hours: FedEx, Nvidia, Intel, AMD, Biogen, source:Yahoo, summary: Yahoo Finance Live's Seana Smith looks at several stocks trending in the after-hours trading session., Headline: An Alzheimer’s Drug’s Big Surprise: What It Means, source:MarketWatch, summary: Biogen and Eisau reported positive results in a trial for their latest attempt to develop a drug that can combat Alzheimer’s. The good news buttressed the..., Headline: Nike, Biogen, CarMax: Stocks That Defined the Week, source:Yahoo, summary: Nike is stepping up its discounts.  Nike’s results are the latest sign of how rapidly retailers and manufacturers found themselves with a surplus of goods, after two years of scrambling to have enough to sell during the pandemic.  Nike shares tumbled 13% Friday.",BIIB
8,2022-10-01,"Headline: Wall Street Breakfast: What Moved Markets, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The major U.S., Headline: When Should You Sell A Stock?, source:SeekingAlpha, summary: The broader market fell ~3% over the past week, but price action remained volatile. Check out our thoughts on when should you sell a stock., Headline: Why the Porsche IPO Generated So Much Excitement, source:Yahoo, summary: In this podcast, Motley Fool analyst Dylan Lewis and Motley Fool senior analyst Tim Beyers discuss:  Why Porsche is going public while other companies are holding off. Down rounds in the private markets.",BIIB
9,2022-10-02,"Headline: Social Security Recipients Might Actually Get to Keep Their 2023 Raise, source:Yahoo, summary: One of the biggest advantages of Social Security is that its payments get annual cost-of-living adjustments (COLAs).  2022's COLA boosted benefits by 5.9% this year, and early estimates make it likely that the COLA that will take effect in early 2023 will be between 8% and 9%.  What's even better news is that, unlike in 2022, many Social Security recipients are more likely to see the full amount of their cost-of-living adjustment actually hit their bank accounts., Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: There&#8217;s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (<span class='tr-stock-ticker' style='color:blue; font-w...",BIIB
10,2022-10-03,"Headline: Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio , source:TalkMarkets, summary: Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio., Headline: Doctor Mizuho spoke to 'very enthusiastic' about Biogen Alzheimer drug, source:Thefly.com, summary: Mizuho analyst Salim Syed... BIIB, Headline: Biogen, Denali announce initiation of Phase 3 LIGHTHOUSE study, source:Thefly.com, summary: Biogen (BIIB) and Denali ... BIIB, DNLI, Headline: Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA, source:Finnhub, summary: CAMBRIDGE - Biogen Inc. announced that the European Medicines Agency has accepted the Marketing Authorization Application for BIIB800, a biosimilar candidate referencing RoACTEMRA1, an... | October 3, 2022, Headline: U.S. SUPREME COURT REJECTS BIOGEN BID TO REVIVE PATENT FOR MULTI…, source:Finnhub, summary: U.S. SUPREME COURT REJECTS BIOGEN BID TO REVIVE PATENT FOR MULTIPLE SCLEROSIS DRUG IN DISPUTE WITH MYLAN PHARMACEUTICALS ... | October 3, 2022, Headline: Biotech Alert: Searches spiking for these stocks today, source:Thefly.com, summary: Stay ahead of biotech stocks seeing a surge in interest from retail and financial professional investors with this exclusive recap from The Fly DNLI, TCRR, PRTA, MOR, QTRX, BMY, BIIB, NVO, Headline: Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations, source:Yahoo, summary: Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2LRRK2 mutations are one of the most common genetic drivers of Parkinson’s diseaseTargeting LRRK2 has the potential to impact the underlying biology and slow the progression of Parkinson’s disease CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that dosing has commenced in the, Headline: Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?, source:Yahoo, summary: Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth., Headline: Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?, source:Yahoo, summary: AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023., Headline: UPDATE 1-U.S. Supreme Court turns away Biogen bid to reinstate MS drug patent, source:Yahoo, summary: The U.S. Supreme Court on Monday declined to hear Biogen Inc's bid to win reinstatement of a patent on the company's blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc subsidiary Mylan Pharmaceuticals Inc.  The justices turned away Biogen's appeal of a lower court's decision to invalidate the patent in a ruling that helped clear the way for Mylan's generic version of Tecfidera.  Biogen sued Mylan, now part of Canonsburg, Pennsylvania-based Viatris, in West Virginia in 2017, saying Mylan's proposed generic version of Tecfidera would infringe Biogen patents., Headline: Is Eli Lilly Stock a Buy Following This Competitor's Major Win?, source:Yahoo, summary: Eli Lilly (NYSE: LLY) was already having a great year in the stock market, but on Sept. 28, the company's shares jumped by about 7%.  The move happened after biotech giant Biogen and its partner Esai reported positive top-line results from a phase 3 clinical trial for an Alzheimer's disease (AD) therapy candidate, lecanemab.  Eli Lilly is working on its own AD treatment, donanemab, and the market counted Biogen's win as Eli Lilly's too., Headline: The 1-Minute Market Report October 2, 2022, source:SeekingAlpha, summary: Asian markets continue to struggle this year, thanks in large part to the weak China market. The only asset class showing positive performance is volatility., Headline: U.S. Supreme Court turns away Biogen bid to reinstate MS drug patent, source:Reuters, summary: The U.S. Supreme Court on Monday declined to hear Biogen Inc's bid to win reinstatement of a patent on the company's blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc subsidiary Mylan Pharmaceuticals Inc., Headline: US Supreme Court Turns Away Biogen's Last Effort To Reinstate Tecfidera Patent, source:Yahoo, summary: The U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen Inc's (NASDAQ: BIIB) blockbuster drug Tecfidera. The ruling clears the way for Viatris Inc (NASDAQ: VTRS) to continue marketing its generic version of the drug, launched more than two years ago. The justices turned away Biogen's appeal of a lower court's decision to invalidate the patent. Related: These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win. Biogen sued Mylan, n",BIIB
11,2022-10-04,"Headline: Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson's disease Associated with LRRK2 Pathogenic Mutations, source:Finnhub, summary: Cambridge - Biogen Inc. and Denali Therapeutics Inc. today announced that dosing has commenced in the global Phase 3 LIGHTHOUSE study to evaluate the efficacy and safety profile of BIIB122 , as... | October 4, 2022, Headline: Biogen Shares Climb Again on Results From Alzheimer`s Study, source:GuruFocus, summary: nan, Headline: Eisai And Biogen: Only APOE4 Carriers Benefit From Lecanemab For Alzheimer's Disease, source:SeekingAlpha, summary: Non-APOE4 carriers do not benefit from treatment with lecanemab, which reduces the rate of progression of APOE4 carriers. Read more here., Headline: 3 Revolutionary Stocks I'd Buy Right Now Without Hesitation, source:Yahoo, summary: Regeneron Pharmaceuticals (NASDAQ: REGN), Vertex Pharmaceuticals (NASDAQ: VRTX), and Biogen (NASDAQ: BIIB) are developing remarkable therapies that, instead of merely treating disorders, have the potential to cure them or at least make an impact that no other drug has to date.  The reason that's not a big cause for alarm is that the company's second-quarter revenue of $2.86 billion would be up 20% over the same period in 2021 if its COVID-19 therapy, REGEN-COV, was excluded from total revenue.  The company's sales of the treatment ended late last year when government contracts for the therapy ended.",BIIB
12,2022-10-05,"Headline: Keep an Eye on SAVA Stock, as Last Month's Frenzy Fades, source:InvestorPlace, summary: SAVA stock got ahead of itself in September, but if it continues to pull back, a solid entry point could emerge for this risky biotech play., Headline: Acumen price target raised to $22 from $15 at BTIG, source:Thefly.com, summary: BTIG analyst Thomas Shrad... ABOS, BIIB, Headline: Should You Sell Your FANGMAN Stocks? , source:TalkMarkets, summary: In addition to energy, investors have been fleeing to healthcare stocks for safety. And they have been selling the big tech names, especially the semiconductors., Headline: Hey Biogen Investors, Don't Chase BIIB Stock!, source:InvestorPlace, summary: If BIIB stock already reflects Biogen's early-stage Alzheimer's disease study results, then the next move could easily be to the downside., Headline: Better Alzheimer's Disease Stock: Eli Lilly or Biogen?, source:Yahoo, summary: One of these stocks has significantly outperformed the other over the past year. Will that continue?, Headline: Hey Biogen Investors, Don’t Chase BIIB Stock!, source:Yahoo, summary: Reportedly, Biogen (NASDAQ:BIIB) and Japanese pharmaceutical company Eisai (OTCMKTS:ESALY) achieved positive test results for their Alzheimer’s disease treatment. As you might expect, BIIB stock exploded higher on this news. However, these are early-stage results and prospective investors should read the fine print. Besides, if the good news has already been priced in, then buying now is tantamount to chasing, which generally isn’t a recommended strategy. Just to provide the backstory, Biogen an, Headline: Should You Sell Your FANGMAN Stocks?, source:Yahoo, summary: Tracey and Kevin discuss the rocky 2022 stock market and the future of growth stocks., Headline: Mizuho Securities Sticks to Their Buy Rating for Biogen (BIIB), source:TipRanks, summary: Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen (BIIB &#8211; Research Report) today and set a price target of $270.00. The company&#8217;s s...",BIIB
13,2022-10-06,"Headline: Biogen price target raised to $309 from $238 at UBS, source:Thefly.com, summary: UBS analyst Colin Bristow... BIIB, Headline: The Petri Dish: Moderna nabs Novartis exec as new CTO, Ginkgo acquires two companies, source:Yahoo, summary: Biogen's patent battles over Tecfidera are over after SCOTUS decision; Ginkgo Bioworks delves into the RNA therapeutics; and Peter Thiel invests in Waltham startup creating ""humanized"" mice., Headline: Interesting BIIB Put And Call Options For November 25th, source:Stock Options Channel, summary: Staff article entitled Interesting BIIB Put And Call Options For November 25th, about stock options, from Stock Options Channel., Headline: Zacks Market Edge Highlights: ExxonMobil, Meta Platforms, UnitedHealth Group, Biogen and NVIDIA, source:Yahoo, summary: ExxonMobil, Meta Platforms, UnitedHealth Group, Biogen and NVIDIA are part of the Zacks Market Edge article., Headline: Is This Stock a Buy After Soaring by 37%?, source:Yahoo, summary: Biotech giant Biogen (NASDAQ: BIIB) was underperforming the market this year -- that is, until the company's shares soared by as much as 37% last week.  The drugmaker's major win in the stock market came after it reported positive top-line results from a phase 3 clinical trial for lecanemab, a potential therapy for Alzheimer's disease (AD).  Biogen is developing lecanemab in collaboration with Japan-based Esai.",BIIB
14,2022-10-07,"Headline: Biogen price target raised to $275 from $200 at Barclays, source:Thefly.com, summary: Barclays analyst Carter G... BIIB, Headline: Biogen upgraded to Buy from Hold at Argus, source:Thefly.com, summary: Argus upgraded Biogen to ... BIIB, Headline: Biogen upgraded to Buy at Argus on positive lecanemab data, source:Thefly.com, summary: Argus analyst Jasper Hell... BIIB, Headline: Unum Group price target raised to $48 from $44 at Truist, source:Thefly.com, summary: Truist analyst Mark Hughe... UNM, BIIB, Headline: Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: Federal Signal upgrade, Lyft downgrade, and Chewy initiation among today's top calls on Wall Street LYFT, UBER, SFT, FSS, GS, NSC, ZM, CHWY, LEVI, HP, U, PSTV, PGR, BIIB, CLB, ZION, Headline: Former J&J exec emerges as top candidate to become Biogen CEO, Statnews reports, source:Thefly.com, summary: Mathai Mammen, a senior r... BIIB, JNJ, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. DKNG, DIS, JNJ, BIIB, AMD, CVS, CANO, BAC, AMBC, LEVI, LYFT, UBER, ZM, GS, NSC, U, META, AAPL, GOOG, GOOGL, PAYO, DXCM, CS, LAC, ALLO, ACCD, AEHR, TLRY, LPRO, NRIX, Headline: Former J&J executive emerges as front-runner for Biogen top job - STAT News, source:Reuters, summary: Mathai Mammen, a former executive at drugmaker Johnson & Johnson, has emerged as a top candidate to head Biogen as chief executive officer, news website STAT reported on Friday, citing people familiar with the discussions.",BIIB
15,2022-10-10,"Headline: 7 Biotech Stocks Set to Boom in 2023, source:InvestorPlace, summary: This article looks at seven biotech stocks that look like good options to move significantly higher in 2023, Headline: Biogen announces first patient dosed in Phase 2/3 AMETHYST study, source:Thefly.com, summary: Biogen announced that the... BIIB, Headline: These 7 Biotech Stocks Are Set to Boom in 2023, source:Yahoo, summary: Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good measure. This combination makes these companies attractive to value investors. In general, however, investing in biotech stocks is not for risk-averse investors. Many of these companies are smaller players. They may or may not be generating revenue, much less profit. But it’s usually at these compa, Headline: Alzheimer’s Drugs Advance but Slowing Disease Remains a Challenge, source:Yahoo, summary: Although Biogen and Eisai’s lecanemab cleared plaque from patients’ brains, researchers say the benefits may be limited, Headline: Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers, source:Yahoo, summary: Recently, Biogen Inc (NASDAQ: BIIB) and Eisai Co (OTC: ESALY) announced encouraging data from the most-watched Alzheimer's therapies in the clinic. Lecanemab cleared accumulations in the brain of beta-amyloid, sticky protein fragments that researchers have long suspected contribute to Alzheimer's. Citing physicians and neurology researchers, Wall Street Journal reported that the drug's benefit to patients might be limited. They said the reduction of cognitive decline that patients experienced wa",BIIB
16,2022-10-11,"Headline: Biotech Stocks Well-Positioned For Fourth Quarter, source:SeekingAlpha, summary: Biotechs benefit if a slowdown pushes the longer-term yields lower. Check out why are biotechs relatively well-positioned now., Headline: 12 Best Ethical Stocks To Buy Now, source:Yahoo, summary: In this article, we will take a look at 12 best ethical stocks to buy now. If you want to see some more of the best ethical stocks to buy, go directly to 5 Best Ethical Stocks To Buy Now. Sometimes investing is more than about just making money. Investing can also be used to […], Headline: Jim Cramer goes over the best and worst Q3 performers in the S&P 500, source:CNBC, summary: Cramer said he wouldn't touch this stock with a 10-foot pole., Headline: Biogen Inc. (BIIB) Stock Moves -0.28%: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed at $254.07 in the latest trading session, marking a -0.28% move from the prior day.",BIIB
17,2022-10-12,"Headline: Biogen upgraded to Buy from Hold at Stifel, source:Thefly.com, summary: Stifel analyst Paul Matte... BIIB, RHHBY, Headline: Fly Intel: After-Hours Movers, source:Thefly.com, summary: QuidelOrtho jumps over 7% after positive Q3 revenue pre-announcement; Applied Materials slips 1% on Q4 guidance cut DCT, GOL, VSCO, QDEL, DWAC, NVRO, AVEO, BMRN, BIIB, AMAT, Headline: 4 Biotech Stocks With Huge Incoming Catalysts, source:Yahoo, summary: All four of these drugmakers are expecting important FDA approval decisions over the next few months., Headline: Does Biogen's Recent Win Make It a Must-Buy Stock?, source:Yahoo, summary: Shares of Biogen (NASDAQ: BIIB) soared late last month after the company again received positive results around one of its Alzheimer's treatments.  It wasn't Aduhelm this time, but a new promising treatment called lecanemab, which the company is hoping can slow down the disease.  Does the price jump signal a turnaround for Biogen, and is now the time to buy shares of the healthcare company before its value rises even further?, Headline: Biotech Stocks Well-Positioned For The Fourth Quarter, source:TalkMarkets, summary: The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.
, Headline: Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Should You Buy?, source:Yahoo, summary: Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Biotech Stock Roundup: DICE Up on Study Data, GILD, BIIB's Updates & More, source:Yahoo, summary: Regulatory and pipeline updates from DICE and RIGL are the key highlights from the biotech sector during the past week., Headline: Biogen Inc. stock falls Wednesday, still outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slipped 0.16% to $253.67 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: What You Missed On Wall Street On Thursday, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. WBA, DAL, AMAT, PDCO, NFLX, CMCSA, CMCSK, ATUS, BIIB, AXP, LVS, NKE, LULU, KR, ACI, GOOG, GOOGL, AMZN, AAPL, SLB, DWAC, INMD, TSM, CNHI, RLMD, PGR, FAST, DPZ, QDEL, ACCO, ACMR, Headline: Elliott Wave Technical Analysis: Biogen, Inc. - Thursday, Oct. 13, source:TalkMarkets, summary: Biogen Inc. is moving as predicted, looking for this pullback to this support as we have had a huge gap to the upside.  ",BIIB
18,2022-10-13,"Headline: Delta, Walgreens, BlackRock, Domino's Rise Premarket; Applied Materials Drops, source:Yahoo, summary: By Peter Nurse, Headline: Early notable gainers among liquid option names on October 13th, source:Thefly.com, summary: Notable gainers among liq... DPZ, DAL, WBA, BIIB, JPM, Headline: Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: Comcast upgrade, American Express downgrade and Nike initiation among today's top calls on Wall Street CMCSA, CMCSK, LVS, ATUS, SHW, BIIB, RHHBY, AXP, GEF, ALB, BP, AVY, NKE, LULU, SKX, UAA, SMAR, ASAN, DOCS, MNDY, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. DPZ, QDEL, ACCO, ACMR, WBA, DAL, KR, ACI, CMCSA, AMAT, PDCO, ATUS, BIIB, AXP, LVS, NKE, LULU, GOOG, GOOGL, AMZN, TTE, AAPL, SONY, HMC, DWAC, INMD, TSM, CNHI, RLMD, PGR, FAST, Headline: Stocks making the biggest moves midday: Digital World, Domino's, Revlon, Albertsons and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®, source:Yahoo, summary: SANTA MONICA, Calif., October 13, 2022--GoodRx (NASDAQ: GDRX), a leading consumer-focused digital healthcare platform, today announced a collaboration with Biogen (NASDAQ: BIIB) that aims to improve the patient and healthcare provider (HCP) experience when initiating a new specialty therapy. HCPs who have decided to start patients with relapsing forms of multiple sclerosis (MS) on VUMERITY® (diroximel fumarate) may now find the enrollment form and submit to the specialty hub through Provider Mod, Headline: Biogen Community Lab: 20 Years of Inspiring Future Scientists, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / October 13, 2022 / Biogen ""I remember this one girl from Cambridge: she was filling out the survey we give to students on their last day,"" says Tracy Callahan, Biogen's first Community Lab teacher. ""She said to ..., Headline: Biogen Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. rose 6.41% to $269.94 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts, source:Yahoo, summary: Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's. It raised the price target from $223 to $299. The analyst worries about residual competitive/commercial risks, notwithstanding the uncertainty around Biogen's future CEO. Stifel views upcoming Roche Holding AG's (OTC: RHHBY) gantenerumab data are unlikely to live up to the high bar lecanemab recently set and thinks there's a meaningful commercial role for lecane, Headline: Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity, source:Yahoo, summary: Biogen could easily take on Roche and Eli Lilly in Alzheimer's treatment, an analyst said Thursday as he upgraded Biogen stock.",BIIB
19,2022-10-14,"Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Brookdale Senior Living (BKD), source:TipRanks, summary: Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (<a href..., Headline: Biogen Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. shed 1.97% to $264.63 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",BIIB
20,2022-10-16,"Headline: Roche's AD drug expected to fall short in trial, says Morgan Stanley, source:Thefly.com, summary: Morgan Stanley analyst Ja... MOR, RHHBY, BIIB",BIIB
21,2022-10-17,"Headline: Biogen: FDA Extends Review of Tofersen in Rare Form of ALS >BIIB, source:MarketWatch, summary: By Colin Kellaher Biogen Inc. on Monday said the U.S. Food and Drug Administration extended its review of its proposed drug for a rare genetic form of..., Headline: Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen, source:Yahoo, summary: The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is April 25, 2023 CAMBRIDGE, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the new drug application (NDA) for tofersen by three months. Tofersen is an investigational treatment for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The updated Prescription Drug User Fee Act (PDUFA) goal d, Headline: U.S. health regulator extends review of Biogen's ALS drug , source:Reuters, summary: Biogen Inc said on Monday the U.S. Food and Drug Administration had extended the review of its experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three months., Headline: UPDATE 1-U.S. health regulator extends review of Biogen's ALS drug, source:Yahoo, summary: The U.S. Food and Drug Administration has extended the review of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three months, the company said on Monday.  Biogen said it had submitted responses to the FDA's information requests, which the agency said would require additional time for review and set a new target action date of April 25, 2023.  The agency had accepted Biogen's application for the drug, tofersen, under its accelerated approval pathway in July this year, with an approval decision expected by Jan. 25., Headline: U.S. health regulator extends review of Biogen's ALS drug, source:Reuters, summary: The U.S. Food and Drug Administration has extended the review of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three months, the company said on Monday., Headline: FDA extends review time for Biogen's ALS treatment candidate, source:Yahoo, summary: Shares of Biogen Inc. gained 1.4% in premarket trading on Monday after telling investors that the Food and Drug Administration extended the review period for its experimental treatment for amyotrophic lateral sclerosis (ALS) by three months. The new decision date is April 25. Biogen's stock is up 10.3% this year, while the S&P 500 is down 24.8%., Headline: IN BRIEF: Biogen application review period in US extended for tofersen, source:Alliance News, summary: No summary, Headline: Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate, source:Yahoo, summary: Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with postpartum depression (PPD). The SKYLARK Study, as previously reported, achieved the primary and all key secondary endpoints. Zuranolone 50 mg showed a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, compared to the placebo. In the presentation at the European College o, Headline: FDA Pushes Extends Review For Biogen's Amyotrophic Lateral Sclerosis Drug, source:Yahoo, summary: The FDA extended the review period for Biogen Inc's (NASDAQ: BIIB) experimental Tofersen treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three months. Biogen had submitted responses to the FDA's information requests, which the agency said would require additional time for review, and set a new target action date of April 25, 2023. The agency had accepted Biogen's application for the drug, tofersen, under its accelerated approval pathway in July, with an approval decisio, Headline: Biogen Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. advanced 1.86% to $269.55 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: Biogen: How To Assess Lecanemab's Potential? Invert The Market's Reaction, source:SeekingAlpha, summary: Lecanemab's successful Phase 3 clinical trial led to Biogen's stock price jumping by 33% in one day. Read why some option strategies might be worth considering., Headline: Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed at $269.55 in the latest trading session, marking a +1.86% move from the prior day.",BIIB
22,2022-10-18,"Headline: Roche exec says Biogen Alzheimer's data was reassuring, source:Yahoo, summary: A Roche executive said on Tuesday that positive trial data on an Alzheimer's disease drug candidate by rival Biogen was encouraging for companies such as Roche also pursing amyloid beta proteins as a drug target.  ""Before that readout there was quite a raging debate, as to whether targeting a amyloid beta does anything whatsoever to clinical signs and symptoms of Alzheimer's. After that data that debate has to take on a different character and it reassures us in the validity of the pathway,"" the head of Roche's pharma unit Bill Anderson said in an analyst call., Headline: Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension, source:Yahoo, summary: The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing., Headline: Biogen Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.27% higher to $270.28 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: An Overview Of Today's Alzheimer's Disease Development Field, source:SeekingAlpha, summary: Alzheimer's is one of the largest unmet medical needs. Today, there are 139 drugs in clinical trials for Alzheimer's. Click here to read more., Headline: Biogen and 10 Other Healthcare Stocks Thriving in This Bear Market, source:MarketWatch, summary: Of the 56 stocks in the S&P 500 that have seen their share prices climb at least 10% since Jan. 3, 11 are healthcare stocks, a Barron's screen found.",BIIB
23,2022-10-19,"Headline: 15 Best Drug Stocks to Buy Now, source:Yahoo, summary: In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […], Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 2.16% to $264.45 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...",BIIB
24,2022-10-20,"Headline: HQH: A Dividend Paymaster That Fails To Register Price Growth, source:SeekingAlpha, summary: Tekla Healthcare Investors is able to generate steady yield and currently trades at a good discount to its NAV. Read more to see why HQH is a Buy., Headline: Top 5 3rd Quarter Trades of Ri - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Empirical Asset Management, LL - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Where Will Biogen Be in 5 Years?, source:Yahoo, summary: Shares of Biogen (NASDAQ: BIIB) have been volatile in the past few years, largely hinging on success of the company's Alzheimer's treatments.  Sales in recent years have been declining, and the loss of patent protection for top-selling multiple sclerosis treatment Tecfidera is only exacerbating those concerns.  What will the company's business look like over the next five years, and is it promising enough for investors to buy shares of Biogen today?, Headline: Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More, source:Yahoo, summary: Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week., Headline: Biogen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slipped 0.68% to $262.65 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...",BIIB
25,2022-10-21,"Headline: 3 Alzheimer's Therapy Stocks to Invest in, source:Yahoo, summary: Alzheimer's therapies are big news lately.  The disease is the leading cause of dementia and memory loss.  The Alzheimer's Association estimates that 6.5 million Americans 65 and older are living with Alzheimer's dementia (AD) and by 2050, the number of people 65 and older with AD is projected to reach 12.7 million., Headline: Biogen (BIIB) to Report Q3 Earnings: Here's What to Expect, source:Yahoo, summary: Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza., Headline: US Earnings to Watch This Week: Apple, Microsoft, Boeing, Exxon, Biogen, source:Yahoo, summary: (Bloomberg) -- Schlumberger’s rosy report Friday -- including its best profit in seven years and a boost to its full-year guidance -- supports expectations for oil giants Exxon and Chevron to continue their earnings expansion streak when they deliver results at the end of the week. Meanwhile, the technology megacap companies reporting this week will look to shake off souring sentiment on digital advertising rates, after Snap’s slowest quarterly sales growth triggered a sell off that wiped out $3, Headline: Biogen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. advanced 1.89% to $267.62 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",BIIB
26,2022-10-24,"Headline: Three things investors will be looking for in Biogen's Q3 earnings, source:Yahoo, summary: The drugmaker will again face analysts on Tuesday amid cautious hope for its neurodegenerative disease drugs and an ongoing CEO search. Here's what to watch for., Headline: With 86% ownership of the shares, Biogen Inc. (NASDAQ:BIIB) is heavily dominated by institutional owners, source:Yahoo, summary: If you want to know who really controls Biogen Inc. ( NASDAQ:BIIB ), then you'll have to look at the makeup of its..., Headline: What You Missed On Wall Street On Tuesday, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. KO, GE, GM, WBD, ADDYY, GPS, ROST, ANET, PLNT, HRT, UPST, TM, DWAC, INTC, TWTR, UL, WEBR, MEDP, CGC, CCK, BRO, PYPL, AMZN, MMM, BIIB, XRX, UPS, AAN",BIIB
27,2022-10-25,"Headline: Biogen reports Q3 adjusted EPS $4.77, consensus $4.15, source:Thefly.com, summary: Reports Q revenue $2.51B,... BIIB, Headline: Biogen raises FY22 EPS view to $16.50-$17.15, consensus $16.49, source:Thefly.com, summary: Raises FY22 non-GAAP EPS ... BIIB, Headline: Biogen Inc. 2022 Q3 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Biogen Inc., Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: General Motors rises, JetBlue falls following quarterly earnings MULN, TSHA, WEBR, KO, UPS, GE, RTX, GM, JBLU, MMM, ITW, CNC, BIIB, ST, Headline: Biogen tops 3Q expectations as cost cutting continues, source:Associated Press, The, summary: No summary, Headline: Biogen nudges revenue outlook higher despite third-quarter slip, source:Alliance News, summary: No summary, Headline: Biogen Inc. (BIIB) Q3 2022 Earnings Call Transcript, source:SeekingAlpha, summary: Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q3 2022 Earnings Conference Call October 25, 2022 08:00 AM ET Company Participants Mike Hencke - Head, Investor Relations Michel Vounatsos - Chief Executive..., Headline: Biogen sales fall 9.7% on Tecifdera competition, source:Reuters, summary: Biogen Inc reported a 9.7% drop in quarterly sales on Tuesday due to rising competition for its blockbuster multiple sclerosis drug Tecfidera, while investors awaited more data on its new Alzheimer's disease drug next month., Headline: UPDATE 3-Biogen confident in Alzheimer's drug ahead of rivals' data, source:Yahoo, summary: Biogen Inc on Tuesday said the Alzheimer's disease drug it is developing with Japan's Eisai Co Ltd would be used by doctors in a competitive market as investors wait for data from rival therapies made by Eli Lilly and Co and Roche.  The drug, lecanemab was shown to slow the progress of the disease by 27% in a trial last month, and additional data is expected next month.  Lecanemab and experimental drugs for the mind-wasting disease from Lilly and Roche belong to a class of treatments that reduces amyloid beta proteins in the brain believed to be an underlying cause of Alzheimer's., Headline: Biogen beats revenue expectations in the third quarter, source:Yahoo, summary: Biogen's stock was up 0.7% in premarket trading on Tuesday after it beat expectations for earnings and revenue in the third quarter of the year. The company had earnings of $1.1 billion, or $7.84 per share, in the third quarter of 2022, compared with $2.5 billion, or $2.22 per share, in the same quarter a year ago. Adjusted earnings per share were $4.77, against a FactSet consensus of $4.13. Biogen said revenue was $2.5 billion for the quarter, down from $2.7 billion in the same three months of, Headline: Biogen Inc. (BIIB) Surpasses Q3 Earnings and Revenue Estimates, source:Yahoo, summary: Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.50% and 1.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?, Headline: Biogen Skids Despite Beat-And-Raise Quarter As Pressure Builds In Alzheimer's Market, source:Yahoo, summary: Biogen stock fell Tuesday despite a beat-and-raise quarter and continued enthusiasm for its experimental Alzheimer's treatment., Headline: Biogen and Eisai make plans to take another Alzheimer's drug to the FDA next year, source:MarketWatch, summary: The companies said last month that their new experimental therapy, called lecanemab, slowed cognitive decline by 27% in a Phase 3 clinical trial., Headline: Biogen confident in Alzheimer's drug ahead of rivals' data, source:Reuters, summary: Biogen Inc on Tuesday said the Alzheimer's disease drug it is developing with Japan's Eisai Co Ltd would be used by doctors in a competitive market as investors wait for data from rival therapies made by Eli Lilly and Co and Roche., Headline: Biogen Raises Annual Guidance Despite Q3 Earning Impacted By Biosimilar Competition, source:Yahoo, summary: Biogen Inc (NASDAQ: BIIB) posted Q3 sales of $2.51 billion, beating the consensus of $2.47 billion, down 10% Y/Y and 8% at constant currency (CC). Multiple sclerosis revenue, including royalties on sales of Ocrevus, of $1.62 billion decreased by 11% (down 9% CC). Spinraza's revenue of $431 million decreased by 3% at actual currency (increased by 2% at CC). Aduhelm generated sales of $1.6 million in Q3, compared to $0.3 million a year ago. Biosimilars' revenue of $188 million decreased by 7% vers, Headline: Biogen paints an optimistic picture ahead of critical FDA decision, source:Yahoo, summary: Biogen Inc. on Tuesday laid out an optimistic picture for analysts and investors, even as questions remain around its new Alzheimer's drug and its leadership team., Headline: Biogen (BIIB) Q3 2022 Earnings Call Transcript, source:Yahoo, summary: At this time, I'd like to welcome everyone to the Biogen third quarter 2022 earnings call and business update.  As a reminder, during the Q&A portion of the call, we kindly ask that you limit yourself to one question., Headline: NEW YORK MARKET CLOSE: Well-received earnings paint Wall Street green, source:Alliance News, summary: No summary, Headline: Biogen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. shed 0.39% to $273.56 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook, source:Yahoo, summary: Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance., Headline: Biogen and Eisai make plans to take another Alzheimer’s drug to the FDA, source:Yahoo, summary: The companies said last month that their new experimental therapy, called lecanemab, slowed cognitive decline by 27% in a Phase 3 clinical trial., Headline: Biogen Lifts Profit Estimates as Investors Look to Alzheimer’s Drug, source:Yahoo, summary: The biotech raised its earnings per share estimate to $16.50 to $17.15 from the previously estimated $15.25 to $16.75 range., Headline: Nasdaq And Small Caps Power Stock Market Gains; Medpace, GM And Coke Earnings Pace Stocks, source:Yahoo, summary: Stock market gains despite slide in consumer confidence General Motors, Coca-Cola, Medpace and others posted earnings bumps.",BIIB
28,2022-10-26,"Headline: Needham Releases a Buy Rating on Biogen (BIIB), source:TipRanks, summary: In a report released yesterday, Ami Fadia from Needham assigned a Buy rating to Biogen (BIIB &#8211; Research Report), with a price target of $300.00. The company&#..., Headline: Biogen price target raised to $325 from $240 at H.C. Wainwright, source:Thefly.com, summary: H.C. Wainwright analyst A... BIIB, Headline: Biogen price target raised to $331 from $310 at RBC Capital, source:Thefly.com, summary: RBC Capital analyst Brian... BIIB, Headline: Biogen price target raised to $325 from $285 at Canaccord, source:Thefly.com, summary: Canaccord analyst Sumant ... BIIB, Headline: Biogen price target raised to $300 from $270 at Cowen, source:Thefly.com, summary: Cowen analyst Phil Nadeau... BIIB, Headline: Biogen price target raised to $325 from $321 at Morgan Stanley, source:Thefly.com, summary: Morgan Stanley analyst Ma... BIIB, Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Taysha Gene Therapies (TSHA), source:TipRanks, summary: There&#8217;s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (<span class='tr-stock-ticker' style='color:blue; font-w..., Headline: Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Timber Pharmaceuticals (TMBR), source:TipRanks, summary: There&#8217;s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (<span class='tr-stock-ticker' style='color:blue; font-w..., Headline: Atlantic Equities Sticks to Its Hold Rating for Biogen (BIIB), source:TipRanks, summary: In a report released today, Steve Chesney from Atlantic Equities maintained a Hold rating on Biogen (BIIB &#8211; Research Report), with a price target of $220.00. ..., Headline: Is Biogen a Buy After It Boosted Guidance?, source:Yahoo, summary: The good news keeps coming in for Biogen (NASDAQ: BIIB). On Tuesday, the drugmaker reported its third-quarter results, and for the first time in a while, investors found something in one of its earnings updates to cheer about., Headline: New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS, source:Yahoo, summary: Final safety and efficacy results from the Phase 3 EVOLVE-MS-1 trial demonstrate decreases in disease activity and favorable tolerability for VUMERITY® (diroximel fumarate) consistent with previous assessmentsPatient-reported outcomes favored TYSABRI® (natalizumab) compared to Ocrevus® (ocrelizumab); new insights on subcutaneous administration one year after approval in GermanyData on interferon exposure during pregnancy showed that treatment with PLEGRIDY® (peginterferon beta-1a) or AVONEX® (in, Headline: Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS, source:Yahoo, summary: Data demonstrate potential of Manual Dexterity Test and Konectom™ smartphone-based technology in measuring MS disease progressionRetrospective analysis applying machine learning, artificial intelligence and radiomics identifies brain imaging patterns that may further the understanding of MS disease and lesion heterogeneityTwo-stage precision medicine models leveraging real-world data from MS PATHS network provide new insights on enabling more individualized predictions of treatment effect CAMBRI, Headline: Stocks making the biggest moves midday: Harley-Davidson, Visa, Microsoft, Biogen and more , source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Biotech Stock Roundup: BIIB & BMY's Q3 Earnings, TCDA Down on Study Update, source:Yahoo, summary: Earnings updates from BIIB and BMY are the key highlights from the biotech sector during the past week., Headline: Biogen Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. advanced 2.51% to $280.43 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Teladoc (TDOC) and Taysha Gene Therapies (TSHA), source:TipRanks, summary: Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (<a href...",BIIB
29,2022-10-27,"Headline: GLOBAL BROKER RATINGS: Kepler cuts Adidas to 'hold' from 'buy', source:Alliance News, summary: No summary, Headline: Biogen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. dropped 0.91% to $277.87 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",BIIB
30,2022-10-28,"Headline: Jerome Dodson's Parnassus Ende - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by Sydnee Gatewood and the topic is about: Discussion of markets and holdings, Headline: Parnassus Fund Comments on Bio - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by Sydnee Gatewood and the topic is about: Guru stock highlight, Headline: Biogen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. advanced 2.31% to $284.29 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: Volunteer Dies Testing Eisai-Biogen Alzheimer’s Drug During Study, source:Yahoo, summary: The subject experienced swelling and bleeding in the brain, an Eisai spokeswoman said. It wasn’t clear if the death was directly caused by the drug lecanemab in a clinical trial.",BIIB
31,2022-10-29,"Headline: Don't Get Used to Lower Medicare Part B Premiums -- Here's Why, source:Yahoo, summary: Medicare might have to begin paying billions of extra dollars for new drugs in the not-too-distant future., Headline: Patient Death in Alzheimer's Study May Limit Drug's Reach, source:Yahoo, summary: Brain swelling and inflammation is a common side effect among plaque-clearing drugs. It may make some patients ineligible for treatment.",BIIB
32,2022-10-31,"Headline: Biogen: Super-Strong Momentum In A Defensive Sector, source:SeekingAlpha, summary: Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. See why I would reenter a position in BIIB stock., Headline: Biogen Inc. stock falls Monday, still outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 0.30% to $283.44 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: ClearBridge Value Equity Strategy Q3 2022 Portfolio Manager Commentary, source:SeekingAlpha, summary: The ClearBridge Value Equity Strategy outperformed its Russell 1000 Value Index during the third quarter 2022. Click here to read the full fund letter., Headline: Deal Activity Could Jumpstart Biotechnology, source:SeekingAlpha, summary: Biotechnology failed to ride the tailwinds of COVID vaccine development. Despite poor sentiment toward biotech, see why we see reasons for optimism., Headline: Biogen: Second Time's A Charm, source:SeekingAlpha, summary: Biogen appears set to obtain approval of a second Alzheimer's drug. Read why any failure to obtain drug approval or payment would send BIIB likely to new lows.",BIIB
33,2022-11-01,"Headline: Biogen price target raised to $325 from $270 at Mizuho, source:Thefly.com, summary: Mizuho analyst Salim Syed... BIIB, Headline: ClearBridge All Cap Growth Strategy Q3 2022 Portfolio Manager Commentary, source:SeekingAlpha, summary: The ClearBridge All Cap Growth Strategy performed in line with its Russell 3000 Growth Index benchmark in the Q3 2022. Click here to read the full fund letter., Headline: Biogen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 1.20% to $280.04 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Top 5 3rd Quarter Trades of Jo - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: ",BIIB
34,2022-11-02,"Headline: Trading Ideas On The Upcoming CTAD 2022 Conference, source:SeekingAlpha, summary: The Clinical Trials on Alzheimerâs Conference will take place from November 29, 2022 to December 2, 2022. Click to read my analysis ahead of the conference., Headline: Biogen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. shed 0.60% to $278.37 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",BIIB
35,2022-11-03,"Headline: Is Biogen Poised for a Bull Run?, source:Yahoo, summary: Biogen (NASDAQ: BIIB) has been a volatile investment in recent years and its outlook still remains cloudy at best.  Meanwhile, its Alzheimer's treatment Aduhelm went from a hero to a zero within a span of just months as questions were raised about its efficacy.  Now, however, there's renewed hope around Biogen., Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.68% higher to $280.25 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",BIIB
36,2022-11-04,"Headline: Biogen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.56% higher to $281.82 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",BIIB
37,2022-11-05,"Headline: Top 5 3rd Quarter Trades of Re - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: ",BIIB
38,2022-11-06,"Headline: Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says, source:Thefly.com, summary: Biogen (BIIB) is consider... BIIB, JNJ",BIIB
39,2022-11-07,"Headline: Biogen Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.99% higher to $284.62 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: BIIB vs. RGEN: Which Stock Is the Better Value Option?, source:Yahoo, summary: BIIB vs. RGEN: Which Stock Is the Better Value Option?",BIIB
40,2022-11-08,"Headline: GREATMARK INVESTMENT PARTNERS, - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Biogen Third Quarter 2022 Earnings: Beats Expectations, source:Yahoo, summary: Biogen ( NASDAQ:BIIB ) Third Quarter 2022 Results Key Financial Results Revenue: US$2.51b (down 9.7% from 3Q 2021). Net..., Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. TTWO, ATVI, DD, LYFT, KSS, LEVI, HIMS, AMGN, SQ, WSM, NVDA, AAPL, GS, TWTR, BIIB, JNJ, SEDG, CTIC, TASK, RIDE, HNHPF, NSTG, RCM, MAPS, PLNT, TWOU, FIVN, NCLH, TRIP, Headline: Here’s Why Biogen (BIIB) Outperformed in the Quarter, source:Yahoo, summary: ClearBridge Investments, an investment management company, released its “ClearBridge Aggressive Growth Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy outperformed its benchmark index, Russell 3000 Growth Index, in the third quarter. The healthcare sector was the primary contributor to the strategy’s performance, while communication services detracted from […], Headline: Biogen Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.54% higher to $286.16 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",BIIB
41,2022-11-09,"Headline: Biogen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. shed 1.35% to $282.31 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Analysts Conflicted on These Healthcare Names: Biogen (BIIB), Apyx Medical (APYX) and Phathom Pharmaceuticals (PHAT), source:TipRanks, summary: Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (<a href..., Headline: Elliott Wave Technical Analysis: Biogen Inc. - Thursday, Nov. 10, source:TalkMarkets, summary: Looking for a clear three-wave move pullback before considering any long-term longs.",BIIB
42,2022-11-10,"Headline: Biogen names Viehbacher president, CEO, source:Thefly.com, summary: Biogen announced that its... BIIB, Headline: Biogen Names Former Sanofi Chief Christopher Viehbacher President, CEO >BIIB, source:MarketWatch, summary: By Colin Kellaher Biogen Inc. on Thursday said it named veteran pharmaceutical executive Christopher Viehbacher president and chief executive, capping a..., Headline: The Petri Dish: Biogen's CEO search stalls again; A setback for Verve, source:Yahoo, summary: The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.  Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.  Inhibikase slapped with clinical hold  The U.S. Food and Drug Administration has ordered a stop to a Phase 1 trial of a drug made by Inhibikase Therapeutics Inc. (Nasdaq: IKT), which has offices in Lexington., Headline: Biogen tabs veteran pharma leader Viehbacher as next CEO, source:Associated Press, The, summary: No summary, Headline: Seres Gets Closer To Good Times, source:SeekingAlpha, summary: After accepting the BLA for SER-109, the FDA has not announced the need for an expert advisory committee. Read more here., Headline: Biogen Names Christopher Viehbacher President and Chief Executive Officer, source:Yahoo, summary: Distinguished Industry Leader Brings Extensive International Experience in Large Pharmaceutical and Entrepreneurial Biotech Companies Christopher A. Viehbacher Christopher A. Viehbacher CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced that its Board of Directors has appointed Christopher A. Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14. Viehbacher succeeds Michel Vounatsos, who has l, Headline: UPDATE 2-Biogen names industry veteran Christopher Viehbacher as CEO, source:Yahoo, summary: Biogen Inc on Thursday tapped pharmaceutical industry veteran Christopher Viehbacher as its new chief executive, after a months-long search for a successor to Michel Vounatsos.  The appointment comes at a crucial time for the U.S. drugmaker as it grapples with intense competition for top-selling drugs and a rocky launch of its highly anticipated Alzheimer's disease drug Aduhelm.  Investors and analysts are now pinning hopes on the second Alzheimer's drug the company is developing with Japan's Eisai Co Ltd after it slowed the progress of the memory-robbing disease by 27% in a trial., Headline: Biogen names former Sanofi chief as new CEO, shares rise, source:Yahoo, summary: Biogen Inc. stock rose 1% in premarket trades on Thursday after Christopher A. Viehbacher was named president and chief executive officer and a member of the board, effective Nov. 14. Viehbacher succeeds CEO Michel Vounatsos, who has led the company since 2017. Biogen Chairman Stelios Papadopoulos said Viehbacher's innovation and understanding of the complexities of the pharma business enabled him to turn around Sanfoi when he was CEO and leave it a much better company. Vounatsos will be leaving, Headline: Biogen announces new CEO, source:Yahoo, summary: Biogen Inc. has finally announced a new CEO, six months after Michel Vounatsos said he would be stepping down., Headline: Biogen hires former Sanofi head Viehbacher as CEO, source:Reuters, summary: Biogen Inc on Thursday tapped former Sanofi boss Christopher Viehbacher as its new chief executive, betting on an industry veteran to help the U.S. drugmaker put behind it a series of setbacks for Alzheimer's drug Aduhelm., Headline: Biogen Names Christopher Viehbacher New CEO, source:Yahoo, summary: The veteran pharmaceutical executive takes charge after the failed launch of Biogen’s once-promising Alzheimer’s disease drug Aduhelm., Headline: Biogen Taps a New CEO. He Faces a Tough Road After Alzheimer’s Drug Failure., source:Yahoo, summary: Biogen's new CEO is Christopher Viehbacher, former head of French pharma giant Sanofi. Biogen faces challenges after the commercial failure of Alzheimer’s disease therapy Aduhelm., Headline: Biogen Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. rose 2.97% to $290.70 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up, source:Yahoo, summary: Ionis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates., Headline: Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles, source:Yahoo, summary: Biogen and Seagen tapped new CEOs on Thursday but the biotech stocks diverged following the long-anticipated announcements., Headline: Why Are Healthcare Stocks Down Today?, source:InvestorPlace, summary: Healthcare stocks are falling after a false tweet from a Twitter account impersonating Eli Lilly. Here's what this news means for investors.",BIIB
43,2022-11-11,"Headline: Here are three things to know about Biogen's new CEO, source:Yahoo, summary: Here's a few things to know about Christopher Viehbacher, the former Sanofi CEO who will soon step into the corner office at Biogen., Headline: Biogen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. dropped 0.43% to $289.45 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",BIIB
44,2022-11-13,"Headline: Last week's biggest management and board changes:  Kohl's, Biogen, adidas, source:Yahoo, summary: By Sarina Isaacs and Senad Karaahmetovic, Headline: Vertex: High Growth For Years Ahead, source:SeekingAlpha, summary: Vertex is the market leader company for Cystic Fibrosis disease. The company reports unexpected sales and earnings growth in recent quarters Q3., Headline: Why Is Cassava Sciences (SAVA) Stock Up Today?, source:InvestorPlace, summary: Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever., Headline: What You Missed On Wall Street On Monday, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. RHHBY, BIIB, LLY, DIS, AAPL, MRNA, AMD, HAS, NIO, BAC, GPN, AMZN, TSLA, GOOG, GOOGL, META, DSKE, FREY, CAN, AMC, RIDE, GOEV, BBBY, TSN, MNDY, TSEM, OTLY, PIII",BIIB
45,2022-11-14,"Headline: MorphoSys shares plunge after partner Roche says Alzheimer's drug trials didn't meet goals, source:MarketWatch, summary: German-listed shares of MorphoSys undefinedundefined lost a third of their value on Monday after its partner Roche said an Alzheimer drug trial failed. Roche..., Headline: Biogen price target raised to $315 from $300 at Oppenheimer, source:Thefly.com, summary: Oppenheimer analyst Jay O... BIIB, SNY, GSK, Headline: Steven Cohen's Top 5 Buys of t - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Biogen scarcity value goes up after Roche miss in Alzheimer's, says Jefferies, source:Thefly.com, summary: After Roche (RHHBY) repor... BIIB, RHHBY, ESALY, Headline: Stocks making the biggest moves in the premarket: Hasbro, Oatly, Advanced Micro Devices and more, source:CNBC, summary: The stocks making the biggest moves in premarket trading include Hasbro, Oatly, Advanced Micro Devices, and more., Headline: Needham Remains a Buy on Biogen (BIIB), source:TipRanks, summary: In a report released today, Ami Fadia from Needham maintained a Buy rating on Biogen (BIIB &#8211; Research Report), with a price target of $300.00. The company&#82..., Headline: SEEYOND's Top 5 Buys of the 3r - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Roche's Alzheimer's drug fails to meet goal in long awaited trial, source:Reuters, summary: Roche's Alzheimer's drug candidate could not be shown to markedly slow dementia progression in two drug trials, leaving rivals Biogen and Eisai as clear leaders in a high-stakes race to launch a treatment for the memory-robbing disease., Headline: Top 5 3rd Quarter Trades of Ma - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: U.S. stocks waver ahead of retail earnings week, source:Yahoo, summary: By Liz Moyer, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. BIIB, LLY, RHHBY, DIS, AAPL, OPNT, AMZN, TSLA, GOOG, GOOGL, WMT, META, AGEN, FREY, RIDE, GOEV, BBBY, TSN, MNDY, TSEM, OTLY, PIII, CAN, AMC, Headline: Biogen shares jump 4.7% premarket on hopes for its Alzheimer's treatment lecanemab, source:Yahoo, summary: Biogen Inc. shares rose 4.7% in premarket trade Monday, after MorphoSys and partner Roche said a trial of a treatment for Alzheimer's disease failed to meet its main goal. German-listed shares of MorphoSys fell 30% on the news, while Roche was down 4% in Zurich as the company said Phase 3 studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia did not meet their primary endpoint of slowing clinical decline. Biogen, which las, Headline: Stocks making the biggest moves midday: Oatly, Amazon, Hasbro and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Biogen Stock Leaps, Eli Lilly Gains As Roche Alzheimer's Drug Trial Falls Short, source:Yahoo, summary: ""While the (trial) results are not what we hoped, we are proud to have delivered a high quality, clear and comprehensive Alzheimer's dataset to the field,"" Roche said., Headline: One Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatments, source:MarketWatch, summary: Biogen stock is rising as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease., Headline: Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others, source:Yahoo, summary: Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled., Headline: S&P 500 struggles for direction as fed officials signal higher for longer rates, source:Yahoo, summary: By Yasin Ebrahim, Headline: Biogen in Pole Position After Roche’s Alzheimer’s Drug Disappoints, source:Yahoo, summary: Swiss pharmaceutical company Roche said the drug failed to slow patients' clinical decline, in contrast to positive results from Biogen earlier this year., Headline: Roche's Alzheimer drug failing was a tailwind for a Biogen rally, Mizuho's Salim Syed, source:CNBC, summary: Salim Syed, Mizuho senior biotech analyst, joins 'Closing Bell' to discuss Biogen stock ticking up after Roche's new Alzheimer's drug didn't meet its goals., Headline: Moderna, Biogen rise; Oatly, Dentsply fall, source:Associated Press, The, summary: No summary, Headline: Stock market today: Dow lower in choppy trade as Fed officials stress more hikes, source:Yahoo, summary: By Yasin Ebrahim, Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. rose 3.32% to $299.06 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers, source:Yahoo, summary: Earlier today, MorphoSys AG (NASDAQ: MOR) and its partner Roche Holdings AG (OTC: RHHBY) reported disappointing results from gantenerumab studies in mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia. Needham writes that with both GRADUATE studies failing to meet the primary endpoint, it removes a potential competitor for Eisai Ltd (OTC: ESALY) and Biogen Inc's (NASDAQ: BIIB) lecanemab. Roche's data was much awaited after Biogen and Eisai said the global Phase 3 con, Headline: One Alzheimer’s drug has failed, but investors are still betting on Biogen and Lilly treatments, source:Yahoo, summary: Biogen stock is rising as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease.",BIIB
46,2022-11-15,"Headline: Hedge Fund Point 72 Builds Position in These Stocks; Should You?, source:TipRanks, summary: Billionaire investor and hedge fund manager Steve Cohen’s Point 72 Asset Management has disclosed some interesting stakes in its September quarter holdings. A Form ..., Headline: Biogen Reaches Analyst Target Price, source:ETF Channel, summary: Staff article entitled Biogen Reaches Analyst Target Price, about ETFs, from ETF Channel., Headline: HealthCor Management, L.P. Buy - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Biogen price target raised to $350 from $265 at Truist, source:Thefly.com, summary: Truist analyst Robyn Karn... BIIB, RHHBY, Headline: Retailers Prepare for Another Reveal on Inflation. It’s Key Intelligence for the Fed., source:Yahoo, summary: Amazon.com is reportedly planning to cut about 10,000 workers, Berkshire Hathaway buys shares of Taiwan Semiconductor, Biden-Xi meeting adds to Chinese market optimism, crypto firms rush to calm fears, and other news to start your day., Headline: Roche (RHHBY) AD Study Failure Puts Spotlight on BIIB & Others, source:Yahoo, summary: Roche's (RHHBY) gantenerumab study for early Alzheimer's disease (AD) fails and puts focus on other companies like BIIB, LLY and PRTA., Headline: Biogen Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.24% higher to $299.78 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: Second Time Might Be the Charm for Alzheimer’s Blockbuster, source:Yahoo, summary: Biogen had been a sinking ship following its Alzheimer’s flop, but positive results in September have changed the company’s trajectory.",BIIB
47,2022-11-16,"Headline: Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm, source:Yahoo, summary: The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders., Headline: Biogen Inc. stock underperforms Wednesday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.08% higher to $300.01 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P...",BIIB
48,2022-11-17,"Headline: 3 Stocks to Avoid Right Now, source:Yahoo, summary: Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective., Headline: Is Biogen (BIIB) a Great Value Stock Right Now?, source:Yahoo, summary: Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks., Headline: Novartis (NVS) Reportedly Looking to Sell Its Business Units, source:Yahoo, summary: Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises., Headline: Biogen Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.68% higher to $302.05 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P...",BIIB
49,2022-11-18,"Headline: Teva Pharmaceutical: Warren Buffett Likely Made A Mistake Selling Shares, source:SeekingAlpha, summary: Teva Pharmaceutical was able to achieve a nationwide settlement to the opioid crisis, proving the ability of the company's management to overcome difficulties., Headline: Biogen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.28% higher to $302.89 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",BIIB
50,2022-11-21,"Headline: Teva names former Sandoz chief Richard Francis as new CEO, source:MarketWatch, summary: Teva Pharmaceutical Industries Ltd. undefined on Monday said its current CEO Kåre Schultz will retire on Dec. 31. Robert Francis, former CEO of Sandoz and an..., Headline: Teva hires ex-Novartis executive to succeed CEO Schultz, source:Reuters, summary: Teva Pharmaceutical on Monday appointed former Novartis and Biogen executive Richard Francis to succeed chief executive officer Kare Schultz who is due to retire later this year.",BIIB
51,2022-11-22,"Headline: We still think there's more room for biotech to go higher, says Jefferies' Yee, source:CNBC, summary: Michael Yee, Jefferies managing director, joins 'Power Lunch' to discuss what's behind the general move higher in biotech stocks, why biotech stocks were under-owned not long ago and if it's too late to 'nibble' on stocks in the sector.",BIIB
52,2022-11-23,"Headline: Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?, source:Yahoo, summary: Here is how AMN Healthcare Services (AMN) and Biogen Inc. (BIIB) have performed compared to their sector so far this year., Headline: Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer, source:Yahoo, summary: Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer., Headline: Biogen Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. shed 1.07% to $303.45 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: BIIB or RGEN: Which Is the Better Value Stock Right Now?, source:Yahoo, summary: BIIB vs. RGEN: Which Stock Is the Better Value Option?",BIIB
53,2022-11-24,"Headline: Why Is Biogen Inc. (BIIB) Up 8.2% Since Last Earnings Report?, source:Yahoo, summary: Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",BIIB
54,2022-11-25,"Headline: Why Is BioMarin (BMRN) Up 14.1% Since Last Earnings Report?, source:Yahoo, summary: BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",BIIB
55,2022-11-26,"Headline: Biogen Inc.'s (NASDAQ:BIIB) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?, source:Yahoo, summary: Biogen (NASDAQ:BIIB) has had a great run on the share market with its stock up by a significant 54% over the last three...",BIIB
56,2022-11-27,"Headline: Biogen Is Set to Release Data on Its New Alzheimer’s Drug. Here Are 5 Things to Watch., source:MarketWatch, summary: Until September, there was little reason to expect that the new treatment, called lecanemab, would work.",BIIB
57,2022-11-28,"Headline: Premarket Movers: Univar Solutions, Ansys, Wynn Resorts, source:MarketWatch, summary: With U.S. stock markets set to open in two hours, (UNVR) was up 10.6% in pre-market trading, and (WYNN) was up 5.9%. (SHOP), (SRPT), and (LVS) were all..., Headline: Stocks making the biggest moves in the premarket: Apple, Taboola, Biogen and more, source:CNBC, summary: The stocks making the biggest moves in premarket trading include Apple, Taboola, Biogen, and more., Headline: Apple, Chevron, Biogen fall premarket; Univar, Pinduoduo rise, source:Yahoo, summary: By Peter Nurse, Headline: 2 Stocks Near 52-Week Highs That Could Climb Higher, source:Yahoo, summary: Rising interest rates and a looming recession that those higher rates could cause are weighing heavily on stock prices across the board.  Shares of Biogen (NASDAQ: BIIB) have been on a roller coaster over the past couple of years.  The stock rocketed higher in 2021 after the FDA granted a highly controversial approval to the company's Alzheimer's disease drug, Aduhelm., Headline: Midday movers: Wynn Resorts, Biogen, Apple and more, source:Yahoo, summary: By Liz Moyer, Headline: Biogen Stock Slumps On Report of Death in Alzheimer's Drug Trial, source:Yahoo, summary: Science.org reported Sunday that a woman participating in the joint Bigoen-Eisai Clarity AD trial of an experimental Alzheimer's treatment has died of a brain hemorrhage., Headline: Stocks making the biggest moves midday: Apple, DraftKings, Biogen, Williams-Sonoma and more, source:CNBC, summary: These are the stocks posting the largest moves midday Monday, Nov. 28., Headline: Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall, source:Yahoo, summary: A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that some researchers link to the drug. Clinical trial death is the second thought associated with the lecanemab. STAT recently reported that an 80-year-old man in lecanemab's phase 3 trial died of a brain hemorrhage linked to the possible interaction between the experimental antibody and the blood thinne, Headline: Biogen Is Set to Release Data on Its New Alzheimer’s Drug. Here Are 4 Things to Watch., source:Yahoo, summary: Until September, there was little reason to expect that the new treatment, called lecanemab, would work., Headline: Axsome Hits The Stratosphere On Alzheimer's News As Biogen Faces A Setback, source:Yahoo, summary: Axsome Therapeutics said its Alzheimer's treatment met the goals of a Phase 3 study, sending AXSM stock into the stratosphere., Headline: US STOCKS-Wall St losses limited as Amazon gains on upbeat Cyber Monday, source:Yahoo, summary: Wall Street's main indexes fell on Monday amid worries about protests in major Chinese cities against strict COVID-19 policies, although gains in Amazon helped limit losses as Cyber Monday sales were set for a record.  Shares of the e-commerce giant rose 2% following an industry report that spending on Cyber Monday, the biggest U.S. online shopping day, might go as high as $11.6 billion, encouraged by some of the biggest discounts and deals to attract inflation-wary consumers., Headline: What to know about the Alzheimer’s drug data coming out this week, source:MarketWatch, summary: Eisai plans to share additional data about the Alzheimer’s disease treatment it's developing with Biogen this week., Headline: Biogen Stock Drops After Report of Patient Death, source:Yahoo, summary: Biogen shares are down 3.7% on Monday morning, making the stock the second-worst performer in the S 500. [Science](https://www.science.org/content/article/second-death-linked-potential-antibody-treatment-alzheimer-s-disease) on Sunday [reported](https://www.wsj.com/livecoverage/stock-market-news-today-11-28-2022/card/stocks-to-watch-apple-wynn-resorts-disney-CwtsIjxRS3HMm4KtVe8C?page=1) that a woman receiving Biogen’s experimental Alzheimer's drug lecanemab had died from a brain hemorrhage. It i, Headline: Biogen Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. shed 4.34% to $291.90 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Dementia/Biogen: causal controversy means investors must take a stance, source:Yahoo, summary: Dementia drug candidates still have one of the highest failure rates in clinical development — 97 per cent according to one study.  Shares in Biogen fell 4.5 per cent on Monday after the website Science reported the early death of an Alzheimer’s disease patient participating in trials of lecanemab.  The US biotech has been developing the treatment with Eisai of Japan., Headline: US STOCKS-Wall Street drops, weighed down by Apple and China worries, source:Yahoo, summary: US STOCKS-Wall Street drops, weighed down by Apple and China worries, Headline: Eisai shares fall following report of patient death in Alzheimer’s trial, source:MarketWatch, summary: Eisai Co.'s shares fell Tuesday following a report that a woman died after receiving the company's experimental Alzheimer's drug., Headline: Eisai shares plunge 10% in Tokyo after report of death in Alzheimer's trial, source:Yahoo, summary: Shares in Japanese drugmaker Eisai Co headed for their biggest plunge in more than a year on Tuesday after a report that a woman  in a trial of the company's Alzheimer's disease treatment died.  A woman receiving lecanemab, an experimental drug developed by Eisai and its U.S. partner Biogen Inc, recently died from a brain haemorrhage, research paper publisher Science.org reported on Sunday.  Eisai's shares sank 10% to 8,595 yen, leading decliners on the benchmark Nikkei index, which slid 0.5% in the morning session., Headline: Eisai, Biogen Plunge After Report of Second Death in Groundbreaking Alzheimer’s Drug Trial, source:Yahoo, summary: (Bloomberg) -- Eisai Co shares fell the most in about 16 months following a report of a second death potentially linked to the groundbreaking experimental drug for Alzheimer’s disease it’s developing with Biogen Inc.Most Read from BloombergApple to Lose 6 Million iPhone Pros From Tumult at China PlantNext Covid-19 Strain May be More Dangerous, Lab Study ShowsThere’s a Job-Market Riddle at the Heart of the Next RecessionStocks Hit by Fedspeak as China Woes Boost Havens: Markets WrapThe case invol, Headline: Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug, source:Yahoo, summary: Just weeks ago at the company’s headquarters, Haruo Naito, the 74-year-old chief executive of Japan’s Eisai, was feeling vindicated after almost four decades of trying to develop an Alzheimer’s drug.  Ahead of the release of detailed information on Eisai’s new drug lecanemab, developed with Biogen, the company’s share price surged 60 per cent after results of a late-stage clinical trial showed that it slowed the progression rate of the memory-degenerating disease.  Initial results published by Eisai in September raised hopes of a new treatment for a disease that pharmaceutical companies have spent billions of dollars over several decades researching, only to be disappointed by repeated failures.",BIIB
58,2022-11-29,"Headline: UPDATE 1-Eisai shares plunge in Tokyo after report of death in Alzheimer's trial, source:Yahoo, summary: Shares in Japanese drugmaker Eisai Co fell more than 6% on Tuesday after a report that a woman in a trial of the company's Alzheimer's disease treatment died.  A woman receiving lecanemab, an experimental drug developed by Eisai and its U.S. partner Biogen Inc, recently died from a brain haemorrhage, research paper publisher Science.org reported on Sunday.  Eisai's shares sank 6.2% to 8,988 yen, leading decliners on the benchmark Nikkei index, which closed 0.5% lower., Headline: Eisai shares plunge in Tokyo after report of death in Alzheimer's trial, source:Reuters, summary: Shares in Japanese drugmaker Eisai Co fell more than 6% on Tuesday after a report that a woman in a trial of the company's Alzheimer's disease treatment died., Headline: Japanese drugmaker Eisai's shares drop on report of death in Alzheimer's trial, source:Reuters, summary: Shares in Japanese drugmaker Eisai Co fell more than 6% on Tuesday after a report that a woman who was enrolled in a trial of the company's Alzheimer's disease treatment had died from brain haemorrhage., Headline: FOCUS-Rare success for Alzheimer's research unlocks hope for future therapies, source:Yahoo, summary: The first big breakthrough in 30 years of Alzheimer’s research is providing momentum for clinical trials of “cocktail” treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives.  The finding validates the theory that clearing the amyloid protein that forms clumps in the brains of Alzheimer’s patients could slow or halt the disease and has strengthened the support from some scientists for simultaneously targeting another notorious protein linked to Alzheimer's: tau.  Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco., Headline: Biogen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 0.17% to $291.41 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Biogen (BIIB) Down on Report of Death in Alzheimer's Study, source:Yahoo, summary: Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies., Headline: It’s Crunch Time for Biogen Stock. Data on Alzheimer’s Trial Are Due Tonight., source:Yahoo, summary: Japan's Eisai , which is developing the treatment with the U.S. pharmaceutical company, said in a September press release that the therapy worked surprisingly well., Headline: A new Alzheimer's treatment may help some patients, though researchers say more safety data is needed, source:MarketWatch, summary: A new study found that Eisai and Biogen's experimental Alzheimer’s drug moderately reduced cognitive decline after a year and a half., Headline: ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE, source:Yahoo, summary: Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (col, Headline: EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE, source:Yahoo, summary: Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (col, Headline: New Alzheimer’s Drug Shows Positive Results but Side Effects, source:Yahoo, summary: The drug from Eisai and Biogen slowed cognitive decline in study volunteers, but many had brain bleeds, swelling or other side effects., Headline: Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focus, source:Reuters, summary: An experimental Alzheimer's disease drug from Eisai and Biogen slowed cognitive decline in a closely-watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday., Headline: A new Alzheimer’s treatment may help some patients, though researchers say more safety data is needed, source:Yahoo, summary: A new study found that Eisai and Biogen's experimental Alzheimer’s drug moderately reduced cognitive decline after a year and a half., Headline: Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors, source:Yahoo, summary: Biogen stock was muted late Tuesday after Eisai unveiled Alzheimer's treatment results likely to spark a debate over the drug's benefits., Headline: Biogen's new Alzheimer's drug slows cognitive decline: study, source:Yahoo, summary: The new Alzheimer's disease drug made by Eisai Inc. and Biogen Inc. is capable of slowing cognitive decline by 27%, as confirmed by a peer-reviewed study., Headline: Biogen shares hit one-year high on new Alzheimer's drug data, source:Yahoo, summary: The new Alzheimer's disease drug made by Eisai Inc. and Biogen Inc. is capable of slowing cognitive decline by 27%, as confirmed by a peer-reviewed study., Headline: UPDATE 1-Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focus, source:Yahoo, summary: An experimental Alzheimer's disease drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday.  The companies said in September that the 18-month trial, which enrolled nearly 1,800 participants with early-stage Alzheimer's, found that treatment with lecanemab reduced the rate of decline on a clinical dementia scale (CDR-SB) by 27% compared to a placebo.  ""All of these amyloid-lowering drugs carry a risk for increased brain hemorrhage,"" said Dr. Ronald Petersen of the Mayo Clinic in Rochester, Minnesota., Headline: Biogen and Eisai’s Alzheimer’s Data Confirm Benefit. Questions Still Loom., source:Yahoo, summary: Japan's Eisai, which is developing the treatment with the U.S. pharmaceutical company, said in a September press release that the therapy worked surprisingly well., Headline: Dow ends over 700 points higher to exit bear market after Powell signals smaller interest-rate hikes ahead, source:MarketWatch, summary: U.S. stocks finished sharply higher Wednesday after Fed Chair Powell said the central bank's pace of interest-rate increases can slow as soon as its December...",BIIB
59,2022-11-30,"Headline: Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focus, source:Reuters, summary: An experimental Alzheimer's drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of serious side effects for certain patients, according to detailed data presented on Tuesday., Headline: Stocks making the biggest moves premarket: Hormel, Petco, CrowdStrike and more, source:CNBC, summary: These are the stocks posting the largest moves before the bell., Headline: Workday, Boeing, Tesla and Airbnb rise premarket; Crowdstrike falls, source:Yahoo, summary: By Peter Nurse, Headline: Stocks Nudge Higher, Powell, Bankman-Fried, Biogen, HPE in Focus -Five Things To Know, source:Yahoo, summary: Stock futures nudge higher will Powell, jobs data in focus; Powell speech may challenge Fed's new rate hike outlook; Sam Bankman-Fried set for DealBook summit appearance after FTC collapse; Biogen shares jump after promising Alzheimer's treatment data and HPE shares surge after Q4 earnings beat, solid near-term outlook., Headline: Biogen Stock Gains On Promising Final Data From Alzheimer's Drug Trial, source:Yahoo, summary: ""These peer-reviewed, published results show lecanemab will provide patients more time to participate in daily life and live independently,"" the Alzheimer's Association said., Headline: Biogen stock up 3% premarket after update on Alzheimer's treatment; Stifel reiterates buy rating, source:Yahoo, summary: Biogen Inc. stock rose 3% in premarket trade Wednesday, after a new study was unveiled late Tuesday that showed the company's experimental Alzheimer's drug being developed with Japan's Eisai moderately reduced cognitive decline after a year and a half. The study assessing lecanemab as a treatment for people with early forms of Alzheimer's disease was published Tuesday night by the New England Journal of Medicine. Eisai also presented the full findings from the trial on Tuesday night at the Clini, Headline: Pharma Stocks Rise on Alzheimer’s Breakthrough  Despite Side-Effect Concerns, source:Yahoo, summary: Shares in pharmaceutical companies rose after the publication of a paper detailing the apparent benefits of lecanemab., Headline: US STOCKS-Futures rise as focus turns to Powell speech, source:Yahoo, summary: U.S. stock index futures edged higher on Wednesday, with those of the Nasdaq rising the most on gains in Tesla shares, while investors treaded cautiously ahead of comments from Federal Reserve Chair Jerome Powell later in day.  Powell's speech will be closely watched for signs of a slowdown in the pace of interest rate hikes by the central bank as well as to assess the general health of the U.S. economy.  ""Fed Chair Powell is speaking, but past comments have done little other than chant 'hike, hike, hike',"" said Paul Donovan, chief economist, UBS Global Wealth Management., Headline: Alzheimer’s Breakthrough Is Boost for Biogen, Eli Lilly Despite Side-Effect Concerns, source:Yahoo, summary: Shares in pharmaceutical companies rose after the publication of a paper detailing the apparent benefits of the lecanemab drug., Headline: Stocks making the biggest moves midday: CrowdStrike, Horizon Therapeutics, Petco and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Biogen Surges on Alzheimer's Drug News: How to Play the Stock, source:Yahoo, summary: Trading volume has picked up in the past three months to help confirm the price gains.  The math-driven On-Balance-Volume (OBV) line shows a rising pattern from June telling us that buyers of the stock have been more aggressive than sellers.  Yes, the OBV line can lead prices!, Headline: Biogen's (BIIB) Lecanemab Shows Benefit but With Side Effects, source:Yahoo, summary: Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of cognitive decline but is associated with adverse events like brain hemorrhage., Headline: Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's, source:Yahoo, summary: According to detailed data, Eisai Limited (OTC: ESALY) and Biogen Inc's (NASDAQ: BIIB) closely watched trial of an experimental Alzheimer's drug slowed cognitive decline but may carry a risk of side effects for certain patients. Lecanemab was associated with a type of brain swelling in 12.6% of trial patients, a side effect previously seen with similar drugs. 17.3% of patients had microhemorrhages in the brain— a symptom linked to two recent deaths of people receiving lecanemab in a follow-on st, Headline: Big Alzheimer’s News for Biogen Just Landed. The Company Didn’t Get a Mention., source:Yahoo, summary: Japan's Eisai presented full data on a new Alzheimer's drug, but without mentioning the U.S. pharmaceutical company, its partner on the treatment., Headline: Biogen Stock Surges As New Drug Offers 'Meaningful Change' For Alzheimer's Patients, source:Yahoo, summary: ""These peer-reviewed, published results show lecanemab will provide patients more time to participate in daily life and live independently,"" the Alzheimer's Association said., Headline: 5 things to know about the new Alzheimer’s drug — including why it may be risky for people who take blood thinners, source:Yahoo, summary: Results of clinical trial point to a stable future for Eisai and Biogen's lecanemab once the therapy is approved by the Food and Drug Administration., Headline: Health Care Up as Biogen, Horizon Surge -- Health Care Roundup, source:MarketWatch, summary: Health-care companies rose as traders rotated into sectors less sensitive to the vagaries of economic growth. Biogen shares surged after the biotech giant's..., Headline: Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate, source:Yahoo, summary: Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD). William Blair analyst says that overall the data is robust and of high impact to both the AD clinician community and regulators and CMS as the next three to nine months carry critical regulatory and reimbursement milestones for the anti-amyloid therapy drug class. Related: Open Questions On Safety Lingers After Eisai-B, Headline: Newest Alzheimer’s Drugs Take Large but Fraught Step Toward Approval, source:Yahoo, summary: Positive study results for Eisai-Biogen lifted the prospects for its medication and one from Eli Lilly—although regulators will have to weigh risks., Headline: Eisai, Biogen Alzheimer's drug could be available to some next year, source:Reuters, summary: Japan's Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients..., Headline: Lecanemab And Alzheimer's: More Data, source:SeekingAlpha, summary: Lecanemab, developed by Eisai and Biogen as anti-amyloid antibody therapy for Alzheimerâs, shows strong numbers in its latest trial. But will the drug really make a difference in treatment?",BIIB
60,2022-12-01,"Headline: Lilly said its Alzheimer's drug clears more amyloid plaque than Aduhelm, source:MarketWatch, summary: Eli Lilly & Co. undefined said Wednesday night that its experimental Alzheimer's treatment did a better job at clearing amyloid plaque than Eisai and..., Headline: Lilly's (LLY) Donanemab Betters Biogen's Alzheimer's Drug, source:Yahoo, summary: Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after six months., Headline: Protecting Patients from Climate Risks: A Conversation with Frontline Health Clinics on Resources, source:Yahoo, summary: After a year of more frequent climate-induced extreme weather, the Center for Climate, Health, and the Global Environment at Harvard T.H., Headline: Repligen (RGEN) Up 4.3% Since Last Earnings Report: Can It Continue?, source:Yahoo, summary: Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: Biogen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slid 1.09% to $301.85 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Biogen Inc. (BIIB) 5th Annual Evercore ISI HealthCONx Conference 2022 - (Transcript), source:SeekingAlpha, summary: Biogen Inc. (NASDAQ:NASDAQ:BIIB) 5th Annual Evercore ISI HealthCONx Conference Call December 1, 2022 10:30 A.M.",BIIB
61,2022-12-02,"Headline: Here's how one hedge fund is going aginst the grain and beating the markets, source:MarketWatch, summary: This fund is crushing it. Here are its top 5 stock picks, Headline: Why Shares of Vaxxinity Soared This Week, source:Yahoo, summary: Positive news regarding a different company's Alzheimer's treatment may have helped Vaxxinity., Headline: Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal, source:Yahoo, summary: Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout., Headline: BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns, source:SeekingAlpha, summary: BBH has an asset base of $520 million, posted strong growth over the past 6 months, and is trading much higher than its pre-pandemic price range. Click here to learn more., Headline: Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue?, source:Yahoo, summary: Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: Biogen Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. sank 0.98% to $298.90 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",BIIB
62,2022-12-03,"Headline: Is Anavex Life Sciences a Smart Stock to Buy Now?, source:Yahoo, summary: Shares of clinical-stage biotechnology company Anavex Life Sciences (NASDAQ: AVXL) recently shot higher.  Investors reacting to great news for its Alzheimer's disease drug candidate, blarcamesine, drove the stock about 40% higher when the market opened on Friday, Dec. 2.  Is Anavex Life Sciences a smart stock to buy now, or will the road ahead be a rocky one full of potholes?",BIIB
63,2022-12-04,"Headline: Is Biogen Stock a Buy Now?, source:Yahoo, summary: Thanks to well-received clinical trial data for its investigational Alzheimer's therapy, lecanemab, shares of Biogen (NASDAQ: BIIB) are up by more than 51% in the past three months -- and the company hasn't even made a single dollar from the positive findings yet.  Including lecanemab, Biogen has a dozen programs in late-stage clinical trials, all but four of which are being developed for indications in neurology.  Its areas of focus within neurology are Alzheimer's disease and Parkinson's disease, though it also has a trio of programs for multiple sclerosis (MS) in development., Headline: Can These 2 Stocks Crush the Market Again in 2023?, source:Yahoo, summary: The list includes Regeneron Pharmaceuticals (NASDAQ: REGN) and Biogen (NASDAQ: BIIB).  Regeneron was having an unimpressive year on the stock market until its shares soared by double-digit percentages in one day in September.  As is often the case with biotechs, Regeneron owes this move to positive clinical developments.",BIIB
64,2022-12-05,"Headline: Biogen: EMA to Review Tofersen in Rare Form of ALS >BIIB, source:MarketWatch, summary: By Colin Kellaher Biogen Inc. on Monday said the European Medicines Agency has accepted its application seeking approval of tofersen for a rare, genetic form..., Headline: European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS, source:Yahoo, summary: SOD1-ALS is a rare, genetic form of ALS,1 comprising approximately 2% of people with ALS2If approved, tofersen would be the first treatment to target a genetic cause of ALS CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for review of tofersen, an investigational drug for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-AL, Headline: Biogen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slipped 2.06% to $292.75 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: Johnson & Johnson: Alzheimer's Disease Pipeline Could Dominate, source:SeekingAlpha, summary: JNJ selected a vaccine to take to Phase 3. Another rival amyloid beta antibody could appear on the market next year. Click here to read more.",BIIB
65,2022-12-06,"Headline: Biogen and Sage Zuranolone Webcast Presentation, source:SeekingAlpha, summary: The following slide deck was published by Biogen Inc., Headline: Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression, source:Yahoo, summary: CAMBRIDGE, Mass., December 06, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a rapid-acting, once-daily, 14-day oral short course treatment in adults with MDD and PPD. The submission, Headline: Biogen Inc. (BIIB) Biogen and Sage Zuranolone Webcast Transcript, source:SeekingAlpha, summary: Biogen Inc. (NASDAQ:NASDAQ:BIIB) Biogen and Sage Zuranolone Webcast December 6, 2022 8:00 AM ET Company Participants Helen Rubinstein â Director-Investor Relations-Sage Therapeutics Chris..., Headline: Alzheimer’s Treatment Thrills Investors as Doctors Debate Effect, source:Yahoo, summary: The data presented for Eisai and Biogen’s drug wasn’t convincing enough to settle a debate among experts, but investors are betting on commercial success anyway., Headline: Anavex Life Sciences: The Little Company That Did, source:SeekingAlpha, summary: Anavex likely has an effective treatment for early Alzheimer's disease. Click here to read our analysis of AVXL stock., Headline: Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe, source:Yahoo, summary: Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe., Headline: Biogen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. shed 0.44% to $291.47 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: 3 Biotech Stocks Aiming to Reinvent Mental Health Treatment, source:Yahoo, summary: Atai, Biogen, and Sage are working to develop new treatments for mental illness.",BIIB
66,2022-12-07,"Headline: Biogen-funded Climate Toolkit for Health Clinics Formally Launched, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / December 7, 2022 / Biogen: Thousands of U.S. community health centers that care for uninsured or underinsured patients around the U.S. face an increasing number of systemic challenges due to extreme weather as a result ..., Headline: Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression, source:Yahoo, summary: Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST., Headline: Why 2023 Could Be a Big Year for Biogen, source:Yahoo, summary: Biogen (NASDAQ: BIIB) is a business that generates more than $10 billion in revenue each year, with its multiple sclerosis treatments bringing in the bulk of its sales.  With the company's sales declining in recent years, Biogen needs a catalyst to turn things around and help inject some bullishness behind the business, and having an effective treatment for Alzheimer's could play a huge role in that objective.  Next year could prove to be a pivotal one for Biogen as investors can finally get some much-needed answers about whether lecanemab, a promising Alzheimer's treatment, could be the game changer the healthcare company is hoping that it will be for the business., Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.23% higher to $292.15 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the Dow..., Headline: Biogen, Eisai prompt Medicare to reevaluate Alzheimer`s coverage after new data, source:Seeking Alpha, summary: No summary",BIIB
67,2022-12-08,"Headline: Zacks Investment Ideas feature highlights: ATAI Life Sciences, Biogen and Sage, source:Yahoo, summary: ATAI Life Sciences, Biogen and Sage have been highlighted in this Investment Ideas article., Headline: See How Biogen Ranks Among Analysts` Top Picks With Strong Buyback Activity, source:The Online Investor, summary: No summary, Headline: Is Biogen (BIIB) Stock Undervalued Right Now?, source:Yahoo, summary: Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks., Headline: Why Is Mirati (MRTX) Down 19.9% Since Last Earnings Report?, source:Yahoo, summary: Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: Biogen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slipped 1.04% to $289.10 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",BIIB
68,2022-12-09,"Headline: Biogen announces FDA accepted for review the aBLA for BIIB800, source:Thefly.com, summary: No summary, Headline: Biogen granted FDA review for Actemra biosimilar, source:Seeking Alpha, summary: No summary, Headline: Biogen: FDA Accepts Application for Actemra Biosimilar >BIIB, source:MarketWatch, summary: By Colin Kellaher Biogen Inc. on Friday said the U.S. Food and Drug Administration has accepted its application seeking approval of BIIB800, a proposed..., Headline: Biogen (BIIB) Investor Presentation - Slideshow, source:SeekingAlpha, summary: The following slide deck was published by Biogen Inc., Headline: New Alzheimer`s drug appears to slow cognitive decline but is ���not a breakthrough`, source:MarketWatch, summary: No summary, Headline: New Alzheimer’s drug appears to slow cognitive decline but is ‘not a breakthrough’, source:MarketWatch, summary: Lecanemab, the drug being tested by Biogen and Eisai, was found to have a modest benefit to patients in a Phase 3 study., Headline: IN BRIEF: Biogen gets FDA review of biosimilar to Actemra, source:Alliance News, summary: No summary, Headline: FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab), source:Yahoo, summary: CAMBRIDGE, Mass., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced that the U.S. Food and Drug Administration (FDA) has accepted for review the abbreviated Biologics License Application (aBLA) for BIIB800, a biosimilar candidate referencing ACTEMRA®1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody. ACTEMRA® is indicated for several indications, including moderate to severe rheumatoid arthritis in adults as well as juvenile idiopathic polyarthritis and sy, Headline: Biogen Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slid 1.29% to $285.37 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: BIIB vs. TECH: Which Stock Is the Better Value Option?, source:Yahoo, summary: BIIB vs. TECH: Which Stock Is the Better Value Option?, Headline: Medicare Part B Premiums Could Be Lower in 2023 – Here’s Why, source:Yahoo, summary: Seniors in the United States haven't had much to cheer about this year, with inflation running well ahead of the 2022 Social Security cost-of-living adjustment and spiraling healthcare costs cutting..., Headline: Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed the most recent trading day at $285.37, moving -1.29% from the previous trading session., Headline: Sage Therapeutics: Zuranolone NDA Near-Term Tailwind, source:SeekingAlpha, summary: Sage's collaboration with Biogen looks to be building momentum around zuranolone. Read more to see why we think there is market potential in SAGE stock.",BIIB
69,2022-12-11,"Headline: Among the Best-Managed Companies of 2022, Some Warning Signs, source:Yahoo, summary: These companies score well overall in the WSJ Management Top 250. But there are red flags in at least one area.",BIIB
70,2022-12-12,"Headline: Frontage partners with Eisai, Biogen to complete the Clarity AD study, source:Thefly.com, summary: No summary, Headline: Pfizer: The Best Long-Term Investment Setup Since 2009, source:SeekingAlpha, summary: Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high. Read more on PFE stock here., Headline: Biogen Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. rallied 1.83% to $290.59 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: CSL appoints current COO Paul McKenzie CEO, replacing Paul Perreault, source:Alliance News, summary: No summary",BIIB
71,2022-12-13,"Headline: Sage Therapeutics Could Be In For A Depressing FDA Review, source:SeekingAlpha, summary: Sage Therapeutics completed its rolling submission to the FDA for zuranolone, a better formulation of its marketed postpartum drug. See why SAGE stock is a Hold., Headline: AbbVie: Clouds Keep Thickening Due To Lack Of Revolutionary Drugs, source:SeekingAlpha, summary: Humira's international sales were $603 million in Q3 2022, down 25.7% year-over-year. Read more on how AbbVie is facing a lack of revolutionary drugs., Headline: 15 Best S&P 500 Stocks That Don’t Pay Dividends, source:Yahoo, summary: In this article, we will be taking a look at the 15 best S&P 500 stocks that don’t pay dividends. To skip our detailed analysis of these stocks and the performance of the S&P 500 so far this year, you can go directly to see the 5 Best S&P 500 Stocks That Don’t Pay Dividends. […], Headline: Biogen Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.22% higher to $291.24 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: Biogen: A Comprehensive Look At The Clarity AD Study Results, source:SeekingAlpha, summary: Pivotal trial data suggest that lecanemab offers similar modest clinical benefits and safety risks as Aduhelm. Results may have been affected by bias. Click here to read more.",BIIB
72,2022-12-14,"Headline: Eli Lilly (LLY) 2023 Guidance Falls Short, Stock Declines, source:Yahoo, summary: Eli Lilly's (LLY) 2023 EPS guidance falls short of the Zacks Consensus Estimates and our model estimates. The company plans to launch four new drugs next year., Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. sank 0.75% to $289.05 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",BIIB
73,2022-12-15,"Headline: Cassava Sciences: Not Betting On This Moon Shot, source:SeekingAlpha, summary: Cassava Sciences' stated mission is to detect and treat Alzheimer's disease. See why I am passing on any investment recommendation around SAVA stock., Headline: Biogen Inc. stock falls Thursday, still outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 1.94% to $283.44 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index..., Headline: Biogen Inc. (BIIB) Stock Moves -1.94%: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed at $283.44 in the latest trading session, marking a -1.94% move from the prior day., Headline: Primecap Odyssey Funds` 2022 Annual Shareholder Letter, source:GuruFocus, summary: No summary",BIIB
74,2022-12-16,"Headline: Eating these simple foods may slow Alzheimer`s by a third, source:MarketWatch, summary: No summary, Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.54% higher to $284.98 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",BIIB
75,2022-12-18,"Headline: IBBQ: Healthcare Dashboard For December, source:SeekingAlpha, summary: The pharmaceuticals/biotechnology subsector has good value and quality scores. Click here to read more about IBBQ ETF., Headline: Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock, source:Yahoo, summary: The bear market has weighed on stocks across industries this year.  Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX) have both climbed in the double digits -- and for good reason.  Which one of these top stocks represents the better bear market buy right now?, Headline: Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move, source:Yahoo, summary: Vertex Pharmaceuticals (NASDAQ: VRTX) is the global leader in cystic fibrosis (CF) treatments.  Vertex's latest CF drug, Trikafta, still has plenty of revenue growth ahead.  Instead, it has to do with Vertex's candidate for blood disorders, exa-cel -- a one-time curative treatment for two blood disorders with limited treatment options today., Headline: The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond, source:Yahoo, summary: Major indices such as the S&P 500 and the Nasdaq Composite may have plunged by double-digits during 2022, but certain areas of the stock market performed strongly throughout the year. One of those areas is among the hottest healthcare stocks. With company-specific catalysts outweighing negative macro factors such as high inflation, rising interest rates, and slowing economic growth, scores of healthcare stocks have delivered strong returns in 2022. However, far from a “one and done” phenomenon,, Headline: Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Biogen (BIIB), source:TipRanks, summary: No summary",BIIB
76,2022-12-19,"Headline: Biogen reaches agreement with Genentech related to glofitamab commercialization, source:Thefly.com, summary: No summary, Headline: Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration, source:Yahoo, summary: Glofitamab is an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 in development for B-cell non-Hodgkin’s lymphoma and other blood cancers CAMBRIDGE, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that it has reached an agreement with Genentech, a member of the Roche Group, related to the commercialization and sharing of economics for glofitamab. Under the terms of the agreement, Biogen will have no payment obligations and will receive tie, Headline: Biogen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slid 0.21% to $284.38 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Mizuho Securities Remains a Buy on Biogen (BIIB), source:TipRanks, summary: No summary",BIIB
77,2022-12-20,"Headline: Top Net Payout Yields - December 2022, source:SeekingAlpha, summary: The top net payout yield stock failed to match the total return of the S&P 500 during 2H' 22 as tech stocks soared. Check out our list of stocks., Headline: Biogen Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. rose 1.10% to $287.51 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...",BIIB
78,2022-12-21,"Headline: Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer`s Disease, source:TalkMarkets, summary: No summary, Headline: Top Biotech Companies Are Making Steady Progress In The Fight Against Alzheimer`s Disease, source:TalkMarkets, summary: No summary, Headline: Top Biotech Companies Are Making Progress In The Fight Against Alzheimer`s Disease, source:TalkMarkets, summary: No summary, Headline: How Well Does Anavex`s New Alzheimer`s Drug Compare Against Biogen`s New Drug?, source:Seeking Alpha, summary: No summary, Headline: How Well Does Anavex's New Alzheimer's Drug Compare Against Biogen's New Drug?, source:SeekingAlpha, summary: The Phase 2b/3 trial of Anavex's Blarcamesine demonstrates major, statistically significant effects in slowing Alzheimer's Disease. Read more here., Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 0.23% to $286.86 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed at $286.86 in the latest trading session, marking a -0.23% move from the prior day., Headline: PureTech Provides End of Year Report on Key Progress, source:Business Wire, summary: No summary",BIIB
79,2022-12-22,"Headline: Biogen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slipped 2.18% to $280.61 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500..., Headline: Biogen's Alzheimer's Antibody Might Have A Third Death Associated With, source:Yahoo, summary: A third death is supposedly linked with Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's antibody, lecanemab. Science has obtained medical records showing that a 79-year-old Florida woman participating in an ongoing antibody trial died in mid-September after experiencing extensive brain swelling, bleeding, and seizures. Treatment with lecanemab reduced clinical decline on the global cognitive and functional scale by 27% at 18 months, relative to the placebo, which was the primary endpoint, Headline: EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA, source:Yahoo, summary: Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that Eisai has initiated submission of data for Biologics License Application (BLA) to the National Medical Products Administration (NMPA) of China for lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody., Headline: A Deadly Legacy Raises the Stakes in the War Over Fast Drug Approvals, source:Yahoo, summary: (Bloomberg) -- For years, a family tree spanning two pages of blueprint paper gathered dust at the back of Cynthia Weber’s closet. Going back to a family matriarch born in 1812, it detailed the relationships and causes of death of more than 350 ancestors. It wasn’t packed away because the family had forgotten about it. Nobody wanted to look at it. Two of Weber’s great grandfather’s cousins died in their 20s, her uncle died at 30, her fourth cousin succumbed at just 25. Three capital letters are, Headline: Biogen and Eisai submit BLA data for lecanemab in China, source:Alliance News, summary: No summary, Headline: Third trial death tied to Biogen and Eisai Alzheimer`s drug, Science reports, source:Thefly.com, summary: No summary",BIIB
80,2022-12-23,"Headline: Stocks making the biggest moves premarket: Tesla, Nutanix, Meta and more, source:CNBC, summary: These are the stocks posting the largest moves before the bell., Headline: Biogen/ Eisai deserve $30K price tag for new Alzheimer`s drug ��� Wells Fargo, source:Seeking Alpha, summary: No summary, Headline: Biogen`s Alzheimer`s Drug Could be Expensive, source:TipRanks, summary: No summary, Headline: New Alzheimer’s Drug Could Be Priced Up to $20,000 a Year: Group, source:Yahoo, summary: Essai and  Biogen  could price their new Alzheimer’s drug as high as $20,000 a year.  The Institute for Clinical and Economic Review, which issues recommendations on drug pricing, said that the drug Lecanemab would need to be priced between $8,500 and $20,600 per year to meet “traditional cost-effectiveness thresholds.”  The institute’s conclusions are preliminary., Headline: 1 Green Flag and 1 Red Flag for Biogen, source:Yahoo, summary: Biogen (NASDAQ: BIIB) is one of the biotech-industry's giants and success stories. At its peak in 2015, the company's market value topped $100 billion. And its annual revenue reached more than $14 billion at its highest, thanks to its blockbuster multiple sclerosis drugs., Headline: Eisai, Biogen's new Alzheimer's drug should be priced below Aduhelm - report , source:Reuters, summary: An influential drug pricing research group said Eisai Co Ltd and Biogen Inc's new Alzheimer's disease treatment lecanemab should be priced lower than the drug Aduhelm that was developed by the companies., Headline: Stocks making the biggest moves midday: Mission Produce, Nutanix, Alphabet, Tesla and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: 3 Nasdaq Stocks That Are Up 25% in 3 Months, source:Yahoo, summary: The Nasdaq Composite has plummeted 33% this year, but there are signs that for at least some stocks, brighter days could be on the horizon.  Entering this week, three Nasdaq stocks were up 25% in just the past three months.  Among the hottest buys of late are chipmaker Nvidia (NASDAQ: NVDA), and healthcare companies Biogen (NASDAQ: BIIB) and Gilead Sciences (NASDAQ: GILD)., Headline: Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma, source:Yahoo, summary: Following the FDA's approval, Roche (RHHBY) Lunsumio is the first CD20xCD3 T-cell engaging bispecific antibody approved to treat follicular lymphoma., Headline: UPDATE 1-Eisai, Biogen's new Alzheimer's drug should be priced below Aduhelm - report, source:Yahoo, summary: An influential drug pricing research group said Eisai Co Ltd and Biogen Inc's new Alzheimer's disease treatment lecanemab should be priced lower than the drug Aduhelm that was developed by the companies.  In a draft report released on Thursday, the Institute for Clinical and Economic Review (ICER) said a price range of between $8,500 and $20,600 annually for lecanemab would meet some commonly used thresholds for cost effectiveness.  Biogen halved the price of its first Alzheimer's drug Aduhelm last year to $28,200 for a person with average weight, amid tepid sales and reimbursement hurdles., Headline: Eisai, Biogen's new Alzheimer's drug should be priced below Aduhelm - report, source:Reuters, summary: An influential drug pricing research group said Eisai Co Ltd and Biogen Inc's new Alzheimer's disease treatment lecanemab should be priced lower than the drug Aduhelm that was developed by the companies., Headline: Biogen Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 0.52% to $279.16 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index..., Headline: Roche's Follicular Lymphoma Therapy Scores FDA Approval, source:Yahoo, summary: The FDA approved Roche Holding AG (OTC: RHHBY) unit Genentech's Lunsumio (mosunetuzumab-axgb) for relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate, making Lunsumio the first CD20xCD3 bispecific to be authorized for this form of non-Hodgkin lymphoma (NHL). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a",BIIB
81,2022-12-25,"Headline: Goldman Sachs highlights key healthcare themes for 2023, source:Seeking Alpha, summary: No summary, Headline: Acumen Pharmaceuticals: An Alzheimer`s `Lottery Ticket`, source:Seeking Alpha, summary: No summary, Headline: Acumen Pharmaceuticals: An Alzheimer's 'Lottery Ticket', source:SeekingAlpha, summary: Acumen Pharmaceuticals is an early-stage developmental concern focusing on development treatments for Alzheimer's. Click here to read ABOS' investment analysis.",BIIB
82,2022-12-26,"Headline: Biogen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary",BIIB
83,2022-12-27,"Headline: Biogen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: No summary",BIIB
84,2022-12-28,"Headline: Needham health/pharmaceuticals analysts hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Is Biogen's Stock Too Risky to Invest in?, source:Yahoo, summary: Healthcare company Biogen (NASDAQ: BIIB) has been a volatile one to invest in over the years, to put it mildly.  Sharp movements in the share price have been par for the course for Biogen because news about its Alzheimer's treatments has at different times created bullishness and bearishness.  Have things stabilized for Biogen, and is it a good buy right now, or is there still too much risk involved with the company?, Headline: The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock, source:Yahoo, summary: Investors are closely watching two Eli Lilly battles that will unfold in 2023 as LLY stock continues a fevered streak, tacking on new highs., Headline: Genentech wins approval of 1st 'chemo-light' bispecific blood cancer drug, source:Yahoo, summary: Another bispecific antibody — linking to two key players in the fight against cancer — could be approved by regulators as soon as this spring., Headline: Biogen Inc. (BIIB) Stock Moves -0.27%: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed at $274.04 in the latest trading session, marking a -0.27% move from the prior day., Headline: What You Missed On Wall Street On Thursday, source:Thefly.com, summary: No summary, Headline: Biogen Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: No summary",BIIB
85,2022-12-29,"Headline: BIIB February 2023 Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: The Petri Dish: Group eyes Biogen Alzheimer's drug price, FDA rejects psych drug application, source:Yahoo, summary: The FDA has elected not to accept a new drug application from Minerva Neurosciences Inc., sending shares plummeting. Read this, and more, in the latest biotech news roundup, The Petri Dish., Headline: House Committee says FDA interactions with Biogen` failed to follow` protocol, source:Thefly.com, summary: No summary, Headline: Biogen responds to Committee on Oversight, stands by `integrity` of actions, source:Thefly.com, summary: No summary, Headline: Biogen, FDA faulted in congressional inquiry into Alzheimer`s drug approval, source:Seeking Alpha, summary: No summary, Headline: Biogen`s Alzheimer`s Drug Likely To Be Approved With Warning Labels, source:Seeking Alpha, summary: No summary, Headline: Biogen's Alzheimer's Drug Likely To Be Approved With Warning Labels, source:SeekingAlpha, summary: A new as-yet-unreported death among those taking Biogen's Lecanemab in an extended post-Phase 3 study has emerged. Click to read my analysis of BIIB stock., Headline: US congressional report slams FDA approval of Biogen Alzheimer's drug, source:Alliance News, summary: No summary, Headline: FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer’s Drug, source:Yahoo, summary: Aduhelm’s approval followed an ‘atypical’ number of contacts between the agency and the company, a congressional report says., Headline: Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer's drug, source:Reuters, summary: The U.S. Food and Drug Administration failed to adhere to its own guidance and internal practices during the approval process for Biogen's Alzheimer's drug Aduhelm, which was ""rife with irregularities,"" a congressional report showed on Thursday., Headline: Congress faults US regulator’s approval of Biogen Alzheimer’s drug, source:Yahoo, summary: Two US congressional committees have accused the Food and Drug Administration of inappropriately collaborating with Biogen before approving the company’s Alzheimer’s drug.  A joint report by the House committees on Oversight and Reform, and Energy and Commerce accused the FDA of granting Aduhelm, Biogen’s Alzheimer’s drug, accelerated approval in 2021 despite an internal advisory committee’s refusal to issue a favourable recommendation, and concerns about the drug’s inconsistent clinical data., Headline: Congressional investigation reveals 'atypical,' 'inappropriate' collaboration between FDA, Biogen, source:Yahoo, summary: A report released by the House Energy and Commerce Committee paints a damning picture of the approval process for aducanumab, generically known as Aduhelm, the first Alzheimer's drug made by Biogen Inc. and Eisai Inc., Headline: Congress Targets FDA, Biogen on Alzheimer's Drug Approval, source:Yahoo, summary: A congressional report finds the FDA's approval process for Biogen's Alzheimer's treatment was 'rife with irregularities' that included 'atypical collaboration.', Headline: Catalyst watch: Tesla deliveries, CES reveals and healthcare updates lead off 2023, source:Seeking Alpha, summary: No summary, Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: No summary, Headline: Biogen (NASDAQ:BIIB) in Trouble Over Aduhelm Drug, source:TipRanks, summary: No summary, Headline: Eisai And Biogen`s Lecanemab: A Flawed Treatment For Alzheimer`s Disease, source:Seeking Alpha, summary: No summary",BIIB
86,2022-12-30,"Headline: House Democrats fault FDA for collaborating improperly with Biogen, source:CNBC, summary: A new report from House Democrats found that the U.S. Food and Drug Administration inappropriately collaborated with Biogen before approving its Alzheimer's treatment Aduhelm. CNBC's 'Squawk Box' team reports., Headline: NEW YORK MARKET CLOSE: Stocks fall at end of brutal year for equities, source:Alliance News, summary: No summary, Headline: Eisai And Biogen's Lecanemab: A Flawed Treatment For Alzheimer's Disease, source:SeekingAlpha, summary: Biogen's Lecanemab only slows down the progression of Alzheimer's disease in APOE4 carriers and is suspected of causing deaths. Click for more on BIIB.",BIIB
87,2022-12-31,"Headline: Jim Simons Stock Portfolio: 10 Biggest Healthcare Stocks, source:Yahoo, summary: In this article we take a look at Jim Simons Stock Portfolio: 10 Biggest Healthcare Stocks. Click to skip ahead and see Jim Simons Stock Portfolio: 5 Biggest Healthcare Stocks. Gilead Sciences, Inc. (NASDAQ:GILD), Novo Nordisk A/S (NYSE:NVO), and Molina Healthcare, Inc. (NYSE:MOH) are three of the healthcare companies that Jim Simons’ quant fund has identified as […]",BIIB
88,2023-01-02,"Headline: Amid criticism for its handling of another Alzheimer`s drug, FDA will decide this week whether to approve lecanemab, source:MarketWatch, summary: No summary",BIIB
89,2023-01-03,"Headline: Amid criticism for its handling of another Alzheimer's drug, FDA will decide this week whether to approve lecanemab, source:MarketWatch, summary: A damning new congressional report found the regulator didn’t follow the correct procedures when it approved Aduhelm in 2021, Headline: Biogen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. shed 1.55% to $272.63 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: The FDA’s Next Call on an Alzheimer’s Drug Is Due This Week, source:Yahoo, summary: Biogen and Eisai are jointly developing lecanemab. A decision on accelerated approval is expected by Friday., Headline: Amid criticism for its handling of another Alzheimer’s drug, FDA will decide this week whether to approve lecanemab, source:Yahoo, summary: A damning new congressional report found the regulator didn’t follow the correct procedures when it approved Aduhelm in 2021, Headline: IBD Stock Of The Day: How These Issues In 2023 Could Spark, Or Slam, Eli Lilly Stock, source:Yahoo, summary: Eli Lilly is the IBD Stock Of The Day as the company explores new methods of treating Alzheimer's and obesity, driving LLY stock near highs., Headline: Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed at $272.63 in the latest trading session, marking a -1.55% move from the prior day.",BIIB
90,2023-01-04,"Headline: Biogen, Alcoyne announce license, collaboration agreement, source:Thefly.com, summary: No summary, Headline: Biogen and Alcyone enter licensing agreement to develop ThecaFlex DRx, source:Alliance News, summary: No summary, Headline: Biogen, Alcyone in agreement for medical device for antisense oligonucleotide therapies, source:Seeking Alpha, summary: No summary, Headline: Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies, source:Yahoo, summary: Alcyone’s ThecaFlex DRx™ System is an implantable medical device in development for intrathecal drug delivery CAMBRIDGE, Mass. and LOWELL, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx™ System, an implantable medical device intended for subcutaneous delivery of antisense oligonucleotide (ASO) therapies into the intrathecal space. Through this agreeme, Headline: Is There An Opportunity With Biogen Inc.'s (NASDAQ:BIIB) 26% Undervaluation?, source:Yahoo, summary: In this article we are going to estimate the intrinsic value of Biogen Inc. ( NASDAQ:BIIB ) by taking the forecast..., Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. dropped 0.67% to $270.81 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: RBC says hotline sign of possible imminent approval for Biogen, source:Thefly.com, summary: No summary, Headline: Biogen Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: No summary",BIIB
91,2023-01-05,"Headline: Biogen promotes Singhal to EVP, Head of Development, source:Thefly.com, summary: No summary, Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Needham health/pharmaceuticals analysts hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Interesting BIIB Put And Call Options For February 24th, source:Stock Options Channel, summary: No summary, Headline: Aurinia`s Patent Dispute Is Over, But Without A Buyout, There`s No Upside, source:Seeking Alpha, summary: No summary, Headline: Aurinia's Patent Dispute Is Over, But Without A Buyout, There's No Upside, source:SeekingAlpha, summary: Aurinia Pharmaceuticals recently settled a patent dispute with Sun Pharma. That seems to have rekindled buyout chatter. Read more on AUPH stock here., Headline: Biogen Names Priya Singhal as Executive Vice President, Head of Development, source:Yahoo, summary: CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that Priya Singhal, M.D., M.P.H., currently Head of Global Safety and Regulatory Sciences and Interim Head of Research & Development (R&D), has been promoted to Executive Vice President, Head of Development, following a decision to separate Research and Development into two distinct functions that will both report directly to the CEO. In addition, Biogen has initiated a search for a new Executive Vice Presid, Headline: Biogen names Priya Singhal as head of development after splitting R&D division, source:Reuters, summary: Biogen Inc on Thursday named Interim Research and Development Chief Priya Singhal as executive vice president, head of development following the separation of the drugmaker's R&D division into two units. (Reporting by Leroy Leo in Bengaluru; Editing by Shounak Dasgupta), Headline: UPDATE 1-Biogen splits R&D division ahead of key decision on Alzheimer's drug, source:Yahoo, summary: Biogen Inc said on Thursday it will split its research and development division into two units ahead of a highly anticipated decision by the U.S. health regulator about the company's second Alzheimer's drug.  The company named interim R&D chief Priya Singhal as executive vice president, head of development following the separation.  Singhal will also serve as the interim head of research till the company completes its search for a new chief for that division., Headline: Biogen separates research and development into two functions, source:Yahoo, summary: MARKET PULSE Biogen Inc. (BIIB) said Thursday that it separated research and development into two functions that report directly to new CEO Christopher Viehbacher. Priya Singhal, currently the head of global safety and regulatory sciences, was promoted to EVP and head of development., Headline: Biogen splits R&D division ahead of key decision on Alzheimer's drug, source:Reuters, summary: Biogen Inc said on Thursday it will split its research and development division into two units ahead of a highly anticipated decision by the U.S. health regulator about the company's second Alzheimer's drug., Headline: Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device, source:Yahoo, summary: Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies., Headline: Plus Therapeutics: Targeting Brain Cancer with Rifle-Shot Precision, source:Yahoo, summary: Plus Therapeutics, Inc. (Nasdaq: PSTV) specializes in targeted radiation treatments Rather than traditional radiation beams, Plus uses needle-sized applicators into brain fluid Focused on brain cancer which is difficult to […], Headline: Biogen trading halted, news pending, source:Thefly.com, summary: No summary, Headline: Lecanemab Alert: What Would Alzheimer`s Drug Approval Mean for Biogen (BIIB) Stock?, source:InvestorPlace, summary: No summary, Headline: FDA approves Biogen Alzheimer`s disease treatment Leqembi, source:Thefly.com, summary: No summary, Headline: FDA grants accelerated approval for Biogen and Eisai Alzheimer`s drug, source:Thefly.com, summary: No summary, Headline: Biogen, Eisai announce FDA approves Leqembi to treat Alzheimer`s disease, source:Thefly.com, summary: No summary, Headline: Eisai announces Leqembi U.S. launch pricing at $26,500 per year, source:Thefly.com, summary: No summary, Headline: FDA approves treatment for people with mild forms of Alzheimer`s, source:MarketWatch, summary: No summary, Headline: Biogen to resume trading at 3:05 p.m. ET, source:Thefly.com, summary: No summary, Headline: Biogen trading resumes, source:Thefly.com, summary: No summary, Headline: Biogen up 7% to $290.76 after FDA approves Leqembi, source:Thefly.com, summary: No summary, Headline: CMS says Biogen approval falls under existing national coverage determination, source:Thefly.com, summary: No summary, Headline: Biogen, Eisai May Have an Alzheimer`s Beater on Their Hands, source:TipRanks, summary: No summary, Headline: Lilly, Anavex, other Alzheimer`s drug developers rise modestly on Biogen lecanemab approval, source:Seeking Alpha, summary: No summary, Headline: Mizuho Securities Remains a Buy on Biogen (BIIB), source:TipRanks, summary: No summary, Headline: What You Missed On Wall Street On Friday, source:Thefly.com, summary: No summary, Headline: Piper stays on sidelines as commercial success of Biogen`s Leqembi unsure, source:Thefly.com, summary: No summary, Headline: Biogen (BIIB) Gets a Buy from Needham, source:TipRanks, summary: No summary",BIIB
92,2023-01-06,"Headline: Alzheimer's drug decision day: FDA to decide on Biogen and Eisai treatments, source:CNBC, summary: CNBC's Meg Tirrell joins 'Squawk Box' to discuss the big day ahead for Alzheimer's medicine., Headline: Biogen Alzheimer's drug could get Medicare coverage in 2025 if approved, says Dr. Scott Gottlieb, source:CNBC, summary: Dr. Scott Gottlieb, former FDA commissioner and CNBC contributor, joins 'Squawk Box' to discuss if Biogen's drug is tackling the root cause of Alzheimer's, what scientists are learning from Biogen's Alzheimer's treatment and more., Headline: Top Picks For 2023: Anavex Life Sciences, source:TalkMarkets, summary: No summary, Headline: FDA approves Alzheimer's drug that slowed cognitive decline in clinical trial, source:CNBC, summary: The FDA's decision comes after clinical trial results indicated that lecanemab slows cognitive decline somewhat in people with mild impairment from Alzheimer's., Headline: FDA approves treatment for people with mild forms of Alzheimer's, source:MarketWatch, summary: Leqembi, which was developed by Eisai and Biogen, will cost about $26,000 a year, Headline: FDA approves Biogen's Alzheimer's drug, source:CNBC, summary: CNBC's Meg Tirrell reports on Biogen and the company receiving FDA approval for an Alzheimer's treatment., Headline: 1 Stock Defying the Downturn to Buy, and 1 to Avoid, source:Yahoo, summary: AstraZeneca is a U.K.-based pharmaceutical company with a long list of products, many of which are hugely successful and generate well over $1 billion in annual sales.  The company's oncology lineup is particularly impressive, with products such as Tagrisso, Imfinzi, Lynparza, and Calquence, all of which are blockbusters.  AstraZeneca's oncology drugs made up about 35% of the company's revenue in the third quarter., Headline: TOP NEWS: US approves new Eisai, Biogen drug to treat Alzheimer's, source:Alliance News, summary: No summary, Headline: Biogen Could Get A Second Alzheimer's OK — But Will Wild Card Medicare Bite?, source:Yahoo, summary: Biogen stock jumped Friday ahead of an FDA decision on the accelerated approval of its experimental Alzheimer's treatment, lecanemab., Headline: NEW YORK MARKET CLOSE: Stocks post bumper gains after mixed US data, source:Alliance News, summary: No summary, Headline: Genetics, Alzheimer's And AI — Why 2023 Could Be The Year For Biotech Stocks, source:Yahoo, summary: If there's one biotech area to watch in 2023, it's genetic medicine, like CRISPR. But other trends also point to a big year for biotech stocks., Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. rallied 2.82% to $279.25 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: ADRs End Higher, Shell and Eisai Trade Actively, source:MarketWatch, summary: By Kathryn Hardison International stocks trading in New York closed higher on Friday. The S&P/BNY Mellon index of American depositary receipts increased 2.2%..., Headline: Health Care Up as Biogen Rises on Alzheimer's Drug Progress -- Health Care Roundup, source:MarketWatch, summary: Health-care companies rose after another breakthrough in Alzheimer's drug treatments. Shares of Biogen and Japanese partner Eisai rose after the Food and..., Headline: CNBC Exclusive: Eisai U.S. CEO on Alzheimer's drug approval, source:CNBC, summary: CNBC's Meg Tirrell talks to Ivan Cheung, Eisai U.S. CEO on the company's Alzheimer's drug receiving approval from the FDA today. With CNBC's Tyler Mathisen and the Fast Money traders, Tim Seymour, Bonawyn Eison, Steve Grasso and Jeff Mills., Headline: New Alzheimer’s Drug Approved by FDA, Promises to Slow Disease, source:Yahoo, summary: Eisai and Biogen’s Leqembi is the first drug to show that reducing a protein linked to Alzheimer’s helped patients., Headline: UPDATE 1-U.S. FDA approves Eisai, Biogen's Alzheimer's drug, source:Yahoo, summary: The U.S. Food and Drug Administration approved Eisai Co Ltd's and Biogen Inc's Alzheimer's drug lecanemab for patients in the earliest stages of the mind-wasting disease, the agency said on Friday.  The drug, to be sold under the brand Leqembi, belongs to a class of treatments that aims to slow the advance of the neurodegenerative disease by removing sticky clumps of the toxic brain protein known as beta amyloid., Headline: Alzheimer’s Drug From Eisai, Biogen Gets FDA Accelerated Approval, source:Yahoo, summary: (Bloomberg) -- Eisai Co. and its partner Biogen Inc. gained initial US regulatory clearance for lecanemab, the first treatment clearly shown to slow the advance of brain-wasting Alzheimer’s disease. Most Read from BloombergWhat We Know About the ‘Kraken’ Covid Variant XBB.1.5 and Why It’s Causing ConcernIf You Have Student Loans, Mark These Dates on Your CalendarTrump’s Troubles Mount as Special Counsel Gets New 2020 EvidenceSalesforce Guts Tableau After Spending $15.7 Billion in 2019 DealUS and, Headline: Alzheimer’s Disease Treatments: What to Know About New and Future Drugs, source:Yahoo, summary: The new drug Leqembi promises to slow the disease in patients, but they will have to balance safety risks and reimbursement issues., Headline: FDA Approves Eisai and Biogen’s New Alzheimer’s Therapy, source:Yahoo, summary: FEATURE  The Food and Drug Administration approved Biogen and Eisai’s Alzheimer’s disease therapy lecanemab on Friday under its accelerated approval pathway.  The approval includes a warning about a side effect known as amyloid-related imaging abnormalities., Headline: FDA approves second Biogen Alzheimer's drug, source:Yahoo, summary: The U.S. Food and Drug Administration has approved a second Alzheimer's disease drug made by Biogen Inc. with its Japanese partner, Eisai Inc., Headline: FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease, source:Yahoo, summary: Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb (Brand Name in the U.S.: LEQEMBI™) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (""prot, Headline: FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway, source:Yahoo, summary: The FDA has approved Biogen Inc's (NASDAQ: BIIB) second Alzheimer's disease treatment, Leqembi (lecanemab-irmb) via the Accelerated Approval pathway. Leqembi is the second of a new category of medications approved for Alzheimer's disease that target the fundamental pathophysiology of the disease. Eisai Co Limited (OTC: ESALY)-partnered lecanemab reduced clinical decline on the global cognitive and functional scale by 27% at 18 months, relative to the placebo, the trial's primary endpoint. In Jun, Headline: FDA approves treatment for people with mild forms of Alzheimer’s, source:Yahoo, summary: The Food and Drug Administration on Friday granted an accelerated approval to Eisai and Biogen’s Alzheimer’s disease treatment, which showed in clinical trials that it can slow the progression of the disease.  U.S.-listed shares of Eisai  (ESALY)  rallied 9.4% after the news was announced on Friday afternoon.  Biogen’s  (BIIB)  stock was halted at the time of publication., Headline: Biogen Stock Surges After Alzheimer's Approval, source:Yahoo, summary: U.S. health regulators [have approved](https://www.wsj.com/articles/new-alzheimers-drug-approved-by-fda-promises-to-slow-disease-11673032312?mod=hp_lead_pos4) Biogen's new Alzheimer's disease drug, and stockholders are reaping the rewards. Biogen shares were recently up 6% shortly after trading resumed on Friday; the stock had been halted shortly before word of the approval became public. Shares of Eli Lilly, which has similar drugs under development, were up 1.5% on Friday., Headline: FDA approves Biogen-Eisai Alzheimer’s drug, China in talks to make Pfizer Paxlovid generic, source:Yahoo, summary: Yahoo Finance health care reporter Anjalee Khemlani highlights the progress on Biogen-Eisai's collaborative Alzheimer's treatment drug and China's plans to distribute Pfizer's Paxlovid pill., Headline: Biogen Gains FDA Approval For New Alzheimer's Drug, But Medicare Remains A Wild Card, source:Yahoo, summary: Biogen stock jumped late Friday after the Food and Drug Administration approved its second Alzheimer's treatment, now called Leqembi., Headline: US STOCKS-Wall St rallies as jobs, services data calm rate hike worries, source:Yahoo, summary: Wall Street's main indexes all gained more than 2% on Friday after December payrolls expanded more than expected even as wage increases slowed and services activity contracted, easing worries about the Federal Reserve's interest rate hiking path.  U.S. nonfarm payrolls rose by 223,000 jobs in December, Labor Department data showed, while a 0.3% rise in average earnings was smaller than expected and less than the previous month's 0.4%., Headline: U.S. FDA approves Eisai, Biogen Alzheimer's drug, source:Reuters, summary: The U.S. Food and Drug Administration on Friday approved the Alzheimer's drug lecanemab developed by Eisai Co Ltd and Biogen Inc for patients in the earliest stages of the mind-wasting disease., Headline: FDA approves Biogen, Eisai Alzheimer’s drug, source:Yahoo, summary: An Alzheimer’s drug from Biogen and Eisai has received accelerated approval from the Food and Drug Administration, the companies and agency announced Friday., Headline: Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease, source:Yahoo, summary: Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher ""Biogen"") announced Eisai has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) supporting the conversion of the Accelerated Approval of LEQEMBI™ (lecanemab-irmb) 100 mg/mL injection for intravenous use to a traditional approval. This sBLA is subject to validation",BIIB
93,2023-01-07,"Headline: Eisai, Biogen get U.S. FDA approval for Alzheimer's drug, apply for full approval, source:Reuters, summary: The U.S. Food and Drug Administration on Friday approved the Alzheimer's drug lecanemab developed by Eisai Co Ltd and Biogen Inc for patients in the earliest stages of the mind-wasting disease., Headline: New Alzheimer’s Drug Leqembi Will Be Out of Reach for Most Patients, source:Yahoo, summary: Medicare won’t pay for the drug unless patients are enrolled in government-sanctioned trials—and no such studies are under way or planned.",BIIB
94,2023-01-08,"Headline: With 88% ownership, Biogen Inc. (NASDAQ:BIIB) boasts of strong institutional backing, source:Yahoo, summary: A look at the shareholders of Biogen Inc. ( NASDAQ:BIIB ) can tell us which group is most powerful. And the group that..., Headline: The Year’s Biggest Healthcare Conference Starts Monday. What to Expect., source:MarketWatch, summary: The J.P. Morgan Healthcare Conference kicks off on Jan. 9 in San Francisco. On the agenda: M&A news, drug pricing, IPOs, and more.",BIIB
95,2023-01-09,"Headline: Royalty Pharma agrees to buy Ionis Pharma royalties for $1.125 bln, source:MarketWatch, summary: Royalty Pharma Plc undefined said Monday it agreed to pay up to $1.125 billion for drug royalties owned by Ionis Pharmaceuticals Inc. undefined. The..., Headline: Ionis, Royalty Pharma Enter Into $1.1 Billion Royalty Agreement for Spinraza, Pelacarsen, source:MarketWatch, summary: By Chris Wack Ionis Pharmaceuticals Inc. and Royalty Pharma PLC said Monday that Royalty Pharma has acquired an interest in Ionis's royalty in Biogen Inc.'s..., Headline: 'The threshold of a new age': CEO of local Alzheimer's group on Biogen's new drug, source:Yahoo, summary: The CEO of the Mass. chapter of the Alzheimer's Association calls the FDA's approval of Leqembi last week ""a disease paradigm change."", Headline: Eisai, Biogen's Alzheimer's drug price should not dent demand - analysts, source:Reuters, summary: The $26,500-per-year price tag for Eisai Co Ltd and Biogen Inc's newly approved Alzheimer's disease drug is slightly above expectations, but should not dent demand for the promising therapy, Wall Street analysts said., Headline: Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's, source:Yahoo, summary: FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi., Headline: Biogen Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 1.62% to $274.72 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index..., Headline: These Stocks Are Moving the Most Monday: Tesla, Zillow, Regeneron, Macy’s, and More, source:Yahoo, summary: FEATURE  Stocks were mixed Monday at market close, losing some of the momentum from a rally last Friday to start a new week of trading.  These stocks made moves Monday:  CinCor Pharma (ticker: CINC) surged 144% to $28., Headline: Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed at $274.72 in the latest trading session, marking a -1.62% move from the prior day., Headline: Shares of Japan's Eisai surge after FDA approves Alzheimer's drug, source:Yahoo, summary: Shares of Eisai Co Ltd surged in early trade in Tokyo on Tuesday after the U.S. Food and Drug Administration approved the Alzheimer's drug lecanemab developed by it and Biogen Inc for patients in the earliest stages of the disease.  Shares of Eisai were up nearly 8% at 0015 GMT.  The drug, to be sold under the brand Leqembi, belongs to a class of treatments that aim to slow the advance of the neurodegenerative disease by removing sticky clumps of the toxic protein beta amyloid from the brain.",BIIB
96,2023-01-10,"Headline: What's next for Leqembi, the new Biogen-Eisai Alzheimer's drug?, source:Yahoo, summary: There are several things that need to happen before the new Alzheimer's drug from Biogen and Eisai gets into the hands of patients. And, unlike with their first Alzheimer's drug, Aduhelm, Eisai is taking the charge on this one — leaving Biogen in a bit of a wait-and-see position., Headline: Biogen CEO Viehbacher outlines a path, including immunology, rare diseases, source:Yahoo, summary: While Biogen's new CEO says he isn't planning any ""radical left turns,"" he does see some ways the company could tap into new markets, including immunology and rare diseases., Headline: Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?, source:Yahoo, summary: You can't blame Biogen (NASDAQ: BIIB) investors if they feel a sense of déjà vu.  The company, along with its partner, Japanese drugmaker Eisai (OTC: ESALY), received U.S. Food and Drug Administration (FDA) approval for Alzheimer's disease drug Leqembi (lecanemab-irmb) last week.  Biogen has been in this position before., Headline: CMS limiting coverage of Alzheimer's drug not a 'fixed' policy, says FDA's Robert Califf, source:CNBC, summary: CNBC's Meg Tirrell and Dr. Robert Califf, FDA commissioner, joins 'Power Lunch' to discuss Biogen's Alzheimer's drug and the health care sector., Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. rallied 2.45% to $281.46 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: FDA Commissioner Denies Wrongdoing in Approval Process for Biogen Alzheimer’s Drug Aduhelm, source:Yahoo, summary: Robert Califf acknowledged the agency made mistakes when it failed to properly document interactions with the company., Headline: EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE, source:Yahoo, summary: Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that Eisai has submitted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mil, Headline: Eisai files for approval of Alzheimer's drug in Europe, source:Reuters, summary: Japanese drugmaker Eisai Co Ltd said on Tuesday it had submitted a marketing application to the European health regulator for review of its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States.",BIIB
97,2023-01-11,"Headline: 1 Hot Growth Stock to Buy Now, and 1 to Avoid, source:Yahoo, summary: Discerning between popular growth stocks that have room to run and those that will leave your portfolio in the red isn't an easy task, especially for companies in the biopharma sector.  AbbVie (NYSE: ABBV) is a pharmaceutical growth stock par excellence because it will be commercializing new medicines and expanding the prescribable indications of its existing set of medicines at a quick clip throughout the rest of the decade.  In 2023, it aims to submit nine approval packages to regulators and potentially get the final stamp of approval for eight other programs for which it already submitted the paperwork., Headline: Ranking The 10 Largest Biotechs By Pipeline, source:SeekingAlpha, summary: The pipeline is the heart of all drug discovery companies, leading to all growth in the future. Here we rank biotechs by pipeline, click to see the list., Headline: Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe, source:Yahoo, summary: Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe., Headline: Biogen Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. rose 1.27% to $285.03 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",BIIB
98,2023-01-12,"Headline: IBB: A History Of Outperformance During Recessions, source:SeekingAlpha, summary: iShares Biotechnology has outperformed the S&P 500 during all 3 recessions in the U.S. since inception in early 2001. See why I'm bullish about IBB ETF now., Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. rallied 1.07% to $288.08 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",BIIB
99,2023-01-14,"Headline: A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them., source:Yahoo, summary: Pharmaceutical companies are grappling with the arrival in the U.S. of sweeping new legislation meant to blunt drug prices.  The impact in 2023 may actually be higher drug prices.  President Biden last year signed into law the bill dubbed the Inflation Reduction Act, empowering Medicare, the country’s biggest buyer of prescription drugs, to negotiate how much it pays for certain high-price therapies.",BIIB
100,2023-01-15,"Headline: BioVie Inc: A Catalyst-Rich Year Ahead, source:SeekingAlpha, summary: BioVie's strong scientific profile and large market opportunity have made it a high-risk/high-reward bet with considerable upside potential. Find out why BIVI is a Buy., Headline: EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN, source:Yahoo, summary: Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that Eisai has submitted a marketing authorization application for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril1 antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia (collectively, Headline: Eisai files for approval of Alzheimer's drug in Japan, source:Reuters, summary: Japanese drugmaker Eisai Co Ltd said on Monday it had submitted a marketing authorisation application in Japan for its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States.",BIIB
101,2023-01-16,"Headline: Denali: Need Patient Data To Justify That High Valuation, source:SeekingAlpha, summary: Denali Therapeutics Inc. has major partnerships and an active set of programs. They are flush with cash. Click for more on DNLI., Headline: Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan, source:Yahoo, summary: Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.",BIIB
102,2023-01-17,"Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.54% higher to $289.59 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: Anavex: Drug Treatments For Early Alzheimer's Disease, source:SeekingAlpha, summary: Anavex 2-73/blarcamesine at high concentrations in early Alzheimer's disease leads to improvements in cognition. Click here to see our take on AVXL stock.",BIIB
103,2023-01-18,"Headline: Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen, source:Yahoo, summary: Neurodegenerative diseases-focused Aprinoia Therapeutics has announced a business combination with Ross Acquisition Corp II (NYSE: ROSS), a special-purpose acquisition company founded by former Commerce Secretary Wilbur Ross, at an equity value of $280 million. Wilbur Ross has personally invested $7.5 million through convertible notes and committed up to $12.5 million of capital infusion at the closing. Aprinoia, founded in 2015, is a clinical-stage biotech company developing novel therapeutics, Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slipped 2.11% to $283.47 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",BIIB
104,2023-01-19,"Headline: If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today, source:Yahoo, summary: The stock hasn't been a great investment in recent years, but there's hope for a brighter future., Headline: Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval, source:Yahoo, summary: The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month., Headline: Biogen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 1.18% to $280.13 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed the most recent trading day at $280.13, moving -1.18% from the previous trading session., Headline: Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug, source:Yahoo, summary: (Reuters) -Eli Lilly and Co on Thursday said the U.S. Food and Drug Administration has rejected accelerated approval of its experimental Alzheimer's drug because it did not submit enough trial data from patients who were treated for at least 12 months.  Lilly said the FDA sent it a complete response letter for donanemab, an antibody designed to remove amyloid protein plaques from the brains of people with early Alzheimer's. Such letters typically outline concerns and conditions that must be addressed to gain U.S. approval.  Lilly said the FDA issued the letter ""due to the limited number of patients with at least 12 months of drug exposure data provided in the submission.""",BIIB
105,2023-01-20,"Headline: Why the FDA didn't grant an approval to Lilly's Alzheimer's drug, source:MarketWatch, summary: The regulator wants to see clinical data from at least 100 patients who have taken donanemab for a year, Headline: Eli Lilly Stock Slips Lower As FDA Rejects Fast Track Approval For Alzheimer's Drug, source:Yahoo, summary: ""We are committed to working with the FDA to ensure the fastest possible path to bring this potential medicine to patients in need,"" Eli Lilly said., Headline: Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts, source:Reuters, summary: The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said., Headline: Why the FDA didn’t grant an approval to Lilly’s Alzheimer’s drug, source:Yahoo, summary: The regulator wants to see clinical data from at least 100 patients who have taken donanemab for a year, Headline: Eli Lilly Alzheimer's drug setback extends rival Biogen's lead, source:Reuters, summary: The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said., Headline: The FDA Rejected Lilly’s Alzheimer’s Drug. Why It’s Only a Setback., source:Yahoo, summary: The company had sought accelerated approval, but the agency said its trial data didn't include enough people who had been on the drug for at least a year., Headline: In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug, source:Yahoo, summary: Eli Lilly stock dipped Friday after the FDA unexpectedly rejected its request for an accelerated approval of its Alzheimer's treatment.",BIIB
106,2023-01-23,"Headline: Novartis: Chasing Revenue Might Lose Sight Of Medicine, source:SeekingAlpha, summary: Novartis is undergoing major change to become a pure-play innovative medicines company. Read more to see why Iâm on the sidelines on this one., Headline: Healthcare Outlook 2023, source:SeekingAlpha, summary: Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. Read more here.",BIIB
107,2023-01-24,"Headline: ClearBridge Value Equity Strategy Q4 2022 Portfolio Manager Commentary, source:SeekingAlpha, summary: ClearBridge is a leading global asset manager committed to active management. Find out more here., Headline: Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again, source:Yahoo, summary: Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report., Headline: Biogen Inc. (BIIB) Stock Moves -0.02%: What You Should Know, source:Yahoo, summary: In the latest trading session, Biogen Inc. (BIIB) closed at $291.88, marking a -0.02% move from the previous day.",BIIB
108,2023-01-25,"Headline: Eagle Pharmaceuticals: Upside Could Be Lying Ahead Very Nicely, source:SeekingAlpha, summary: Eagle Pharmaceuticals is an interesting opportunity to benefit from volatility in stock markets. Click here to find out why EGRX stock is a Hold., Headline: Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?, source:Yahoo, summary: Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market., Headline: 12 Cheap Biotech Stocks To Buy, source:Yahoo, summary: In this article, we will be taking a look at 12 cheap biotech stocks to buy. To skip our detailed analysis of the biotech sector, you can go directly to see 5 Cheap Biotech Stocks To Buy. The biotechnology sector has been on the rise over the past three decades. Several forecasts expect the sector […]",BIIB
109,2023-01-26,"Headline: The Petri Dish: Morphic, J&J part ways; FDA committee to review another Biogen drug, source:Yahoo, summary: Waltham biotech Morphic Holding Inc. is no longer working with Johnson & Johnson Inc. after the pharma giant elected to terminate a nearly four-year-old collaboration agreement., Headline: Is Biogen Stock a Buy Now?, source:Yahoo, summary: Moving new medicines to the market can sometimes make biopharmaceutical companies tons of returns.  Biogen (NASDAQ: BIIB) just scored a major new drug approval for an Alzheimer's disease therapy, so investors are understandably rushing to evaluate whether to buy the stock.  One key factor that could drive Biogen's outperformance in the next few years is the launch of a new neurology medicine., Headline: Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization, source:MarketWatch, summary: By Sabela Ojea Biogen Inc. said Thursday that the European Medicines Agency committee has accepted a marketing authorization application for its Alzheimer's..., Headline: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency, source:Yahoo, summary: TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of, Headline: UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen, source:Yahoo, summary: Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug.  The application to the EMA was based on results from a late-stage study that showed the drug slowed down the rate of cognitive decline in patients with early Alzheimer's by 27%, compared with a placebo.  Eisai has also filed for approval of the drug in Japan., Headline: EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen, source:Reuters, summary: Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug.",BIIB
110,2023-01-27,"Headline: Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance, source:Yahoo, summary: Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.",BIIB
111,2023-01-29,"Headline: 15 Most Famous Hedge Fund Managers and Their Top Stock Picks, source:Yahoo, summary: In this article, we discuss 15 most famous hedge fund managers and their top stock picks. If you want to see more hedge fund managers, check out 5 Most Famous Hedge Fund Managers and Their Top Stock Picks. According to data provider Hedge Fund Research (HFR), hedge funds in 2022 reported their worst performance since […], Headline: LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN, source:Yahoo, summary: Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid-β (Aβ) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare (MHLW). Priority Review in J, Headline: Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen, source:Reuters, summary: Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Sunday the Japanese Ministry of Health, Labour and Welfare has given priority review for their Alzheimer's disease drug., Headline: UPDATE 1-Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen, source:Yahoo, summary: Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc said in a joint statement that the Japanese Ministry of Health, Labour and Welfare has granted priority review status to their Alzheimer's disease treatment.  In their Jan. 29 statement, the companies said priority review in Japan is granted to new medicines recognised as having high medical utility for serious diseases.  Once the priority status has been granted, the target total review period is shortened, they said., Headline: Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen, source:Reuters, summary: Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc said in a joint statement that the Japanese Ministry of Health, Labour and Welfare has granted priority review status to their Alzheimer's disease treatment.",BIIB
112,2023-01-30,"Headline: Approval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi Approved, source:SeekingAlpha, summary: FDA grants emergency approval of Biogen/Eisai's Leqembi based solely on Phase 2 trial results. Read why approval For Anavex's Blarcamesine looks inevitable., Headline: 15 Biggest Neuroscience Companies in the World, source:Yahoo, summary: In this article, we will discuss the 15 Biggest Neuroscience Companies in the World. You can skip our industry overview and go directly to the 5 Biggest Neuroscience Companies in the World. As the name suggests, neuroscience concerns itself with the development, structure, and functions of the nervous system, intending to enhance neurological health. According […], Headline: Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.",BIIB
113,2023-02-01,"Headline: Why the FDA's Rejection of Eli Lilly's Alzheimer's Drug Is Actually Great News for the Stock, source:Yahoo, summary: When the Food and Drug Administration (FDA) rejects a key drug from a healthcare company, it can send the stock spiraling into a sell-off.  In order for the FDA to be confident in a drug's effectiveness, it needs to have a large enough sample size to evaluate it.  Unfortunately, in Eli Lilly's case, it simply didn't have enough data points for the agency to make a positive conclusion about the treatment and grant it accelerated approval., Headline: Biogen Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.24% higher to $291.60 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023, source:Yahoo, summary: Thanks to the wild events of 2022, discerning investors enjoy plenty of bargains, particularly in the arena of the most undervalued Nasdaq stocks. Given the exchange’s bias toward technology players (including biotech), wagering in this space carries the advantage of relevance. Even if circumstances look shoddy right now, at some point, these enterprises have a shot at upside eventually. Now, a word of caution is in order following the utterances of the last few words above. With the most underv",BIIB
114,2023-02-02,"Headline: Biogen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slid 1.40% to $287.52 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",BIIB
115,2023-02-03,"Headline: Biogen Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slid 1.35% to $283.63 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...",BIIB
116,2023-02-05,"Headline: Biogen: What To Do Ahead Of Q4 2022 Financial Report, source:SeekingAlpha, summary: Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. Find out why BIIB stock is a Hold.",BIIB
117,2023-02-06,"Headline: Biogen, Sage Get FDA Priority Review of Zuranolone >BIIB SAGE, source:MarketWatch, summary: By Colin Kellaher Biogen Inc. and Sage Therapeutics Inc. on Monday said the U.S. Food and Drug Administration granted priority review to the application..., Headline: FDA grants Priority Review to depression drug; Sage’s stock rallies, source:MarketWatch, summary: Shares of Sage Therapeutics Inc. gained about 5% in premarket trading on Monday after the company said the experimental treatment for major depressive..., Headline: Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression, source:Yahoo, summary: CAMBRIDGE, Mass., February 06, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD. The application has been granted priority revie, Headline: Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression, source:Yahoo, summary: Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD)Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatme, Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. advanced 1.64% to $288.28 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive', source:Yahoo, summary: The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) zuranolone for major depressive disorder (MDD) and postpartum depression (PPD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of August 5, 2023. William Blair views the acceptance as an important milestone for the company. The analyst believes the granting of priority review, though not surprising, is an incremental positive, Headline: Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day.",BIIB
118,2023-02-07,"Headline: Is Biogen Inc. (NASDAQ:BIIB) Trading At A 24% Discount?, source:Yahoo, summary: How far off is Biogen Inc. ( NASDAQ:BIIB ) from its intrinsic value? Using the most recent financial data, we'll take a..., Headline: Sage and Biogen's NDA for Depression Drug Gets Priority Review, source:Yahoo, summary: Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review., Headline: Biogen Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. advanced 1.09% to $291.43 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",BIIB
119,2023-02-08,"Headline: Will Biogen (BIIB) Beat Estimates This Earnings Season?, source:Yahoo, summary: Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza., Headline: Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth, source:Yahoo, summary: Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: 2 Top Biotech Stocks Defying the Bear Market, source:Yahoo, summary: The bear market crushed many top healthcare stocks -- from young high-growth players to long-established companies generating billions of dollars in earnings.  Vertex is the worldwide leader in the cystic fibrosis (CF) treatment market.  In fact, last year product revenue climbed 18% to more than $8.9 billion.",BIIB
120,2023-02-10,"Headline: 25 Biggest Massachusetts Companies and Stocks, source:Yahoo, summary: In this article, we will be taking a look at the 25 biggest Massachusetts companies and stocks. To skip our detailed analysis, you can go directly to see the 5 biggest Massachusetts companies and stocks. If all U.S. states were countries, Massachusetts would be 32nd largest economy in the world based on a 2021 GDP […], Headline: IWS: Little Added Value In This Value Index, source:SeekingAlpha, summary: The iShares Russell Mid-Cap Value ETF tracks the Russell Midcap Value Index. Click here to read why I see little added value in IWS.",BIIB
121,2023-02-11,"Headline: With 88% institutional ownership, Biogen Inc. (NASDAQ:BIIB) is a favorite amongst the big guns, source:Yahoo, summary: Every investor in Biogen Inc. ( NASDAQ:BIIB ) should be aware of the most powerful shareholder groups. We can see that...",BIIB
122,2023-02-12,"Headline: Earnings Growth Improves As Investors Ready Themselves For Retailers, source:Seeking Alpha, summary: No summary",BIIB
123,2023-02-13,"Headline: Investors Are Awaiting The Name Of The New BoJ Governor, source:TalkMarkets, summary: No summary, Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. rallied 1.45% to $290.46 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",BIIB
124,2023-02-14,"Headline: Top 5 4th Quarter Trades of SEEYOND, source:GuruFocus, summary: No summary, Headline: Tamarack Advisers, LP Buys 1, Sells 4 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: Hyperfine could have `interesting` opportunity in Alzheimer`s, says Evercore ISI, source:Thefly.com, summary: No summary, Headline: All eyes on Biogen Q4 results with focus on future of Alzheimer`s drug Leqembi, source:Seeking Alpha, summary: No summary, Headline: Biogen`s Alzheimer`s therapy Aduhelm gets updated warning on brain hemorrhage risk, source:Seeking Alpha, summary: No summary, Headline: Notable companies reporting before tomorrow`s open, source:Thefly.com, summary: No summary, Headline: Biogen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. shed 0.48% to $289.08 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: GLOBAL BRIEFING: Stocks called lower ahead of UK inflation figures, source:Alliance News, summary: No summary, Headline: What You Missed On Wall Street On Wednesday, source:Thefly.com, summary: No summary",BIIB
125,2023-02-15,"Headline: Biogen reports Q4 EPS $4.05, consensus $3.48, source:Thefly.com, summary: No summary, Headline: Biogen sees FY23 EPS $15.00-$16.00, consensus $15.72, source:Thefly.com, summary: No summary, Headline: Biogen beats Q4 top and bottom line estimates; initiates FY23 outlook, source:Seeking Alpha, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Applied DNA Sciences (APDN) and Provention Bio (PRVB), source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and ChitogenX (OtherCHNXF), source:TipRanks, summary: No summary, Headline: 7 stocks to watch on Wednesday: Telsa, Airbnb, Krispy Kreme and more, source:Seeking Alpha, summary: No summary, Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: No summary, Headline: Airbnb, TripAdvisor, Tesla rise premarket; Barclays, Devon Energy fall, source:Yahoo, summary: By Peter Nurse, Headline: Biogen`s stock gains after company beats Q4 revenue and earnings expectations, source:MarketWatch, summary: No summary, Headline: Stocks making the biggest moves premarket: Kraft Heinz, Paramount, Airbnb, Tripadvisor and more, source:CNBC, summary: Here are the companies making headlines before the bell on Monday., Headline: Biogen net income up across 2022, fourth quarter; revenue down, source:Alliance News, summary: No summary, Headline: Biogen Beats Q4 Earnings & Sales Estimates, Stock Up, source:TalkMarkets, summary: No summary, Headline: Biogen expects new Alzheimer`s drug to weigh on 2023 outlook, source:Seeking Alpha, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Biogen Inc. (BIIB) Q4 2022 Earnings Call Transcript, source:SeekingAlpha, summary: Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q4 2022 Results Conference Call February 15, 2023 8:00 AM ETCompany ParticipantsMike Hencke - Head, Investor RelationsChristopher Viehbacher - CEOMichael..., Headline: Investors in Biogen (NASDAQ:BIIB) have made a respectable return of 35% over the past year, source:Yahoo, summary: These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick..., Headline: Biogen earnings beat estimates on boost from muscle disorder drug, source:Reuters, summary: Biogen Inc beat Wall Street expectations for quarterly profit and sales on Wednesday, riding on strong demand for its spinal muscular atrophy drug, Spinraza, and forecast modest revenue from its Alzheimer's disease drug this year., Headline: Biogen sees modest 2023 revenue from Alzheimer's disease drug, source:Yahoo, summary: (Reuters) -Biogen Inc said on Wednesday that Alzheimer's disease drug Leqembi would bring in modest revenue for the year although it might not be enough to offset costs tied to its launch.  The company is banking on Leqembi, which was granted accelerated U.S. approval in January, to drive its sales at a time when many of Biogen's top drugs face increasing competition.  Biogen has a 50% share of U.S. profits on Leqembi, which it developed with lead partner Eisai Co Ltd., Headline: Medicare mulls limiting per month costs for generic drugs at $2, source:Seeking Alpha, summary: No summary, Headline: Biogen Tops Profit Expectations as Alzheimer’s and Depression Drugs Remain in Focus, source:Yahoo, summary: The expected rollouts of both drugs this year are vital to the company's future because its remaining offerings face intense competitive pressure., Headline: Biogen’s stock gains after company beats Q4 revenue and earnings expectations, source:Yahoo, summary: Shares of Biogen Inc.  (BIIB)  gained about 1.7% in premarket trading on Wednesday after the company beat revenue and earnings expectations in the fourth quarter.  Biogen had earnings of $550.4 million, or $3.79 per share, in the fourth quarter, up from $368.2 million, or $2.50 per share, in the same three months of 2021.  Adjusted earnings per share were $4.05, against a FactSet consensus of $3.49., Headline: UPDATE 2-Biogen CEO bets on Alzheimer's drug, pipeline to return to growth, source:Yahoo, summary: Biogen Inc Chief Executive Officer Christopher Viehbacher said on Wednesday he is banking on high-profile launches of Alzheimer's disease treatment Leqembi and depression drug zuranolone, as well as deals, to help the company return to revenue growth.  Industry veteran Viehbacher joined the U.S. biotech in November, at a time when sales have been hit by competition for top-selling drugs such as Tecfidera for multiple sclerosis and Spinraza for spinal muscular atrophy.  A controversial approval and problematic launch of previous Alzheimer's disease drug Aduhelm, which like Leqembi was developed with Eisai Co Ltd, have further dented investor sentiment., Headline: Biogen Inc. (BIIB) Q4 Earnings and Revenues Beat Estimates, source:Yahoo, summary: Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.38% and 4.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?, Headline: Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales, source:Yahoo, summary: Biogen stock inched higher Wednesday after the company beat quarterly expectations, but offered disappointing 2023 guidance., Headline: Drugmaker Biogen tops 4Q forecasts despite sales slip, source:Yahoo, summary: Biogen closed 2022 with a better-than-expected fourth quarter, as more cost cutting helped counter sales declines for some key treatments.  The drugmaker said Wednesday that total cost and expenses fell 17% in the quarter, and Biogen’s bottom line grew nearly 50% to $550.4 million.  Adjusted earnings totaled $4.05 per share., Headline: Why Biogen Stock Is Falling Today, source:Yahoo, summary: Biogen Inc (NASDAQ: BIIB) posted Q4 sales of $2.54 billion, beating the consensus of $2.44 billion, down 7% Y/Y and 4% at constant currency (CC). Multiple sclerosis revenue of $1.27 billion decreased by 17% (down 14% CC). Multiple sclerosis drug Tysabri sales are down to $488.4 million from $512.7. Spinraza's revenue of $458.8 million increased by 4% at actual currency (increased by 10% at CC). Aduhelm generated sales of $0.3 million in Q4, compared to $1.0 million a year ago. Biosimilars' reven, Headline: Biogen CEO bets on Alzheimer's drug, pipeline to return to growth, source:Reuters, summary: Biogen Inc Chief Executive Officer Christopher Viehbacher said on Wednesday he is banking on high-profile launches of Alzheimer's disease treatment Leqembi and depression drug zuranolone, as well as deals, to help the company return to revenue growth., Headline: Biogen hints at more cost-cutting under new CEO as revenue falls, source:Yahoo, summary: Biogen Inc. may see new drug approvals this year — but first, new CEO Christopher Viehbacher is looking at ways to cut costs as the company continues to struggle with falling revenue., Headline: Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up, source:Yahoo, summary: Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market., Headline: NEW YORK MARKET CLOSE: Stocks stage late rally to end higher, source:Alliance News, summary: No summary, Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slipped 3.49% to $278.98 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: Leqembi: Medicare coverage needs ‘a convincing set of evidence’ for FDA approval, analyst says, source:Yahoo, summary: William Blair Biotech Equity Research Analyst Myles Minter joins Yahoo Finance Live to discuss his Outperform rating on Biogen stock, Biogen’s Alzheimer and depression treatment drugs, full-year guidance, profit growth, cost-cutting efforts, and the outlook for the company., Headline: Health Care Down as Biogen Weighs -- Health Care Roundup, source:MarketWatch, summary: Health-care companies fell after a selloff in one big biotech. Biogen shares slid after the biotech giant posted a sharp drop in 2022 revenue, and warned of..., Headline: Compared to Estimates, Biogen Inc. (BIIB) Q4 Earnings: A Look at Key Metrics, source:Yahoo, summary: Although the revenue and EPS for Biogen Inc. (BIIB) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers., Headline: Biogen Boss Turns Corner on Alzheimer’s Miscues, source:Yahoo, summary: The biotech company needs to embark on new growth path as former Sanofi CEO Chris Viehbacher takes the helm., Headline: Biogen (BIIB) Q4 2022 Earnings Call Transcript, source:Yahoo, summary: At this time, I would like to welcome everyone to the Biogen fourth quarter and full year 2022 earnings call and business update.  On today's call, I am joined by our president and chief executive officer, Christopher Viehbacher; Dr. Priya Singhal, head of development; and our CFO, Mike McDonnell., Headline: Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount, source:Yahoo, summary: Biogen stock was hamstrung Wednesday on mixed 2023 guidance that assumes expenses for its new Alzheimer's drug will outpace sales., Headline: Biogen (BIIB) Gets a Buy from Morgan Stanley, source:TipRanks, summary: No summary, Headline: Bank of America Securities Sticks to Their Hold Rating for Biogen (BIIB), source:TipRanks, summary: No summary",BIIB
126,2023-02-16,"Headline: Biogen price target lowered to $310 from $320 at Oppenheimer, source:Thefly.com, summary: No summary, Headline: Biogen price target raised to $351 from $345 at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: H.C. Wainwright Reaffirms Their Buy Rating on Biogen (BIIB), source:TipRanks, summary: No summary, Headline: BMO Capital Gives a Buy Rating to Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Biogen price target raised to $315 from $300 at Cowen, source:Thefly.com, summary: No summary, Headline: GLOBAL BROKER RATINGS: LBBW cuts LVMH; DZ Bank cuts Kering, source:Alliance News, summary: No summary, Headline: Analysts` Top Healthcare Picks: Alkermes (ALKS), Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Biogen price target lowered to $333 from $359 at RBC Capital, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Amedisys (AMED), Biogen (BIIB) and Waters (WAT), source:TipRanks, summary: No summary, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), SAGE Therapeutics (SAGE) and Karyopharm Therapeutics (KPTI), source:TipRanks, summary: No summary, Headline: Biogen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slid 2.67% to $271.53 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index..., Headline: Biotech Stock Roundup: BIIB's Q4 Results, EBS and BPMC Offer Updates, source:Yahoo, summary: Earnings results from Biogen (BIIB) and updates from EBS are the key highlights from the biotech sector during the past week., Headline: Biogen has nearly made good on reported plan to cut 1,000 jobs in 2022, source:Yahoo, summary: In late 2021, the Cambridge drugmaker reportedly began drafting plans to get rid of more than 1,000 positions. Now, it appears to have nearly accomplished that goal., Headline: Biogen Inc. (NASDAQ:BIIB) Q4 2022 Earnings Call Transcript, source:Yahoo, summary: Biogen Inc. (NASDAQ:BIIB) Q4 2022 Earnings Call Transcript February 15, 2023 Operator: Good morning. My name is Bettina , and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Fourth Quarter and Full Year 2022 Earnings Call and Business Update. All lines have been placed […]",BIIB
127,2023-02-17,"Headline: RA CAPITAL MANAGEMENT, L.P. Buys 2, Sells 3 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: GLOBAL BROKER RATINGS: Citigroup likes Coca-Cola; DZ cuts Kraft Heinz, source:Alliance News, summary: No summary, Headline: Barclays Remains a Hold on Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage, source:CNBC, summary: Even if the FDA grants full approval of the Alzheimer's treatment Leqembi, the rollout will take years. , Headline: Biogen (BIIB) Gets a Buy from SVB Securities, source:TipRanks, summary: No summary, Headline: Senators call on Medicare to offer broad coverage of Alzheimer's treatments as public pressure grows, source:CNBC, summary: Eighteen Republicans and two Democrats, led by Sens. Susan Collins and Shelley Moore Capito, pushed Medicare to expand coverage for Alzheimer's treatments., Headline: Senators urge swift action to expand Medicare coverage for Alzheimer`s therapies, source:Seeking Alpha, summary: No summary, Headline: Jeff Auxier Buys 2, Sells 3 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: Stocks making the biggest moves midday: Deere, Airbnb, AutoNation, Moderna and more, source:CNBC, summary: Deere shares popped on strong earnings. , Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. rallied 2.52% to $278.38 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Steven Cohen’s Point72 Hedge Fund Backs Salesforce, Broadcom And Meta While Cutting Palo Alto And Workday Stakes, source:Fintel, summary: nan",BIIB
128,2023-02-19,"Headline: Biogen Inc.'s (NASDAQ:BIIB) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?, source:Yahoo, summary: It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined 7.7...",BIIB
129,2023-02-21,"Headline: Sage Therapeutics Looking To FDA Approval Of Zuranolone, source:SeekingAlpha, summary: Sage Therapeutics specializes in psychiatric drug therapies, and the stock price has fluctuated greatly over the years. Click here to read why SAGE is a Buy., Headline: HealthCor Management, L.P. Buys 2, Sells 3 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: Jeff Auxier Downloads Adobe, Boosts British American Tobacco, source:GuruFocus, summary: No summary, Headline: Biogen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slid 2.32% to $271.93 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: Analyst Favorites With Strong Buyback Activity: Biogen Ranks As a Top Pick, source:The Online Investor, summary: No summary",BIIB
130,2023-02-22,"Headline: Stanley Druckenmiller Buys the Dip on Nvidia, Exits Amazon, source:GuruFocus, summary: No summary, Headline: May 19th Options Now Available For Biogen (BIIB), source:Stock Options Channel, summary: No summary, Headline: Biogen Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.23% higher to $272.55 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P..., Headline: UPDATE 1-U.S. Medicare says no change to Alzheimer's drug restrictions, source:Yahoo, summary: The U.S. government health plan for people over the age of 65  on Wednesday said it would not reconsider strict coverage limits put in place last year for new Alzheimer's treatments, rejecting a request from the Alzheimer's Association.  The Centers for Medicare and Medicaid Services (CMS) reaffirmed its policy allowing coverage for drugs designed to clear amyloid plaques from the brains of Alzheimer's patients only if a medication is approved under the Food and Drug Administration's standard review process, not under its accelerated review program.  The Alzheimer's Association said in a statement it ""is appalled that the Biden Administration is extending its unjust decision to deny access to FDA-approved treatments for people living with Alzheimer's - a fatal disease.""",BIIB
131,2023-02-23,"Headline: Medicare says coverage limits on Alzheimer`s drugs is not under review, source:Seeking Alpha, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Medtronic (MDT) and Biogen (BIIB), source:TipRanks, summary: No summary, Headline: TG Therapeutics` Briumvi: A Tough Sell For Multiple Sclerosis Treatment Market, source:Seeking Alpha, summary: No summary, Headline: TG Therapeutics' Briumvi: A Tough Sell For Multiple Sclerosis Treatment Market, source:SeekingAlpha, summary: TG Therapeutic's Briumvi for MS is unlikely to make the company profitable before its patent expires. Click here to read why TGTX stock is a Strong Sell., Headline: Medicare rejects Alzheimer's Association request for unrestricted coverage of treatments like Leqembi, source:CNBC, summary: The Alzheimer's Association, in a statement Wednesday, said it was ""appalled"" by CMS' decision., Headline: We Think Biogen (NASDAQ:BIIB) Can Stay On Top Of Its Debt, source:Yahoo, summary: Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility..., Headline: Biogen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. dropped 0.22% to $271.95 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",BIIB
132,2023-02-24,"Headline: Biogen Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. shed 0.71% to $270.02 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",BIIB
133,2023-02-25,"Headline: 3 Biotech Stocks To Watch Ahead Of March 2023, source:StockMarket, summary: Do you have these three biotech stocks on your watchlist right now?",BIIB
134,2023-02-26,"Headline: Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca, source:SeekingAlpha, summary: Chengdu Keymed Bio and Lepu Biopharma out-licensed global rights for their partnered Claudin 18.2 antibody drug conjugate to AstraZeneca. Read more here..., Headline: Reata in selloff ahead of FDA decision on lead asset as top agency official departs (Update), source:Seeking Alpha, summary: No summary",BIIB
135,2023-02-27,"Headline: Biogen license application for lecanemab designated for priority review in China, source:Thefly.com, summary: No summary, Headline: Reata in selloff ahead of FDA decision on lead asset as top agency official departs, source:Seeking Alpha, summary: No summary, Headline: Amyloid Gains Converts in Debate Over Alzheimer’s Treatments, source:Yahoo, summary: The drug’s success has helped quell a dispute over a theory of what causes the disease and how to treat it. However, critics say scientists still aren’t sure how amyloid removal slows down Alzheimer’s., Headline: Biogen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slumped 0.30% to $269.20 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: Lightning Round: This is Boeing's time if they don't screw it up, source:CNBC, summary: Mad Money host Jim Cramer weighs in on all manner of stocks, including Accenture, Boeing, Biogen, Union Pacific, Meta, Nokia and Enphase Energy., Headline: Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration, source:Yahoo, summary: TOKYO and CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril antibody, has been designated for Priority Review by the National Medical Products Ad, Headline: Eisai, Biogen say Alzheimer's drug Lecanemab getting priority review in China, source:Reuters, summary: Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc said on Tuesday that Chinese authorities have given priority review status to Lecanemab, their jointly-developed Alzheimer's disease treatment drug., Headline: Biogen, Eisai`s Alzheimer`s therapy lecanemab gets priority review in Chinna, source:Seeking Alpha, summary: No summary",BIIB
136,2023-02-28,"Headline: Biogen Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.25% higher to $269.86 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P..., Headline: FDA neurosciences chief Billy Dunn to leave immediately, analysts raise concern, source:Yahoo, summary: The U.S. Food and Drug Administration neurosciences head Billy Dunn will retire from his role effective immediately, the health regulator told Reuters on Tuesday.  Wall Street analysts said Dunn's departure could impact the regulator's stance on neurological drug decisions in the near term, sending down shares of Reata Pharmaceuticals Inc 30% on Monday when media reports on the exit surfaced.  Texas-based Reata is expecting FDA's decision by Tuesday on its drug to treat a rare neuromuscular disorder called Friedreich's ataxia., Headline: Reata’s stock soars 150% after FDA approves rare-disease drug amid uncertainty about approach to neuroscience treatments, source:Yahoo, summary: The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.’s treatment for Friedreich’s ataxia, a rare inherited disease that causes damage to the nervous system.  Reata’s  (RETA)  stock jumped more than 150% in after-hours trading, after being halted in advance of the FDA’s decision.  The drug, omaveloxolone, is now called Skyclarys and has been approved to treat adults 16 and older with the degenerative disease, which often appears when a patient is a teenager.",BIIB
137,2023-03-01,"Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Outset Medical (OM) and Prometheus Biosciences (RXDX), source:TipRanks, summary: No summary, Headline: Roche`s Genentech sues Biogen over additional patent royalties from Tysabri sales, source:Seeking Alpha, summary: No summary, Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.87% higher to $272.21 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow..., Headline: Genentech sues Biogen for royalties on blockbuster MS drug, source:Yahoo, summary: Roche's Genentech Inc sued Biogen MA Inc on Tuesday in San Francisco federal court, claiming Biogen owes additional patent royalties from worldwide sales of its blockbuster multiple-sclerosis and Crohn's disease drug Tysabri.  Genentech's lawsuit said Biogen owes royalties for all the Tysabri that was produced using Genentech's patents before the patents expired, even if it was sold later., Headline: UPDATE 1-Genentech sues Biogen for royalties on blockbuster MS drug, source:Yahoo, summary: Roche's Genentech Inc sued Biogen MA Inc on Tuesday in San Francisco federal court, claiming Biogen owes additional patent royalties from worldwide sales of its blockbuster multiple-sclerosis and Crohn's disease drug Tysabri.  Genentech's lawsuit said Biogen owes royalties for all the Tysabri that was produced using Genentech's patents before the patents expired, even if it was sold later.",BIIB
138,2023-03-02,"Headline: Biogen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 1.27% to $268.75 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",BIIB
139,2023-03-03,"Headline: Medicare just crushed the hopes of 750,000 Alzheimer`s patients a year, source:MarketWatch, summary: No summary, Headline: Biotech Stocks Fell on Fear of Less Flexible FDA. This Analyst Isn’t Worried., source:MarketWatch, summary: Investors panicked on Monday in response to the retirement of an official seen as a standard bearer for flexibility on approvals of certain neurological drugs., Headline: Biogen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.57% higher to $270.27 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",BIIB
140,2023-03-05,"Headline: Eisai, Biogen say FDA accepted sBLA for LEQEMBI, granted Priority Review, source:Thefly.com, summary: No summary, Headline: FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease, source:PR Newswire, summary: No summary, Headline: FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease, source:Yahoo, summary: Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval Priority Review accelerates FDA review time with a Prescription Drug User Fee Act (PDUFA) target action on July 6, 2023 TOKYO and CAMBRIDGE, Mass., March 05, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A., Headline: Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab, source:Reuters, summary: Japanese drugmaker Eisai Co Ltd and its U.S. partner Biogen Inc said on Monday that the U.S. Food and Drug Administration granted priority review for traditional approval of their Alzheimer's treatment Lecanemab., Headline: US FDA accepts application for traditional Leqembi approval - Biogen, source:Alliance News, summary: No summary, Headline: Biogen, Eisai`s Alzheimer`s drug Leqembi gets FDA priority review for traditional approval, source:Seeking Alpha, summary: No summary",BIIB
141,2023-03-06,"Headline: FDA will review Eisai and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July, source:CNBC, summary: Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval., Headline: Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi, source:Yahoo, summary: The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023., Headline: Biogen Inc. (BIIB) 43rd Annual Cowen Healthcare Conference (Transcript), source:SeekingAlpha, summary: Call Start: 09:50 January 1, 0000 10:21 AM ETBiogen Inc., Headline: Biogen Inc. (BIIB) 43rd Annual Cowen Healthcare Conference Conference (Transcript), source:SeekingAlpha, summary: Biogen Inc. (NASDAQ:NASDAQ:BIIB) 43rd Annual Cowen Healthcare Conference Call March 6, 2023 9:50 AM ETCompany ParticipantsChristopher Viehbacher - Chief Executive OfficerConference Call..., Headline: FDA Will Weigh Full Approval for Alzheimer’s Drug. Why It Matters for Biogen Stock., source:Yahoo, summary: The drug already has accelerated approval. Full approval would open the door for Medicare to pay for the treatment for more patients., Headline: Biogen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. dropped 0.01% to $270.25 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment, source:Yahoo, summary: The FDA has accepted Eisai Co Ltd (OTC: ESALY) and Biogen Inc's (NASDAQ: BIIB) supplemental Biologics License Application (sBLA) for Leqembi (lecanemab-irmb) 100 mg/mL injection, supporting the conversion of the accelerated approval of Leqembi to a traditional approval. The Leqembi application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of July 6, 2023. The FDA plans to hold an Advisory Committee to discuss this application but has not publicly ann, Headline: FDA to decide on full approval of Alzheimer's treatment Leqembi in early July, source:Yahoo, summary: The FDA will decide on July 6 whether to grant full approval to the new Alzheimer's treatment Leqembi, Japanese drugmaker Eisai and its U.S. partner Biogen said., Headline: Biogen Should Resume Strong Growth With Zuranolone Approval, source:SeekingAlpha, summary: Biogen's revenue will continue to decline if the FDA (or payers) declines to approve both zuranolone and Leqembi. Find out why BIIB stock is a Buy.",BIIB
142,2023-03-07,"Headline: Biden to announce plan to keep Medicare solvent beyond 2050, source:Seeking Alpha, summary: No summary, Headline: The Data Will Speak Louder Than Powell. Fed Rate Is Veering Toward 6%., source:Yahoo, summary: China ramps up U.S. tensions, JetBlue merger faces legal action, the return of luxury consumers, and other news to start your day., Headline: Biogen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 1.99% to $264.88 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: U.S. Wide-Moat Stocks On Sale - The March 2023 Heat Map, source:SeekingAlpha, summary: We are only interested in those targets that are attractively valued in historical comparison. Click here for our 3-step process that focuses on wide-moat stocks.",BIIB
143,2023-03-08,"Headline: Biogen, Sage Therapeutics: FDA has no plans to discuss NDA for zuranolone, source:Thefly.com, summary: No summary, Headline: FDA to not hold panel meeting for Biogen, Sage`s depression therapy zuranolone, source:Seeking Alpha, summary: No summary, Headline: Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone, source:Business Wire, summary: No summary, Headline: Biogen elects Dorsa as Chair of the Board of Directors, source:Thefly.com, summary: No summary, Headline: Biogen elects new board chairperson, source:Seeking Alpha, summary: No summary, Headline: Biogen Names Dorsa to Succeed Papadopoulos as Chairman >BIIB, source:MarketWatch, summary: By Colin Kellaher Biogen Inc. on Wednesday said it has designated long-time board member Caroline Dorsa to succeed Stelios Papadopoulos as chairman of the..., Headline: Elliott Wave Technical Analysis: Biogen Inc. - Wednesday, March 8, source:TalkMarkets, summary: No summary, Headline: Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors, source:Yahoo, summary: CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced that the Board of Directors has elected Caroline Dorsa as Chair of the Board of Directors, effective immediately following the Company’s 2023 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to take place on June 14, 2023. Ms. Dorsa will succeed Stelios Papadopoulos, Ph.D., who announced he would not stand for reelection to the Board at the Annual Meeting. Dr. Papadopoulos said: “The e, Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. shed 0.70% to $263.02 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index..., Headline: Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed the most recent trading day at $263.02, moving -0.7% from the previous trading session.",BIIB
144,2023-03-09,"Headline: No ad com suggests positive potential outcome for Sage`s zura, says BofA, source:Thefly.com, summary: No summary, Headline: Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock, source:InvestorPlace, summary: No summary, Headline: Needham healthcare analyst to hold an analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study, source:Yahoo, summary: Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease., Headline: Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed, source:Yahoo, summary: Eli Lilly stock and Biogen stock diverged Thursday after Lilly said a decade-long study of an Alzheimer's treatment definitively failed., Headline: Biogen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. slid 1.53% to $258.99 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",BIIB
145,2023-03-10,"Headline: Biogen Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. dropped 0.94% to $256.56 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...",BIIB
146,2023-03-12,"Headline: Biosimilars expected to save $180B over next five years as more gain approval, source:Seeking Alpha, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Crinetics Pharmaceuticals (CRNX) and 89bio (ETNB), source:TipRanks, summary: No summary, Headline: VA to widely cover new Alzheimer`s treatment from Eisai and Biogen, STAT says, source:Thefly.com, summary: No summary, Headline: Biogen `welcomes` VHA recent decision to provide coverage to Leqembi, source:Thefly.com, summary: No summary, Headline: Biogen Takes Over #202 Spot From Bank of New York Mellon, source:The Online Investor, summary: No summary",BIIB
147,2023-03-13,"Headline: Biogen price target raised to $350 from $335 at RBC Capital, source:Thefly.com, summary: No summary, Headline: Sage upgraded to outperform at RBC on greater confidence in zuranolone approval, source:Seeking Alpha, summary: No summary, Headline: Biogen Inc. stock underperforms Monday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.78% higher to $258.55 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: Veterans Health Administration will cover Alzheimer's treatment Leqembi, Eisai says, source:CNBC, summary: Veterans with early Alzheimer's who meet certain VHA criteria can get the treatment covered, according to drugmaker Eisai. , Headline: Veterans Affairs to Be First Major Insurer to Cover Alzheimer’s Drug Leqembi, source:Yahoo, summary: Eisai  ’s new Alzheimer’s disease drug Leqembi will be covered by the U.S. Department of Veterans Affairs, the first major insurer to agree to pay for the drug since its approval by U.S. regulators earlier this year.  Eisai said Monday veterans with the early stages of Alzheimer’s would get the drug covered under criteria set by the VA.  An estimated 167,954 veterans receiving care through the VA have Alzheimer’s dementia, according to government estimates., Headline: UPDATE 1-US VA to cover Eisai, Biogen Alzheimer's treatment Leqembi, source:Yahoo, summary: Eisai Co Ltd and Biogen Inc said on Monday that the U.S. Department of Veteran Affairs (VA) will provide coverage of their Alzheimer's treatment Leqembi to veterans at an early stage of the memory-robbing disease.  The VA did not immediately respond to a request for comment, but a document on its website shows that the agency added Leqembi to its list nonformulary drugs, making it available provided patients request it, receive prior approval, and meet strict inclusion criteria for the drug's use., Headline: US VA to cover Eisai, Biogen Alzheimer's treatment Leqembi, source:Reuters, summary: Eisai Co Ltd and Biogen Inc said on Monday that the U.S. Department of Veteran Affairs (VA) will provide coverage of their Alzheimer's treatment Leqembi to veterans at an early stage of the memory-robbing disease.",BIIB
148,2023-03-14,"Headline: Analysts` Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Illumina (ILMN) and Arcutis Biotherapeutics (ARQT), source:TipRanks, summary: No summary, Headline: Biogen appoints Triano as Head of Investor Relations, source:Thefly.com, summary: No summary, Headline: Veterans Health to cover Eisai, Biogen`s new Alzheimer`s drug, source:MarketWatch, summary: No summary, Headline: Biogen Appoints Chuck Triano as Head of Investor Relations, source:Yahoo, summary: CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations effective 10 April 2023. Mr. Triano will report to Michael McDonnell, Executive Vice President and Chief Financial Officer. “Chuck will bring invaluable industry insights and a strong network of relationships to Biogen, and I’m pleased to welcome him to our leadership team,” said Michael McDonnell, Executive Vice Pres, Headline: Veterans Health to cover Eisai, Biogen’s new Alzheimer’s drug, source:Yahoo, summary: Eisai Co. Ltd.  (JP:4523)  said Tuesday that the Veterans Health Administration will cover Leqembi, the Alzheimer’s disease treatment it developed with Biogen Inc.  (BIIB)  that received an accelerated approval in January.  The drug is not broadly covered at this time by the Centers for Medicare and Medicaid Services given its accelerated approval status.  “We see the VHA decision as the beginning of a potential series of wins on the reimbursement front for Leqembi, with the larger catalyst being the CMS potentially revisiting the currently restrictive [national coverage determination] after full approval,” William Blair analysts told investors on Monday., Headline: 1 Reason to Buy Biogen Stock, and 1 Reason to Sell, source:Yahoo, summary: Biogen (NASDAQ: BIIB) has been one of the more notable names in the biotech industry in the past four years -- and not always for the best of reasons.  U.S. approval of Biogen's Aduhelm for treating Alzheimer's disease (AD) turned out to be a bit of a flop as the medicine isn't generating anywhere near the kinds of sales the drugmaker hoped to see.  Let's consider one reason the answer might be yes, and one reason to be wary of Biogen's future., Headline: The VA Will Pay for Leqembi. It’s a Step in Right Direction for Biogen., source:Yahoo, summary: The biotech and its partner Eisai are seeking to get Medicare to pay for the new Alzheimer's disease therapy., Headline: Biogen Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. rallied 1.47% to $262.35 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Biogen Inc. (BIIB) closed at $262.35, marking a +1.47% move from the previous day.",BIIB
149,2023-03-15,"Headline: Needham healthcare analyst to hold an analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.01% higher to $262.37 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P..., Headline: Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed the most recent trading day at $262.37, moving +0.01% from the previous trading session.",BIIB
150,2023-03-16,"Headline: Biogen receives favorable court ruling on TECFIDERA, source:Thefly.com, summary: No summary, Headline: Biogen gets EU court ruling in favor of blocking Tecfidera generic entry, source:Seeking Alpha, summary: No summary, Headline: PBE: Healthcare Dashboard For March, source:SeekingAlpha, summary: Healthcare equipment is the less attractive subsector regarding both valuation and quality. Click here to find out why PBE is a Hold., Headline: Wall Street Breakfast: Credit Suisse`s $54B Lifeline, source:Seeking Alpha, summary: No summary, Headline: Biogen And Eisai`s Leqembi: A Dose Of Reality For Alzheimer`s Disease, source:Seeking Alpha, summary: No summary, Headline: Wall Street Breakfast: Credit Suisse's $54B Lifeline, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify., Headline: Biogen And Eisai's Leqembi: A Dose Of Reality For Alzheimer's Disease, source:SeekingAlpha, summary: Biogen and Eisai are confident that the FDA will grant full approval for Leqembi for Alzheimer's disease. Find out why BIIB and ESALY could experience a substantial boost., Headline: Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection, source:Yahoo, summary: CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Court of Justice of the European Union decided in favor of Biogen, the European Medicines Agency (EMA), and the European Commission in their appeal of a General Court decision annulling the EMA’s refusal to evaluate a generic version of TECFIDERA® (dimethyl fumarate) because of TECFIDERA’s regulatory data and marketing protection. With this favorable decision, Biogen believes that TECFIDERA i, Headline: Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges, source:Yahoo, summary: Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth., Headline: Biogen Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. rose 1.10% to $265.25 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments, source:Yahoo, summary: https://cdn.benzinga.com/files/images/story/2023/03/16/dementia-3051832_1920.jpg?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 The Alzheimer's Association has launched a grassroots lobbying campaign while deploying 1,000 people, either patients or caring for someone with the disease, to meet with all 535 members of Congress across the U.S. and urge them to press Medicare program for the drugs starting with Biogen Inc (NASDAQ: BIIB) Leqembi (lecanemab). According to interviews with four Associa",BIIB
151,2023-03-17,"Headline: Stifel trims Biogen target, but has more confidence lecanemab `best-in-class`, source:Thefly.com, summary: No summary, Headline: Is There An Opportunity With Biogen Inc.'s (NASDAQ:BIIB) 27% Undervaluation?, source:Yahoo, summary: Key Insights The projected fair value for Biogen is US$362 based on 2 Stage Free Cash Flow to Equity Biogen's US$265..., Headline: Biogen Inc. (BIIB) Down 2.3% Since Last Earnings Report: Can It Rebound?, source:Yahoo, summary: Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: Biogen Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. dropped 0.79% to $263.16 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Sangamo Shares Down 8% After Hours as Novartis, Biogen End Collaborations, source:MarketWatch, summary: By Josh Beckerman Sangamo Therapeutics Inc. shares were down 8% to $1.84 after hours as the company said Novartis AG and Biogen Inc. terminated collaboration..., Headline: Stocks to Watch: Credit Suisse, First Republic Bank, Sangamo, source:MarketWatch, summary: By Sabela Ojea Credit Suisse Group AG is in discussions for all or parts of the bank to be taken over by UBS Group AG, the Financial Times reported on...",BIIB
152,2023-03-19,"Headline: Should You Buy Biogen Before a Big July Decision?, source:Yahoo, summary: Over time, Biogen (NASDAQ: BIIB) created a true success story.  Competition for Biogen's MS blockbuster Tecfidera, and for other key products, entered the market.  Now, though, Biogen may have found that new growth source.",BIIB
153,2023-03-20,"Headline: Analysts Conflicted on These Healthcare Names: Biogen (BIIB), Sarepta Therapeutics (SRPT) and G1 Therapeutics (GTHX), source:TipRanks, summary: No summary, Headline: FDA posts briefing document for advisors` review of Biogen`s ALS drug, source:Thefly.com, summary: No summary, Headline: FDA scientists weigh potential effect of Biogen ALS drug ahead of advisory meeting, source:Seeking Alpha, summary: No summary, Headline: Biogen, Eisai Alzheimer`s drug Leqembi covered by VA, source:Seeking Alpha, summary: No summary, Headline: UPDATE 2-FDA staff says safety issues with Biogen's ALS drug to not prevent approval, source:Yahoo, summary: The U.S. health regulator's staff said on Monday safety issues with Biogen Inc's drug to treat an ultra-rare form of amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig's disease, should not prevent its accelerated approval.  A panel of outside advisers to the U.S. Food and Drug Administration on Wednesday will closely scrutinize mixed efficacy data from the drug's late-stage trial and vote on the drug's effectiveness, and if reduction of a key protein related to the disease is enough to conclude that it may benefit ALS patients., Headline: FDA staff says Biogen's ALS drug may have a 'clinical benefit' on a rare form of the disease, source:CNBC, summary: The FDA staff on Monday said Biogen's investigational ALS drug tofersen may have a ""clinical benefit"" on a rare and aggressive form of the disease., Headline: FDA staff says safety issues with Biogen's ALS drug to not prevent approval, source:Reuters, summary: The U.S. health regulator's staff said on Monday safety issues with Biogen Inc's drug to treat an ultra-rare form of amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig's disease, should not prevent its accelerated approval., Headline: Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo, source:Yahoo, summary: https://cdn.benzinga.com/files/images/story/2023/03/20/sgmo_logo_light__df15263084666d45f8f072d9581b42da.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. On Friday, the company filed an SEC document, Novartis AG (NYSE: NVS) terminated the Collaboration and License Agreement dated July 27, 2020, effective June 11, 2023. The Novartis and Sangamo were engaged in programs to rese",BIIB
154,2023-03-21,"Headline: FDA briefing docs suggest FDA in favor of Biogen`s tofersen, says BofA, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Danaher (DHR) and Blueprint Medicines (BPMC), source:TipRanks, summary: No summary, Headline: Wall Street predicts approval for another ALS drug, source:MarketWatch, summary: No summary, Headline: Wall Street analysts predict approval for another ALS drug, source:MarketWatch, summary: An FDA advisory committee is set to meet this week to discuss a drug developed by Biogen and Ionis to treat a rare form of Lou Gehrig's disease., Headline: Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit, source:Yahoo, summary: FDA's Peripheral and Central Nervous System Drugs Advisory Committee will virtually meet on Wednesday, March 22, to discuss Biogen Inc's (NASDAQ: BIIB) ALS drug tofersen. FDA staff, citing a briefing document, said Biogen's investigational ALS drug might have a ""clinical benefit"" on a rare and aggressive form of the disease, despite failing a broader late-stage clinical trial last year. ""Despite the notable limitations of a failed study and the many post hoc exploratory analyses conducted after, Headline: Biogen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slipped 0.66% to $266.15 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: 7 Healthcare Stocks to Buy for Long-Term Growth and Stability, source:Yahoo, summary: Stock market investors have been on a rollercoaster ride over the past year. The Federal Reserve continues to be hawkish in controlling inflation. All while the global economic backdrop is marred by China and the Russia/Ukraine War. Therefore, investing in defensive investment options, such as the best healthcare stocks to buy, is perhaps a more prudent strategy now. Healthcare stocks typically exhibit resilience during economic downturns. All thanks to heightened government healthcare spending,, Headline: Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session.",BIIB
155,2023-03-22,"Headline: Biogen ALS drug tofersen wins unanimous FDA panel recommendation, source:Seeking Alpha, summary: No summary, Headline: Biogen ALS drug tofersen earns mixed voting by FDA advisory panel, source:Seeking Alpha, summary: No summary, Headline: Veterans Health Administration will cover new Alzheimer`s drug. Why won`t Medicare?, source:MarketWatch, summary: No summary, Headline: Inozyme appoints Matthew Winton as COO, source:Thefly.com, summary: No summary, Headline: Biogen provides update on AdCom meeting on Tofersen for SOD1-ALS, source:Thefly.com, summary: No summary, Headline: FDA Peripheral/Central Nervous System Drugs Advisory Committee holds meeting, source:Thefly.com, summary: No summary, Headline: Why won`t Medicare cover the new Alzheimer`s drug?, source:MarketWatch, summary: No summary, Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 1.85% to $261.22 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the disease , source:CNBC, summary: FDA advisors voted against the effectiveness of Biogen's investigational ALS drug, which could become the first to target a genetic cause of the disease., Headline: Biogen ALS drug considered not effective by FDA advisory panel, source:MarketWatch, summary: Biogen Inc. received a setback late Wednesday after a Food and Drug Administration advisory committee said the biotech drug maker’s proposed amyotrophic..., Headline: UPDATE 2-US FDA panel says current data not 'convincing' for Biogen's ALS drug, source:Yahoo, summary: A panel of advisers to the U.S. health regulator said on Wednesday there was not enough convincing evidence to show the effectiveness of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS).  The U.S. Food and Drug Administration (FDA) panel voted 5 to 3 that the late-stage data for the drug, tofersen, did not show it was an effective treatment for ALS patients with mutations in a specific gene that leads to accumulation of toxic levels of a protein known as superoxide dismutase 1 (SOD1).  One panelist abstained., Headline: US FDA panel says current data not 'convincing' for Biogen's ALS drug, source:Reuters, summary: A panel of advisers to the U.S. health regulator said on Wednesday there was not enough convincing evidence to show the effectiveness of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS)., Headline: Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS, source:Yahoo, summary: SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United StatesCAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). On the question, “Is the available evidenc",BIIB
156,2023-03-23,"Headline: Raymond James Sticks to Its Hold Rating for Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Biogen (BIIB) Receives a Hold from BTIG, source:TipRanks, summary: No summary, Headline: Analysts` Top Healthcare Picks: Biogen (BIIB), Applied DNA Sciences (APDN), source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Regeneron (REGN) and Alcon (ALC), source:TipRanks, summary: No summary, Headline: Elliott Wave Technical Analysis: Biogen Inc. - Thursday, March 23, source:TalkMarkets, summary: No summary, Headline: The Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnership, source:Yahoo, summary: Takeda paid Nimbus Therapeutics $4 billion for a psoriasis drug in December. It just met its primary goal in a midstage trial., Headline: US FDA panel backs accelerated approval for Biogen's ALS drug, source:Reuters, summary: A panel of advisers to the U.S. drug regulator voted that data on Biogen Inc's experimental treatment for ALS, also known as Lou Gehrig's disease, shows that the drug could work, potentially paving the way for an accelerated approval., Headline: May 5th Options Now Available For Biogen (BIIB), source:Stock Options Channel, summary: No summary, Headline: FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder, source:Yahoo, summary: The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 9 yes - 0 no, indicating sufficient evidence showing a reduction in plasma neurofilament light chain (NfL) concentration in tofersen-treated patients is reasonably likely to predict the clinical benefit of tofersen for SOD1-ALS patients. Biogen Inc (NASDAQ: BIIB) licensed tofersen from Ionis Pharmaceuticals Inc (NASDAQ: IONS) under a collaborative development and license agreement. Neurofilament light chain (NfL) is a, Headline: Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA, source:Yahoo, summary: The FDA committee supports an accelerated approval of Biogen's (BIIB) tofersen for treating SOD1-ALS. The committee does not believe the data supports a traditional/standard approval for tofersen., Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. advanced 1.51% to $265.17 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval, source:Yahoo, summary: Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week., Headline: 7 Blue-Chip Stocks Sitting in the Sweet Spot, source:Yahoo, summary: Although blue-chip stocks often carry a reputation for being lumbering giants that might not kill your portfolio but certainly won’t do it any favors, specific stalwarts can get the business done. In other words, these enterprises hit the sweet spot: they’re tied to well-established businesses that also offer double-digit (percentage) upside potential, as determined by Wall Street analysts. Further, adding to the sweet nature of these blue-chip stocks, they’re all undervalued based on earnings m, Headline: Biogen Pops — But Ionis Hands Back Gains — After ALS Drug Wins A Key Endorsement, source:Yahoo, summary: Biogen stock jumped — as Ionis stock gave back early gains — after a FDA panel offered a mixed view of their ALS treatment.",BIIB
157,2023-03-24,"Headline: 5 Best Healthcare Stocks to Invest in Now, According to Analysts, source:TipRanks, summary: No summary, Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. advanced 1.83% to $270.03 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",BIIB
158,2023-03-26,"Headline: Biogen Inc. (NASDAQ:BIIB) is a favorite amongst institutional investors who own 88%, source:Yahoo, summary: Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...",BIIB
159,2023-03-27,"Headline: Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study, source:Yahoo, summary: Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)., Headline: Biogen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. shed 0.02% to $269.98 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed at $269.98 in the latest trading session, marking a -0.02% move from the prior day.",BIIB
160,2023-03-28,"Headline: nan, source:TipRanks, summary: No summary, Headline: VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver Best Returns?, source:TipRanks, summary: No summary, Headline: VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver the Highest Returns?, source:TipRanks, summary: No summary, Headline: VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver the Highest Return?, source:TipRanks, summary: No summary, Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.10% higher to $270.25 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",BIIB
161,2023-03-29,"Headline: Ionis Pharmaceuticals` IONIS-MAPTRx shows tau reduction efficacy in Alzheimer`s, source:Thefly.com, summary: No summary, Headline: Biogen says BIIB080 `substantially reduced` tau protein level in early-stage AD, source:Thefly.com, summary: No summary, Headline: New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease, source:Yahoo, summary: The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regionsPhase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau protein (CSF t-tau and p-tau181) in the cerebral spinal fluid (CSF) throughout the open-label long-term extension (LTE)Neurofibrillary tangles in the brain are composed of tau proteins and are a key pathology associated with Alzheimer’s disease1 CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Biog, Headline: Biogen Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. advanced 1.39% to $274.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed at $274.01 in the latest trading session, marking a +1.39% move from the prior day.",BIIB
162,2023-03-30,"Headline: Biogen announces detailed analyses from phase 2 study of Lecanemab, source:Thefly.com, summary: No summary, Headline: 15 Cheap Beginner Stocks to Buy, source:Yahoo, summary: In this article, we will take a look at 15 cheap stocks to buy now for beginners. If you want to explore similar stocks, you can also take a look at 5 Cheap Beginner Stocks to Buy. Morgan Stanley’s Big Bear: “It’s Just A Much Less Predictable World” On March 27 Morgan Stanley’s chief U.S. […], Headline: Novavax (NVAX) Down 2.9% Since Last Earnings Report: Can It Rebound?, source:Yahoo, summary: Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: Biogen Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.41% higher to $275.13 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting, source:Yahoo, summary: TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life (QOL), from the re, Headline: ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS, source:Yahoo, summary: Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that three additional detailed analyses from the Phase IIb clinical study (Study 201), evaluating the efficacy and safety of lecanemab for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD), were published in the peer-reviewed journals.",BIIB
163,2023-03-31,"Headline: Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug, source:Yahoo, summary: Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced that three additional detailed analyses from the Phase IIb clinical study (Study 201) of lecanemab for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD were published in the peer-reviewed journals. In the core 201 study, lecanemab was shown to reduce brain Aβ accumulation measured by amyloid PET in a dose- and time-dependent manner after 12 and 18 months of treatment, and corresponding changes in plasma, Headline: Biogen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. advanced 1.05% to $278.03 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",BIIB
164,2023-04-01,"Headline: Do Fundamentals Have Any Role To Play In Driving Biogen Inc.'s (NASDAQ:BIIB) Stock Up Recently?, source:Yahoo, summary: Biogen's (NASDAQ:BIIB) stock is up by 3.0% over the past week. As most would know, long-term fundamentals have a strong...",BIIB
165,2023-04-03,"Headline: US to create Alzheimer`s research database in ~$300M project - report, source:Seeking Alpha, summary: No summary, Headline: Biogen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slid 0.25% to $277.34 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",BIIB
166,2023-04-04,"Headline: Biogen appoints Keeney as Head of Corporate Development, source:Thefly.com, summary: No summary, Headline: Biogen names Adam Keeney to head corporate development, source:Seeking Alpha, summary: No summary, Headline: Biogen Appoints Adam Keeney as Head of Corporate Development, source:Yahoo, summary: CAMBRIDGE, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen’s Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer. “We welcome Adam Keeney to our executive leadership team in this important role at this pivotal time for Biogen. Adam brings considerable expe, Headline: Biogen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. shed 0.75% to $275.25 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: In the latest trading session, Biogen Inc. (BIIB) closed at $275.25, marking a -0.75% move from the previous day., Headline: U.S. Wide-Moat Stocks On Sale - The April 2023 Heat Map, source:SeekingAlpha, summary: We believe that the most widely used valuation multiples are terribly flawed. Click here for a complete analysis.",BIIB
167,2023-04-05,"Headline: JPMorgan sees favorable risk/rewards for Eli Lilly, Biogen into data, source:Thefly.com, summary: No summary, Headline: Eli Lilly says experimental Alzheimer's drug reduces brain plaque in early study, source:CNBC, summary: Eli Lilly said a higher dose of the up-and-coming Alzheimer's treatment remternetug had a larger effect on clearing amyloid plaque. , Headline: Top Insider Picks For March 2023, source:SeekingAlpha, summary: The month of March had a couple of very interesting insider purchases. In this article, we discuss some of the biggest insider purchases by value. Read more here., Headline: Biogen Inc. stock underperforms Wednesday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Biogen Inc. rose 3.18% to $283.99 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",BIIB
168,2023-04-06,"Headline: Biogen And Eisai, Cassava Sciences, And Anavex: Clinical Trial Results In Need Of Revisions, source:SeekingAlpha, summary: Biogen, Eisai, Cassava Sciences, and Anavex have all provided data for their Alzheimerâs drugs that hide a deeper reality. See why AVXL stock is a Buy., Headline: FDA forces pre-term birth drug off the market after 12 years, source:Seeking Alpha, summary: No summary, Headline: Ionis And Biogen: Tofersen PDUFA Looms - Positive Outcome May Kick Off Bull Run For Both Stocks, source:SeekingAlpha, summary: Ionis and Biogen have been partnering on antisense drug development for a decade. Read why significant growth could be ahead for this alliance., Headline: The 35% return delivered to Biogen's (NASDAQ:BIIB) shareholders actually lagged YoY earnings growth, source:Yahoo, summary: These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick..., Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.99% higher to $286.80 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P..., Headline: Alzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai says, source:CNBC, summary: Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows. , Headline: The 3 Best Millionaire-Maker Stocks to Buy for April 2023, source:InvestorPlace, summary: No summary",BIIB
169,2023-04-07,"Headline: RBC Capital Sticks to Their Buy Rating for Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Steven Cohen Loads Up on Esperion Therapeutics as Shares Slide, source:GuruFocus, summary: No summary",BIIB
170,2023-04-09,"Headline: FDA AdCom to convene on June 9th to discuss Biogen/Eisai`s LEQEMBI in AD, source:Thefly.com, summary: No summary",BIIB
171,2023-04-10,"Headline: Pfizer CEO signs open letter calling for reversal of Texas abortion pill ruling, source:CNBC, summary: Pfizer's CEO was among the more than 200 pharmaceutical company executives who signed the letter after a federal judge's controversial ruling on mifepristone., Headline: Biogen, Eisai to face FDA AdCom in June for full approval of Alzheimer`s drug, source:Seeking Alpha, summary: No summary, Headline: US FDA advisers to weigh full approval for Eisai-Biogen's Alzheimer's drug, source:Reuters, summary: The U.S. Food and Drug Administration (FDA) plans to hold a meeting of its outside experts in June to discuss full approval of the Alzheimer's drug developed by Eisai Co Ltd and Biogen Inc, according to a federal filing on Monday., Headline: Biogen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. shed 1.37% to $282.86 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",BIIB
172,2023-04-11,"Headline: Drugmakers call for abortion pill ruling reversal, Reuters reports, source:Thefly.com, summary: No summary, Headline: US DOJ asks appeals court to block Texas judge abortion pill ruling, source:Seeking Alpha, summary: No summary, Headline: 3 Biotech Stocks to Watch for Potential Breakthroughs, source:InvestorPlace, summary: No summary, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (CNC), Ionis Pharmaceuticals (IONS) and Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Is Biogen (NASDAQ:BIIB) Using Too Much Debt?, source:Yahoo, summary: Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility..., Headline: Biogen Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.29% higher to $283.69 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500..., Headline: Needham Reiterates Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Why Healthcare Stocks Are A Prescription For Investors In Q2 2023, source:SeekingAlpha, summary: The recent drop in biopharma stocks presents a buying opportunity for investors. Find out why XLV seems like the best fit.",BIIB
173,2023-04-12,"Headline: Biogen price target lowered to $307 from $310 at Barclays, source:Thefly.com, summary: No summary, Headline: Biogen price target lowered to $349 from $351 at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: Biogen exercises option with Denali to develop its ATV:ABeta program, source:Thefly.com, summary: No summary, Headline: Biogen licenses amyloid beta-related program from Denali, source:Seeking Alpha, summary: No summary, Headline: Truist biotechnology analyst to hold an analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta, source:Yahoo, summary: Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagementCAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV):Amyloid beta program (ATV:Aβ). Accumulation of Aβ plaque in the brain is a defining feature of, Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.74% higher to $285.79 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P..., Headline: Biogen exercises option to license Denali treatment, source:Alliance News, summary: No summary, Headline: Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation, source:Fintel, summary: nan",BIIB
174,2023-04-13,"Headline: Appeals court permits limited access to abortion pill, blocks part of Texas ruling, source:Seeking Alpha, summary: No summary, Headline: June 2nd Options Now Available For Biogen, source:Stock Options Channel, summary: No summary, Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. rallied 1.37% to $289.70 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: Earnings Week Ahead: Tesla, AT&T, Charles Schwab, Netflix, and more, source:Seeking Alpha, summary: No summary",BIIB
175,2023-04-14,"Headline: Ghana 1st in world to approve new malaria vaccine by Oxford, source:Seeking Alpha, summary: No summary, Headline: Biogen Moves Deeper In Alzheimer`s With Denali, source:TalkMarkets, summary: No summary, Headline: Catalyst Watch: Earnings season picks up steam, housing data due, source:Seeking Alpha, summary: No summary, Headline: Biogen Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 0.54% to $288.13 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...",BIIB
176,2023-04-16,"Headline: 7 Sorry Pharma Stocks to Sell in April Before It`s Too Late, source:InvestorPlace, summary: No summary, Headline: Biogen Inc.'s (NASDAQ:BIIB) Intrinsic Value Is Potentially 32% Above Its Share Price, source:Yahoo, summary: Key Insights Biogen's estimated fair value is US$379 based on 2 Stage Free Cash Flow to Equity Biogen's US$288 share..., Headline: 3 Stocks to Buy That Could Be the Next Biotech Breakthrough, source:Yahoo, summary: In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky. If they fail, their stocks can languish at very low prices… or worse. But if they succeed, shareholders can see outstanding returns. It’s not quite a zero-sum game, but it’s close. That said, there are ways to limit risk when buying biotech stocks. Specifically, I look for undervalued companies that have already produced positive clinical trial data., Headline: What You Missed On Wall Street On Monday, source:Thefly.com, summary: No summary, Headline: Biogen upgraded to overweight at Piper Sandler on bullish Leqembi outlook, source:Seeking Alpha, summary: No summary",BIIB
177,2023-04-17,"Headline: Biogen upgraded to Overweight from Neutral at Piper Sandler, source:Thefly.com, summary: No summary, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Prometheus Biosciences (RXDX), Staar Surgical (STAA) and Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Biogen price target raised to $320 from $315 at Argus, source:Thefly.com, summary: No summary, Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: Biogen`s Leqembi has questionable efficacy, cost effectiveness, ICER says, source:Seeking Alpha, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Wedbush Sticks to Their Hold Rating for Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Wedbush Maintains Biogen (BIIB) Neutral Recommendation, source:Fintel, summary: nan, Headline: Piper Sandler Upgrades Biogen (BIIB), source:Fintel, summary: nan, Headline: Argus Research Maintains Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Notable Tuesday Option Activity: BIIB, NKE, SBUX, source:Stock Options Channel, summary: No summary",BIIB
178,2023-04-18,"Headline: Is Biogen Stock a Buy Now?, source:Yahoo, summary: Biotech giant Biogen (NASDAQ: BIIB) has been trying to develop a successful therapy for Alzheimer's disease (AD) for a long time, and its efforts seem to be about to pay off.  Earlier this year, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Leqembi, a treatment for AD that Biogen co-markets with Japan-based drug company Esai.  Accelerated approval currently comes with severe restrictions in the U.S., but Leqembi is under consideration for full approval by the FDA., Headline: Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline, source:Yahoo, summary: Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.56% higher to $293.83 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...",BIIB
179,2023-04-19,"Headline: Agios Pharmaceuticals appoints Capello to board of directors, source:Thefly.com, summary: No summary, Headline: Four Biotech Stocks for Parkinson's Disease Awareness Month, source:Nasdaq, summary: Anyone whose life has been touched by Parkinson's disease knows the importance of awareness and the development of more effective treatments. Every six minutes, someone in the U.S. is diagnosed with Parkinson's., Headline: Biogen (BIIB) to Report Q1 Earnings: Here's What to Expect, source:Yahoo, summary: Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of multiple sclerosis drugs, while sales of Spinraza are likely to have improved., Headline: Biogen Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. dropped 0.53% to $292.27 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: Supreme Court Extends Decision on Abortion Pills to Friday, source:Yahoo, summary: The court’s decision has broad implications for reproductive rights, for the power of the judicial system, and for the pharmaceutical industry.",BIIB
180,2023-04-20,"Headline: Amgen (AMGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?, source:Yahoo, summary: Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Biogen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slid 0.68% to $290.27 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: Better Big Biotech Buy: Biogen vs. Vertex, source:Yahoo, summary: Two great examples are Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX).  Biogen is known for its blockbuster multiple sclerosis drugs, including top seller Tecfidera.  Biogen's immunology drug, Rituxan, has also seen sales slip due to biosimilars in the market., Headline: Biopharma Deals Are Hot. There’s More to Come—and These Stocks Can Benefit., source:MarketWatch, summary: In the first quarter of this year, total healthcare and life sciences M&A in the U.S. was about $71 billion, according to KPMG., Headline: Catalyst watch: Earnings blitz, Mobileye lockup expiration and the new one-day VIX debut, source:Seeking Alpha, summary: No summary",BIIB
181,2023-04-21,"Headline: Analysts Are Bullish on These Healthcare Stocks: AmerisourceBergen (ABC), Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: AmerisourceBergen (ABC), Biogen (BIIB) and Elevance Health (ELV), source:TipRanks, summary: No summary, Headline: Biogen price target raised to $300 from $295 at BofA, source:Thefly.com, summary: No summary, Headline: Biogen To Report Q1 Earnings: Here`s What To Expect, source:TalkMarkets, summary: No summary, Headline: Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more, source:Seeking Alpha, summary: No summary, Headline: B of A Securities Maintains Biogen (BIIB) Neutral Recommendation, source:Fintel, summary: nan, Headline: Biogen Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. advanced 1.28% to $293.99 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!, source:Yahoo, summary: Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid brain plaques can help patients. Lilly plans to release results from a trial of its experimental amyloid-targeting drug donanemab before the end of June. More study data on Leqembi from Eisai Co Ltd (OTC: ESALY)/Biogen Inc (NASDAQ: BIIB) is also expected in the coming months. FDA granted accelerated",BIIB
182,2023-04-23,"Headline: What is behind biotech M&A resurgence?, source:Seeking Alpha, summary: No summary, Headline: FDA PDUFA Date for Ionis Pharmaceuticals & Biogen Tofersen is April 25, 2023, source:Thefly.com, summary: No summary",BIIB
183,2023-04-24,"Headline: Weekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro Recap, source:Yahoo, summary: By Vlad Schepkov, Headline: Notable earnings before Tuesday`s open, source:Seeking Alpha, summary: No summary, Headline: Biogen Q1 results in focus amid Leqembi conundrum, ALS drug future, source:Seeking Alpha, summary: No summary, Headline: Biogen Earnings Beat Expectations. All Eyes Are on the Alzheimer’s Drug., source:MarketWatch, summary: The biotch said it was dropping a number of drug-development initiatives, but is open to M&A. The CFO said the company could spend up to $10 billion., Headline: Biogen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. shed 0.33% to $293.03 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index..., Headline: Biogen Reports Earnings Tuesday. Watch for Alzheimer’s Drug Updates, source:Yahoo, summary: Investors already know that the biotech company's base business is shrinking, so few are looking there for growth., Headline: FDA grants accelerated approval to Biogen treatment for rare form of ALS, source:MarketWatch, summary: No summary, Headline: Biogen confirms FDA grants accelerated approval for Qalsody, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Cognetivity Neurosciences (OtherCGNSF), source:TipRanks, summary: No summary",BIIB
184,2023-04-25,"Headline: Biogen price target raised to $371 from $349 at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: Biogen (BIIB) Gets a Buy from Morgan Stanley, source:TipRanks, summary: No summary, Headline: Biogen reports Q1 EPS $3.40, consensus $3.28, source:Thefly.com, summary: No summary, Headline: Biogen backs FY23 EPS view $15.00-$16.00, consensus $15.48, source:Thefly.com, summary: No summary, Headline: Biogen Non-GAAP EPS of $3.40 beats by $0.12, revenue of $2.46B beats by $120M, source:Seeking Alpha, summary: No summary, Headline: FDA approves Ionis Pharma/Biogen`s QALSODY as first treatment in ALS, source:Thefly.com, summary: No summary, Headline: Biogen (BIIB) Gets a Buy from Mizuho Securities, source:TipRanks, summary: No summary, Headline: Biogen trims down R&D programs, Q1 revenue dips but reaffirms FY23 outlook, source:Seeking Alpha, summary: No summary, Headline: Biogen tops estimates as revenue slides 3% from a year ago, source:MarketWatch, summary: Biogen Inc. said Tuesday it had net income of $387.9 million, or $2.67 a share, for the first quarter, up from $303.8 million, or $2.06 a share, in the..., Headline: PepsiCo, McDonald's and Spotify rise premarket; First Republic slumps, source:Yahoo, summary: Investing.com -- Stocks in focus in premarket trade on Tuesday, April 25th. Please refresh for updates., Headline: Biogen Inc. Beats Q1 Earnings And Revenue Estimates, source:TalkMarkets, summary: No summary, Headline: Biogen beats profit estimates on strong Spinraza sales, source:Yahoo, summary: The drugmaker said it would terminate the late and mid-stage studies for an experimental neurological drug due to operational challenges that would help reduce full-year research expenses modestly.  Biogen will also put on hold a mid-stage study of an ischemic stroke drug candidate and scrap its early-stage trial of an experimental treatment for a rare neurodegenerative disease.  The company's new CEO, Christopher Viehbacher, has been looking for ways to keep costs low as Biogen prepares for high-profile launches of its second Alzheimer's disease treatment, Leqembi, and depression drug zuranolone., Headline: Cantor thinks M&A premium `baked into` TG Therapeutics shares will increase, source:Thefly.com, summary: No summary, Headline: UPDATE 1-Biogen beats profit estimates on strong Spinraza sales, source:Yahoo, summary: Biogen Inc on Tuesday beat expectations for quarterly profit on strong sales of spinal muscular atrophy drug Spinraza, but said it would pause or discontinue some studies to cut costs.  Biogen will also put on hold a mid-stage study of an ischemic stroke drug candidate and scrap its early-stage trial of an experimental treatment for a rare neurodegenerative disease.  The company's new CEO, Christopher Viehbacher, has been looking for ways to keep costs low as Biogen prepares for high-profile launches of its second Alzheimer's disease treatment, Leqembi, and depression drug zuranolone., Headline: Biogen On The Hunt, source:TalkMarkets, summary: No summary, Headline: FDA approves Biogen`s Qalsody for ALS patients with SOD1 gene mutation, source:Thefly.com, summary: No summary, Headline: BTIG Reaffirms Their Hold Rating on Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Biogen Inc. (BIIB) Beats Q1 Earnings and Revenue Estimates, source:Yahoo, summary: Biogen Inc. (BIIB) delivered earnings and revenue surprises of 4.62% and 5%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?, Headline: Biogen touts development pipeline despite quarterly revenue decline, source:Alliance News, summary: No summary, Headline: Biogen Inc. (BIIB) Q1 2023 Earnings Call Transcript, source:SeekingAlpha, summary: Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q1 2023 Earnings Conference Call April 25, 2023 8:00 AM ETCompany ParticipantsChuck Triano - Head of Investor RelationsChristopher Viehbacher - President..., Headline: Biogen, Ionis win FDA nod for ALS therapy Qalsody, source:Seeking Alpha, summary: No summary, Headline: FDA grants accelerated approval to Biogen`s treatment for rare form of ALS, source:MarketWatch, summary: No summary, Headline: FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease, source:CNBC, summary: The FDA's approval requires Biogen to further study its ALS drug tofersen to further verify its clinical benefits. , Headline: Biogen Inc. (BIIB) Reports Q1 Earnings: What Key Metrics Have to Say, source:Yahoo, summary: The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals., Headline: Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says, source:CNBC, summary: Biogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab. , Headline: FDA grants accelerated approval to Biogen’s treatment for rare form of ALS, source:DowJones, summary: The U.S. Food and Drug Administration said Tuesday it has granted accelerated approval to Biogen Inc.’s torferson, a treatment for a rare form of amyotrophic..., Headline: Biogen tops 1Q forecast despite sales slip for key products, source:Yahoo, summary: Biogen beat Wall Street’s first-quarter expectations even as revenue from the drugmaker’s biggest product group tumbled.  Sales of Biogen's multiple sclerosis treatments, which include Tecfidera and Tysabri, fell 19% to $1.12 billion compared to last year’s quarter, the company said Tuesday.  Sales of the drugmaker’s spinal muscular atrophy treatment Spinraza also dropped 6% to $443 million in the quarter., Headline: Biogen trims pipeline programs to cut costs, focus on Alzheimer's drug launch, source:Reuters, summary: Biogen Inc said on Tuesday it will pause or discontinue at least four studies of experimental drugs to focus on more potentially lucrative options including its second Alzheimer's treatment, Leqembi, in the latest attempt by the new CEO to trim costs., Headline: Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs, source:Yahoo, summary: Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading., Headline: Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs, source:Yahoo, summary: Biogen Inc (NASDAQ: BIIB) posted Q1 FY23 sales of $2.46 billion, beating the consensus of $2.34 billion, down 3% Y/Y and flat% at constant currency (CC). Multiple sclerosis revenue of $1.125 billion decreased by 19% (down 17% CC). Multiple sclerosis drug Tysabri sales are down to $472.8 million from $520.8 million. Spinraza's revenue of $443.3 million decreased by 6.2% in actual currency (decreased by 2.5% at CC). Biosimilars' revenue of $192.4 million decreased by 1%. Adjusted EPS of $3.40 decr, Headline: Biogen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. shed 3.62% to $282.41 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: UPDATE 2-US FDA approves Biogen's ALS drug, source:Yahoo, summary: The U.S. Food and Drug Administration said on Tuesday it had approved Biogen Inc's drug for treating a form of amyotrophic lateral sclerosis (ALS), making it the first available treatment targeting a genetic cause of the disease.  Biogen will be required to provide more data on the drug's effectiveness for it to remain on the market and for the FDA to grant traditional approval.  Qalsody's approval is based on data that showed it reduced levels of neurofilament protein, an indicator of nerve cell degeneration believed to be tied with progression of the symptoms of the disease., Headline: Drug for rare form of Lou Gehrig’s disease OK'd by FDA, source:Yahoo, summary: Food and Drug Administration regulators on Tuesday approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease, though they are requiring further research to confirm it truly helps patients.  The FDA approved Biogen's injectable drug for patients with a rare genetic mutation that's estimated to affect less than 500 people in the U.S. It's the first drug for an inherited form of ALS, or amyotrophic lateral sclerosis, a deadly disease that destroys nerve cells needed for basic functions like walking, talking and swallowing.  Approval came via FDA’s accelerated pathway, which allows drugs to launch based on promising early results, before they’re confirmed to benefit patients., Headline: Biogen's ALS drug granted accelerated approval by the FDA, source:Yahoo, summary: On Tuesday, Biogen said the FDA had approved the drug — which will be marketed under the name Qalsody — to treat ALS patients with a mutation in SOD1 gene., Headline: Biogen shifts gene therapy focus as it builds $200M facility in RTP, source:Yahoo, summary: Biogen is shifting its focus away from certain gene therapy programs as it builds out a nearly $200 million gene therapy manufacturing facility in Research Triangle Park., Headline: FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS, source:Yahoo, summary: FDA granted accelerated approval of QALSODY based on a reduction of neurofilament, a marker of neurodegeneration1Superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) is a devastating, uniformly fatal,2 and ultra-rare genetic form of ALS3-4 with approximately 330 people in the U.S. living with the disease5 CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY™ (tofersen) 10, Headline: US FDA approves Biogen's ALS drug, source:Reuters, summary: The U.S. Food and Drug Administration said on Tuesday it had approved Biogen Inc's drug for treating a form of amyotrophic lateral sclerosis (ALS), making it the first available treatment targeting a genetic cause of the disease., Headline: Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat, source:Yahoo, summary: The FDA approved Biogen's new ALS drug on Tuesday, but Biogen stock remained hamstrung on a ""low-quality earnings beat."", Headline: RBC says CMS clarity on Leqembi reimbursement should reduce Biogen overhang, source:Thefly.com, summary: No summary, Headline: Biogen gains as Medicare to cover new Alzheimer`s drug with full FDA approval, source:Seeking Alpha, summary: No summary, Headline: Q1 2023 Biogen Inc Earnings Call, source:Yahoo, summary: Q1 2023 Biogen Inc Earnings Call",BIIB
185,2023-04-26,"Headline: Analysts` Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Centene (CNC) and Danaher (DHR), source:TipRanks, summary: No summary, Headline: Biogen price target lowered to $302 from $307 at Barclays, source:Thefly.com, summary: No summary, Headline: Biogen price target raised to $325 from $310 at Oppenheimer, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Lineage Therap (LCTX) and Laboratory (LH), source:TipRanks, summary: No summary, Headline: Biogen wins accelerated FDA approval for treatment for rare form of ALS, source:MarketWatch, summary: No summary, Headline: Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Amylyx Pharmaceuticals Inc (AMLX), source:TipRanks, summary: No summary, Headline: Biogen price target lowered to $346 from $347 at UBS, source:Thefly.com, summary: No summary, Headline: Biogen price target lowered to $321 from $325 at Needham, source:Thefly.com, summary: No summary, Headline: Biogen price target raised to $330 from $325 at Canaccord, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Harvard Bioscience (HBIO) and Disc Medicine (IRON), source:TipRanks, summary: No summary, Headline: Jefferies Remains a Buy on Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Boston Scientific (BSX) and Danaher (DHR), source:TipRanks, summary: No summary, Headline: Biogen price target lowered to $340 from $344 at RBC Capital, source:Thefly.com, summary: No summary, Headline: EU publishes proposed reforms for pharma industry, source:Seeking Alpha, summary: No summary, Headline: Barclays Maintains Biogen (BIIB) Equal-Weight Recommendation, source:Fintel, summary: nan, Headline: Atlantic Equities Maintains Biogen (BIIB) Neutral Recommendation, source:Fintel, summary: nan, Headline: Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation, source:Fintel, summary: nan, Headline: Needham Maintains Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Lilly to report Q1 2023 results with pipeline updates in spotlight, source:Seeking Alpha, summary: No summary, Headline: Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates, source:Yahoo, summary: Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector., Headline: Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says, source:CNBC, summary: Medicare has severely restricted access to the medication Leqembi, which costs $26,500 per year, because the FDA approved it just on an expedited basis., Headline: Eli Lilly Earnings Are Soon. All Eyes Are on Its Diabetes Drug, Mounjaro., source:MarketWatch, summary: Expectations for first-quarter sales of its diabetes treatment, Mounjaro, are $433 million., Headline: Biogen Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. rose 1.99% to $288.04 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA, source:Yahoo, summary: The FDA approved Biogen Inc's (NASDAQ: BIIB) Qalsody (tofersen) for amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on a reduction in plasma neurofilament light chain (NfL) observed in patients treated with Qalsody. Neurofilaments are proteins released from neurons when damaged, making them a marker of neurodegeneration. Continued approval for this indication may be contingen, Headline: RBC Capital Maintains Biogen (BIIB) Outperform Recommendation, source:Fintel, summary: nan, Headline: Canaccord Genuity Maintains Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Wedbush Reiterates Biogen (BIIB) Neutral Recommendation, source:Fintel, summary: nan, Headline: Oppenheimer Maintains Biogen (BIIB) Outperform Recommendation, source:Fintel, summary: nan, Headline: HC Wainwright & Co. Reiterates Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan",BIIB
186,2023-04-27,"Headline: Wall Street Breakfast Podcast: Meta Platforms Soars, source:SeekingAlpha, summary: Meta earnings call: Never mind the ad beat, here's the AI future (and present). Disney sues Florida Gov. DeSantis after district clampdown. Biogen gains as Medicare to cover Alzheimer's drug, Headline: The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio, source:Yahoo, summary: Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog., Headline: Biotech Alert: Searches spiking for these stocks today, source:Thefly.com, summary: No summary, Headline: Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Lineage Therap (LCTX), source:TipRanks, summary: No summary, Headline: Drugmakers brace for serious headwinds ahead, source:Yahoo, summary: Yahoo Finance’s Anjalee Khemlanin joins the Live show to discuss quarterly earnings for Abbvie, Merck & Company, and Biogen, the headwinds facing drugmakers, and what they mean for investors watching the pharmaceuticals space., Headline: PureTech Announces Annual Results for Year Ended December 31, 2022, source:Business Wire, summary: No summary",BIIB
187,2023-04-28,"Headline: The 3��Most Promising Biotech Innovations in 2023 and the Stocks to Buy, source:InvestorPlace, summary: No summary, Headline: Buy Biogen For Runups To��Imminent Regulatory Decisions, source:Seeking Alpha, summary: No summary, Headline: Buy Biogen For Runups To Imminent Regulatory Decisions, source:SeekingAlpha, summary: Advisory Committee meeting for Biogen's LEQEMBI is set for June 9 and the Prescription Drug User Fee Act action date is on July 6. Read why BIIB stock is a buy., Headline: The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy, source:Yahoo, summary: The biotech sector is up 4.76% so far in 2023. This continues the nice run that biotech stocks had in 2022. The gains in biotech were in stark contrast to the broader market. All the major exchanges were down last year with growth investors finding few places to hide. But growth-oriented investors don’t have to look back too far to see how quickly things can change. In 2021, biotech stocks were down 25% and even the most innovative biotech stocks found it hard to get a bid. There are many reason, Headline: Biogen Inc. 2023 Q1 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Biogen Inc., Headline: Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 87% of the company, source:Yahoo, summary: Key Insights Institutions' substantial holdings in Biogen implies that they have significant influence over the..., Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. rallied 3.58% to $304.23 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",BIIB
188,2023-04-29,"Headline: 27 Largest Biotech Companies in the US, source:Yahoo, summary: In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US have a total market cap of $88 trillion. Latest Developments in […]",BIIB
189,2023-05-01,"Headline: Biogen upgraded to Buy from Neutral at Guggenheim, source:Thefly.com, summary: No summary, Headline: Morgan Stanley`s Wilson screens for stocks as earnings stabilize but data disappoints, source:Seeking Alpha, summary: No summary, Headline: Biogen up as Guggenheim upgrades citing full approval for Leqembi, source:Seeking Alpha, summary: No summary, Headline: Biogen upgraded to Buy at Guggenheim on potential for growth, source:Thefly.com, summary: No summary, Headline: Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments , source:CNBC, summary: Attorneys general from 23 states, the District of Columbia, and two U.S. territories called on Medicare to cover Alzheimer's treatments without restrictions. , Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: Guggenheim Upgrades Biogen (BIIB), source:Fintel, summary: nan, Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. advanced 2.26% to $311.11 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",BIIB
190,2023-05-02,"Headline: Biogen Inc. (NASDAQ:BIIB) Q1 2023 Earnings Call Transcript, source:Yahoo, summary: Biogen Inc. (NASDAQ:BIIB) Q1 2023 Earnings Call Transcript April 25, 2023 Biogen Inc. beats earnings expectations. Reported EPS is $3.4, expectations were $3.28. Operator: Good morning. My name is Bettina and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen First Quarter 2023 Earnings Call […], Headline: Biogen prices ALS therapy Qalsody at $14K a dose - report, source:Seeking Alpha, summary: No summary, Headline: Biogen prices new ALS treatment at $14,230 per vial, source:MarketWatch, summary: Biogen Inc. has priced its recently approved ALS treatment Qalsody at $14,230 per vial, a spokesperson confirmed to MarketWatch on Tuesday. The drug, also..., Headline: Biogen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slipped 0.59% to $309.28 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500..., Headline: Eli Lilly`s positive results from a Alzheimer`s trial seen as ���potentially very important`, source:MarketWatch, summary: No summary, Headline: Notable Wednesday Option Activity: BIIB, GPRE, CHK, source:Stock Options Channel, summary: No summary, Headline: Lilly sends Alzheimer`s drug developers higher after trial data, source:Seeking Alpha, summary: No summary",BIIB
191,2023-05-03,"Headline: Biogen price target raised to $340 from $315 at Mizuho, source:Thefly.com, summary: No summary, Headline: Eli Lilly stock jumps 5% after Alzheimer's treatment slows disease progression in major trial, source:MarketWatch, summary: After one year, nearly half of the trial's participants showed no disease progression, Lilly said., Headline: Eli Lilly stock jumps 8% after Alzheimer`s treatment slows disease progression in major trial, source:MarketWatch, summary: No summary, Headline: Eli Lilly Drug Aids Alzheimer’s Patients but Safety Is an Issue, source:MarketWatch, summary: The company says a Phase 3 study shows that donanemab 'significantly slowed cognitive and functional decline' in people with early symptomatic Alzheimer’s., Headline: Lilly`s Gain Is Biogen`s Pain After Promising Alzheimer`s Data, source:TipRanks, summary: No summary, Headline: Biogen slips after competitor Eli Lilly`s Alzheimer`s trial hits target, source:Thefly.com, summary: No summary, Headline: Stocks making the biggest moves premarket: Starbucks, AMD, Pearson, PacWest & more, source:CNBC, summary: These are the stocks posting the largest moves in premarket trading. , Headline: Another Sucess In Alzheimer`s Disease, source:TalkMarkets, summary: No summary, Headline: Biogen wins EU exclusivity for Tecfidera until 2025, source:Seeking Alpha, summary: No summary, Headline: Lilly`s New Donanemab Data For Alzheimer`s, source:Seeking Alpha, summary: No summary, Headline: Eli Lilly Surges On Promising Data From Late-Stage Alzheimer's Drug Trial, source:Yahoo, summary: ""This is the first Phase 3 trial of any investigational medicine for Alzheimer's disease to deliver 35% slowing of clinical and functional decline,"" Eli Lilly said., Headline: Eli Lilly stock jumps 5% after Alzheimer`s treatment slows disease progression in major trial, source:MarketWatch, summary: No summary, Headline: Biogen says EC extends Tecfidera regulatory market protection to February 2025, source:Thefly.com, summary: No summary, Headline: Eli Lilly Results Signal Arrival of Blockbuster New Drug Class, source:Yahoo, summary: Its Alzheimer’s treatment results might look better than Biogen’s, but both companies will likely benefit., Headline: Biogen Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.56% higher to $311.00 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P..., Headline: Eli Lilly Hits A Record-Smashing $400 Billion Market Cap Following Its Alzheimer's Win, source:Yahoo, summary: Eli Lilly stock popped Wednesday after the company said its experimental Alzheimer's treatment significantly slowed cognitive decline., Headline: Obesity drug could be a 'big upside' for Eli Lilly, says Wells Fargo's Mohit Bansal, source:CNBC, summary: Mohit Bansal, Wells Fargo managing director, joins 'Fast Money' to talk Eli Lilly drug trials, it's competition with Biogen for an alzheimer's drug, and more., Headline: Eli Lilly: Positive results on its new Alzheimer's drug, source:Yahoo, summary: Eli Lilly stock is up on news that its new Alzheimer's drug showed reduction in cognitive decline., Headline: Lilly's New Donanemab Data For Alzheimer's, source:SeekingAlpha, summary: Eli Lilly made headlines on May 3, 2023 with an announcement that their anti-amyloid antibody donanemab hit its endpoints in a Phase III clinical trial.",BIIB
192,2023-05-04,"Headline: AstraZeneca chair says it is paying CEO enough to ward off US rivals, source:Yahoo, summary: The new chair of AstraZeneca believes the drugmaker has extinguished the threat of chief executive Pascal Soriot quitting for lucrative roles in the US, saying that the benefit of increasing his pay in recent years outweighed the criticism from some shareholders.  Under Soriot, who has led AstraZeneca for more than a decade, the group has become the most valuable company on the London market, with a market capitalisation of £185bn.  Sales of its innovative cancer drugs has helped propel the group to three times the size of UK rival GSK., Headline: Eli Lilly price target raised to $490 from $420 at Credit Suisse, source:Thefly.com, summary: No summary, Headline: Eli Lilly price target raised to $475 from $430 at JPMorgan, source:Thefly.com, summary: No summary, Headline: Q1 2023 Ionis Pharmaceuticals Inc Earnings Call, source:Yahoo, summary: Q1 2023 Ionis Pharmaceuticals Inc Earnings Call, Headline: Biogen price target raised to $320 from $300 at BofA, source:Thefly.com, summary: No summary, Headline: Eli Lilly price target raised to $505 from $430 at BMO Capital, source:Thefly.com, summary: No summary, Headline: Good results from Alzheimer`s drug trial seen as ���potentially very important`, source:MarketWatch, summary: No summary, Headline: Ionis Pharma upgraded at Citi after quarterly update, source:Seeking Alpha, summary: No summary, Headline: Is Biogen Inc.'s (NASDAQ:BIIB) Recent Stock Performance Influenced By Its Fundamentals In Any Way?, source:Yahoo, summary: Biogen's (NASDAQ:BIIB) stock is up by a considerable 12% over the past month. As most would know, fundamentals are what..., Headline: Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match, source:Yahoo, summary: Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023., Headline: B of A Securities Maintains Biogen (BIIB) Neutral Recommendation, source:Fintel, summary: nan, Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.83% higher to $313.57 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P..., Headline: Buy/Sell: Wall Street`s top 10 stock calls this week, source:Thefly.com, summary: No summary, Headline: New Alzheimer`s drug trial seen as ���potentially very important`, source:MarketWatch, summary: No summary",BIIB
193,2023-05-05,"Headline: Biogen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. advanced 1.43% to $318.06 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: Eli Lilly`s Donanemab: The Anti-Amyloid Saga Continues, source:Seeking Alpha, summary: No summary",BIIB
194,2023-05-06,"Headline: Mizuho Securities Reaffirms Their Buy Rating on Biogen (BIIB), source:TipRanks, summary: No summary",BIIB
195,2023-05-07,"Headline: Fly Insider: Zions Bancorp, Albertsons among week`s notable insider trades, source:Thefly.com, summary: No summary",BIIB
196,2023-05-08,"Headline: Two Alzheimer’s drugs offer hope to patients after decades of waiting, source:Yahoo, summary: In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide, Headline: Elliott Wave Technical Analysis: Biogen Inc. - Monday, May 8, source:TalkMarkets, summary: No summary, Headline: Coya Therapeutics: Developing Treatments For Serious Neurodegenerative And Autoimmune Diseases, source:SeekingAlpha, summary: Coyaâs pipeline candidates have undergone initial human trials depicting efficacy and safety of its Treg-modulating therapies. Read why COYA stock is a buy., Headline: Lilly and Biogen Want Medicare to Cover New Alzheimer’s Drugs. It’s Not Happening., source:Yahoo, summary: Even after the latest Lilly data showing that its drug slowed the disease, the agency that runs the program isn't budging., Headline: Biogen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. shed 1.16% to $314.37 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index..., Headline: Cassava Sciences adds 14% most since September, source:Seeking Alpha, summary: No summary",BIIB
197,2023-05-09,"Headline: Vigil Neuroscience appoints Haeberlein to board of directors, source:Thefly.com, summary: No summary, Headline: See How Biogen Ranks Among Analysts` Top Picks With Strong Buyback Activity, source:The Online Investor, summary: No summary, Headline: Biogen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. slumped 0.12% to $314.00 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500..., Headline: Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus, source:Yahoo, summary: Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates., Headline: 15 Biggest Immunotherapy Companies in the World, source:Yahoo, summary: In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power […], Headline: Meta Platforms Takes Center Stage Among Moat Stocks, source:SeekingAlpha, summary: A punishing 2022 for Meta Platforms created a valuation opportunity - one that has paid off as it becomes the top contributor year-to-date for the Morningstar Wide Moat Focus Index.",BIIB
198,2023-05-10,"Headline: PTC Therapeutics: A Gem In The Rare Diseases Treatment Market, source:SeekingAlpha, summary: PTC Therapeutics specializes in developing and subsequently commercializing next-generation drugs to treat orphan diseases. Find out why PTCT stock is a Buy., Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. sank 0.24% to $313.26 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",BIIB
199,2023-05-11,"Headline: Lundbeck, Otsuka`s Rexulti wins FDA approval for agitation linked with Alzheimer`s, source:Seeking Alpha, summary: No summary, Headline: Biogen price target raised to $350 from $320 at Argus, source:Thefly.com, summary: No summary, Headline: Biogen's (NASDAQ:BIIB) investors will be pleased with their favorable 64% return over the last year, source:Yahoo, summary: Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly..., Headline: Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal, source:Yahoo, summary: Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors., Headline: Argus Research Maintains Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Biogen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. shed 0.86% to $310.56 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds, source:Yahoo, summary: Wide coverage of Alzheimer's drug Leqembi would raise future costs for the U.S. Medicare health plan by $2 billion to $5 billion a year, according to a study led by researchers at the University of California, Los Angeles (UCLA).  Leqembi, sold by partners Eisai Co Ltd and Biogen Inc at an annual list price of $26,500, was approved this year under the U.S. Food and Drug Administration's accelerated pathway.  The Centers for Medicare and Medicaid Services (CMS), the agency that runs the health plan for people age 65 and older, currently covers the medication only for patients enrolled in clinical trials., Headline: Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 billion a year, study finds, source:Reuters, summary: Wide coverage of Alzheimer's drug Leqembi would raise future costs for the U.S. Medicare health plan by $2 billion to $5 billion a year, according to a study led by researchers at the University of California, Los Angeles (UCLA).",BIIB
200,2023-05-12,"Headline: BiomX appoints Jason Marks, Michael Dambach to board of directors, source:Thefly.com, summary: No summary, Headline: 3 Reasons to Buy Biogen Stock (and 1 to Sell), source:Yahoo, summary: The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi., Headline: Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates, source:CNBC, summary: The authors said the estimated costs of Leqembi to Medicare are conservative and spending on the Alzheimer's treatment may increase more than anticipated. , Headline: Biogen Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 0.31% to $309.60 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",BIIB
201,2023-05-14,"Headline: Biogen`s new Alzheimer`s drug to raise annual Medicare costs by up to $5B ��� study, source:Seeking Alpha, summary: No summary, Headline: These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win, source:Yahoo, summary: Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies.  Biogen's prior attempt at an Alzheimer's medicine to hit the market was a train wreck, but its latest drug seems to be avoiding a repeat.  Meanwhile, Eli Lilly has yet to submit its candidate for regulatory review.",BIIB
202,2023-05-15,"Headline: Canadian Solar subsidiary signs aggregation deal for 100MW in Texas, source:Thefly.com, summary: No summary, Headline: Biogen (BIIB) Receives a Hold from Bank of America Securities, source:TipRanks, summary: No summary, Headline: Recurrent Energy Signs Aggregation Deal for 100 MW of Solar Energy in Texas with Industry Consortium, source:PR Newswire, summary: No summary, Headline: Eli Lilly price target raised to $507 from $478 at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: Biogen Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.73% higher to $311.87 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: Jim Cramer compares market conditions to 2011 as debt ceiling showdown continues, source:CNBC, summary: 'Mad Money' host Jim Cramer talks market performance after the Dow breaks its losing streak and compares market conditions to 2011., Headline: Jim Cramer expects defensive stocks to be resilient as debt ceiling talks drag on, source:CNBC, summary: CNBC's Jim Cramer is looking to 2011 for investing guidance during the ongoing debt ceiling uncertainty. , Headline: Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says., source:Yahoo, summary: Lilly's Alzheimer's treatment could reach blockbuster status by 2025, an analyst said Monday. Eli Lilly stock is trading near a record high., Headline: Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease, source:Yahoo, summary: TOKYO and CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of early Alzheimer’s disease (mild cogniti",BIIB
203,2023-05-16,"Headline: Health Canada accepts Biogen's submission for Alzheimer's drug Leqembi, source:Alliance News, summary: No summary, Headline: Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far, source:Yahoo, summary: Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need., Headline: Biogen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. shed 1.37% to $307.61 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",BIIB
204,2023-05-17,"Headline: Prothena adds former FDA neuro chief Billy Dunn to director board, source:Seeking Alpha, summary: No summary, Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. dropped 0.44% to $306.25 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: Sen. Wyden presses HHS, CMS on access to new Alzheimer`s therapies, source:Seeking Alpha, summary: No summary",BIIB
205,2023-05-18,"Headline: Supreme Court rules against Amgen in Rapatha patent dispute with Sanofi/ Regeneron, source:Seeking Alpha, summary: No summary, Headline: Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron, source:Seeking Alpha, summary: No summary, Headline: Cognition Therapeutics stock rises after CT1812 shows promise in Alzheimer`s study, source:Seeking Alpha, summary: No summary, Headline: Biogen Inc.'s (NASDAQ:BIIB) Intrinsic Value Is Potentially 29% Above Its Share Price, source:Yahoo, summary: Key Insights Biogen's estimated fair value is US$394 based on 2 Stage Free Cash Flow to Equity Biogen's US$306 share..., Headline: Biogen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. shed 0.26% to $305.45 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",BIIB
206,2023-05-19,"Headline: 1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market, source:Yahoo, summary: Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak., Headline: 3 Biotech Stocks That Are Revolutionizing Healthcare in 2023, source:Yahoo, summary: The biotechnology (or biotech) sector is a crystal-clear illustration of risk and reward. Many biotech companies work on drugs and therapeutics for some of the most pernicious conditions affecting our society and healthcare system. But finding the best biotech stocks to buy is not always simple. Many biotech companies work on drugs for years. And these biotech stocks will swing wildly on the news. Positive results from a clinical trial can send stocks soaring. Conversely, disappointing results c, Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.99% higher to $308.48 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",BIIB
207,2023-05-21,"Headline: Billions of dollars at stake as FDA shortcut allows half-proven drugs - report, source:Seeking Alpha, summary: No summary, Headline: Biogen collaborator Eisai submits marketing application for Lecanemab, source:Alliance News, summary: No summary",BIIB
208,2023-05-22,"Headline: Biogen reports Eisai submitted MAA for lecanemab for early Alzheimer's to MHRA, source:Thefly.com, summary: No summary, Headline: Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?, source:Yahoo, summary: Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously..., Headline: Biogen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. shed 0.52% to $306.87 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",BIIB
209,2023-05-23,"Headline: Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Biogen (BIIB) and Blueprint Medicines (BPMC), source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Blueprint Medicines (BPMC) and Cerevel Therapeutics Holdings (CERE), source:TipRanks, summary: No summary, Headline: Wedbush Reiterates Biogen (BIIB) Neutral Recommendation, source:Fintel, summary: nan, Headline: Biogen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. shed 1.21% to $303.15 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",BIIB
210,2023-05-24,"Headline: Wednesday’s Top Analyst Upgrades and Downgrades: Chevron, Microsoft, Nucor, Salesforce, Wheaton Precious Metals and More, source:247WallSt, summary: No summary, Headline: Biogen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. sank 0.52% to $301.56 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: 10 Dementia Medications that are Approved or in Clinical Trials, source:Yahoo, summary: In this article, we will be taking a look at the 10 dementia medications that are approved or in clinical trials. To skip our detailed analysis, you can go directly to see the 5 dementia medications that are approved or in clinical trials. Advancements in medicine have absolutely changed the way we live right now, […]",BIIB
211,2023-05-25,"Headline: 14 Best Biotech Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […], Headline: New Alzheimer’s drug could bring hope to patients, but could be out of reach for people on Medicare, source:MarketWatch, summary: No summary, Headline: Biogen Inc. (BIIB) Up 4.7% Since Last Earnings Report: Can It Continue?, source:Yahoo, summary: Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: Biogen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 1.47% to $297.13 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index..., Headline: Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender, source:SeekingAlpha, summary: Biggest sales growth driver for Roche Holding AG is Vabysmo, approved for wet age-related macular degeneration and other uses. Click here for our RHHBF stock review.",BIIB
212,2023-05-26,"Headline: Elon Musk's Neuralink gets FDA nod to start human trial of brain implant, source:Seeking Alpha, summary: No summary, Headline: Biogen Unusual Options Activity For May 26, source:Benzinga, summary: No summary, Headline: Alkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue?, source:Yahoo, summary: Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: Biogen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.51% higher to $298.66 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",BIIB
213,2023-05-29,"Headline: Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 88% of the company, source:Yahoo, summary: Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...",BIIB
214,2023-05-30,"Headline: Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?, source:TalkMarkets, summary: No summary, Headline: Biogen Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.01% higher to $298.69 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...",BIIB
215,2023-05-31,"Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. shed 0.76% to $296.41 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: Medicare unveils plan for coverage of new Alzheimer’s drugs, source:MarketWatch, summary: No summary",BIIB
216,2023-06-01,"Headline: Biogen price target raised to $360 from $346 at Piper Sandler, source:Thefly.com, summary: No summary, Headline: Medicare to cover Alzheimer's drugs granted full FDA approval, source:Seeking Alpha, summary: No summary, Headline: Biogen (BIIB) Receives a Buy from Mizuho Securities, source:TipRanks, summary: No summary, Headline: Goldman Sachs Remains a Buy on Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Medicare to cover new Alzheimer's drug after full approval , source:Reuters, summary: The Centers for Medicare & Medicaid Services said on Thursday that the U.S. Medicare health plan would cover new Alzheimer's drugs such as Eisai Co Ltd and Biogen Inc's Leqembi if they gain full U.S. approval., Headline: 15 Best Healthcare Stocks To Buy Now, source:Yahoo, summary: In this article, we will take a look at the 15 best healthcare stocks to buy now. For more stocks, head on over to 5 Best Healthcare Stocks To Buy Now. In the midst of uncertain economic conditions globally, the healthcare sector has displayed a notable degree of resilience. Historically, the demand for healthcare products […], Headline: Piper Sandler Maintains Biogen (BIIB) Overweight Recommendation, source:Fintel, summary: nan, Headline: Medicare Will Pay for Biogen’s Alzheimer’s Drug, With a Caveat, source:Yahoo, summary: The agency that oversees the medical program for seniors will pick up the bill only if doctors submit treatment data to a nationwide registry., Headline: Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump, source:Yahoo, summary: Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments., Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. rallied 2.02% to $302.41 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: Medicare Plans to Cover Alzheimer’s Drugs, source:Yahoo, summary: Medicare plans to widen coverage of Alzheimer’s drugs that could win full approval as soon as this summer.  The Centers for Medicare and Medicaid Services on Thursday said it would cover Biogen and Eisai’s treatment Leqembi if the drug wins full approval and patients and doctors contribute to a registry that collects evidence on how the medication works.  Most Alzheimer’s patients in the U.S. are Medicare enrollees.",BIIB
217,2023-06-02,"Headline: Medicare will cover Biogen, Eisai's Alzheimer's drug, WSJ reports, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Stericycle (SRCL), Biogen (BIIB) and Acadia Healthcare (ACHC), source:TipRanks, summary: No summary, Headline: Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study, source:Yahoo, summary: Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks., Headline: Biogen Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slumped 0.73% to $300.20 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: RBC Capital Reiterates Biogen (BIIB) Outperform Recommendation, source:Fintel, summary: nan",BIIB
218,2023-06-04,"Headline: $100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today, source:Benzinga, summary: No summary, Headline: Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays., source:MarketWatch, summary: No summary",BIIB
219,2023-06-05,"Headline: Biogen, Denali shift focus of Parkinson's Disease clinical development program, source:Thefly.com, summary: No summary, Headline: Denali's LRRK2 program changes 'unsurprising but negative,' says Stifel, source:Thefly.com, summary: No summary, Headline: IN BRIEF: Biogen revises development program of BIIB122 in Parkinson's, source:Alliance News, summary: No summary, Headline: Biogen Inc. stock underperforms Monday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.64% higher to $302.13 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500..., Headline: Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure, source:Yahoo, summary: In its ongoing R&D reorganization, Biogen Inc (NASDAQ: BIIB) will discontinue a Phase 3 program evaluating BIIB122 as a treatment for patients with Parkinson’s disease related to LRRK2 mutations with partner Denali Therapeutics Inc (NASDAQ: DNLI). Before the planned revisions, the BIIB122 development program encompassed the following: The Phase 2b LUMA study in participants with early-stage Parkinson’s disease commenced in May 2022. The Phase 3 LIGHTHOUSE study in participants with Parkinson’s d, Headline: Biogen withdraws from Jefferies Healthcare Conference, source:Thefly.com, summary: No summary, Headline: Notable Tuesday Option Activity: BIIB, OZK, TRUP, source:Stock Options Channel, summary: No summary",BIIB
220,2023-06-06,"Headline: Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122, source:Yahoo, summary: Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's, Headline: Biogen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. dropped 0.77% to $299.79 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Biogen (BIIB) Receives a Buy from Goldman Sachs, source:TipRanks, summary: No summary",BIIB
221,2023-06-07,"Headline: FDA posts briefing document ahead of review of Biogen and Eisai's Leqembi, source:Thefly.com, summary: No summary, Headline: Mizuho Securities Reaffirms Their Buy Rating on Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Biogen briefing docs 'super clean' with no surprises, says Mizuho, source:Thefly.com, summary: No summary, Headline: Novo Nordisk and Golden Entertainment have been highlighted as Zacks Bull and Bear of the Day, source:Yahoo, summary: Novo Nordisk and Golden Entertainment are part of the Zacks Bull and Bear of the Day article., Headline: FDA briefing docs 'appear largely supportive' of Biogen's Leqembi, says Wedbush, source:Thefly.com, summary: No summary, Headline: Biogen's Lequembi likely to be granted full approval by FDA, says Baird, source:Thefly.com, summary: No summary, Headline: Biogen gains on “super clean” FDA docs on Alzheimer’s drug ahead of AdCom vote, source:Seeking Alpha, summary: No summary, Headline: Do Its Financials Have Any Role To Play In Driving Biogen Inc.'s (NASDAQ:BIIB) Stock Up Recently?, source:Yahoo, summary: Biogen's (NASDAQ:BIIB) stock is up by a considerable 14% over the past three months. We wonder if and what role the..., Headline: Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action , source:CNBC, summary: Sen. Bernie Sanders said the $26,500 annual price for Alzheimer's treatment Leqembi would financially burden on Medicare and increase premiums for seniors., Headline: FDA staff say Eisai's Alzheimer's drug may get full approval despite concerns, source:Yahoo, summary: Staff reviewers of the U.S. Food and Drug Administration (FDA) said on Wednesday that Eisai and Biogen's Alzheimer's drug, Leqembi, may still be eligible for a full approval despite concerns of brain hemorrhage from using blood thinners along with the drug.  The FDA staff's comments about the drug were made in documents released ahead of a meeting of the panel of external advisers on Friday to discuss the Japanese company's application for a traditional approval., Headline: Eisai-Biogen Alzheimer's drug data confirms benefits, FDA staff says, source:Reuters, summary: Staff reviewers of the U.S. drug regulator said trial data on Eisai and Biogen's Leqembi confirmed benefits of the early Alzheimer's drug and the prospects of a full approval were unaffected by higher risks of brain hemorrhage., Headline: Biogen Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. rallied 1.70% to $304.90 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near, source:Yahoo, summary: Biogen stock rose Wednesday after the FDA posted documents that suggest the agency will approve Alzheimer's treatment Leqembi., Headline: Thinking Of Buying Boston Properties? Here Are The Properties And Tenants You'd Add To Your Portfolio, source:Yahoo, summary: When investors consider the purchase of a real estate investment trust (REIT), along with performance and dividends, they need to consider the properties and tenants that accompany that REIT. Several questions must be answered: Are the tenants long-term and stable? Are they strong enough to survive recessions and market downturns? Is the portfolio diversified by location, type and annualized base rent (ABR)? Take a look at one of the largest office REITs today to see whether it answers the above, Headline: Mastering the Double-Bottom Pattern (Unveiling 3 Intriguing Setups in Today's Market), source:Yahoo, summary: A double-bottom base is a chart pattern commonly used in technical analysis to identify a solid reward-to-risk zone in a stock. Stock Strategist Andrew Rocco walks you through the pattern and unveils 3 juicy setups., Headline: Baird Reiterates Biogen (BIIB) Prior Recommendation, source:Fintel, summary: nan, Headline: Eisai and Biogen’s Alzheimer’s Drug Moves Closer to Full US Approval, source:Yahoo, summary: (Bloomberg) -- Eisai Co. and Biogen Inc. moved closer to full US approval for their Alzheimer’s drug Leqembi after the Food and Drug Administration posted documents indicating it sees no barriers to clearance, setting the product up for likely government health-plan coverage. Most Read from BloombergMystery Bet Before SEC Crypto Crackdown May Mint Trader MillionsThese Are the World’s 20 Most Expensive Cities for Expats in 2023Messi Spurns $400 Million Saudi Offer to Join Beckham’s MiamiFlights t, Headline: Biogen notes Eisai files marketing authorisation for Alzheimer's drug, source:Alliance News, summary: No summary",BIIB
222,2023-06-08,"Headline: Analysts Conflicted on These Healthcare Names: Avita Medical (RCEL), 4D Molecular Therapeutics (FDMT) and Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Biogen briefing documents 'appear benign,' says Barclays, source:Thefly.com, summary: No summary, Headline: Biogen briefing documents bode well for full approval, says Canaccord, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Paycor HCM (PYCR), Crispr Therapeutics AG (CRSP) and Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Analysts’ Top Healthcare Picks: HashiCorp (HCP), Astria Therapeutics (ATXS), source:TipRanks, summary: No summary, Headline: Expert Ratings for Biogen, source:Benzinga, summary: No summary, Headline: Interesting BIIB Put And Call Options For July 28th, source:Stock Options Channel, summary: No summary, Headline: Eisai submits marketing authorization application for lecanemab in South Korea, source:Thefly.com, summary: No summary, Headline: Needham Reiterates Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval, source:Yahoo, summary: FDA Peripheral and Central Drugs Advisory Committee is meeting Friday (June 9) to discuss a supplemental marketing application for Leqembi (lecanemab) submitted by Eisai Co Ltd (OTC: ESALY) for Alzheimer's disease, initiated in patients with mild cognitive impairment or mild dementia stage of the disease. The Leqembi application has been granted Priority Review, with a Prescription Drug User Fee Act action date of July 6. Eisai is collaborating with Biogen Inc (NASDAQ: BIIB) for lecanemab. The A, Headline: Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More, source:Yahoo, summary: Regulatory and pipeline updates from GSK plc (GSK) and Biogen (BIIB) are in focus in the biotech sector., Headline: Biogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod, source:Yahoo, summary: Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month., Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. advanced 1.31% to $308.88 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable', source:Yahoo, summary: Senator Bernie Sanders urged the U.S. Department of Health and Human Services (HHS) to immediately address the exorbitant cost of Eisai Co Ltd (OTC: ESALY)/Biogen Inc (NASDAQ: BIIB) Alzheimer's treatment Leqembi (lecanemab). Wednesday, the FDA released briefing documents ahead of the meeting that appears to support a full FDA approval for Leqembi. In a letter to HHS Secretary Xavier Becerra, Sanders, who chairs the Senate Health Committee, expressed his deep concern over the annual price for Leq, Headline: Barclays Maintains Biogen (BIIB) Overweight Recommendation, source:Fintel, summary: nan, Headline: FDA panel votes 6-0 to back Biogen, Eisai's Leqembi, source:Thefly.com, summary: No summary, Headline: FDA panel recommends full approval for Biogen, Esai Alzheimer's drug, source:Seeking Alpha, summary: No summary, Headline: FDA panel recommends full approval for Biogen, Eisai Alzheimer's drug, source:Seeking Alpha, summary: No summary",BIIB
223,2023-06-09,"Headline: FDA advisers vote in favor of Biogen and Eisai’s collaborative Alzheimer’s treatment, source:MarketWatch, summary: No summary, Headline: Eisai, Biogen: FDA panel votes unanimously to confirm benefit of Leqembi, source:Thefly.com, summary: No summary, Headline: Biogen Takes Alzheimer’s Drug to FDA Advisers. The Last Time Was a Disaster., source:Yahoo, summary: The agency's Peripheral and Central Nervous System Drugs Advisory Committee will consider whether a Phase 3 study confirms the drug's clinical benefit., Headline: Biogen on hold for trading ahead of FDA AdCom vote on Alzheimer’s drug, source:Seeking Alpha, summary: No summary, Headline: Biogen trading on Nasdaq halted as US FDA probes Alzheimer's drug, source:Alliance News, summary: No summary, Headline: Biogen Stock in Focus on Key Vote on Lequembi, source:TipRanks, summary: No summary, Headline: SVB Securities Sticks to Its Buy Rating for Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Zimmer Biomet Holdings (ZBH) and Innate Pharma SA (OtherIPHYF), source:TipRanks, summary: No summary, Headline: Biogen shares halted as FDA advisory panel meets to discuss Alzheimer's drug, source:Yahoo, summary: Investing.com -- Biogen Inc. (NASDAQ:BIIB) announced that the Nasdaq (NASDAQ:NDAQ) exchange had halted trading of its stock on Friday., Headline: FDA advisors weigh whether Alzheimer's drug Leqembi should receive full approval, source:CNBC, summary: Medicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the treatment., Headline: FDA panel to debate US approval for Alzheimer's drug from Eisai and Biogen , source:Reuters, summary: A panel of experts on Friday will discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment., Headline: FDA panel to debate US approval for Alzheimer's drug from Eisai and Biogen, source:Yahoo, summary: A panel of experts on Friday will discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment.  Leqembi won accelerated approval by the Food and Drug Administration in January based on its ability to remove toxic amyloid plaques from the brain., Headline: UPDATE 1-FDA panel weighs US approval for Alzheimer's drug from Eisai and Biogen, source:Yahoo, summary: A panel of expert advisers on Friday began their meeting to discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment.  Leqembi won accelerated approval by the Food and Drug Administration in January based on its ability to remove toxic amyloid plaques from the brain., Headline: Biogen Stock Halted as FDA Committee Considers Alzheimer’s Drug, source:Yahoo, summary: Trading in shares of Biogen remains halted Friday morning as a Food and Drug Administration advisory committee meets to discuss whether the Alzheimer's drug Leqembi from the company and partner Eisai merits full approval., Headline: Eisai shares jump on FDA advisers vote on Alzheimer’s treatment, source:MarketWatch, summary: Eisai Co. Ltd. shares were up 9.4% Friday after advisers to the U.S. Food and Drug Administration voted unanimously in favor of the Eisai and Biogen..., Headline: Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment, source:Yahoo, summary: Biogen stock was halted Friday as a panel of experts to the FDA debated the merits of its Alzheimer's treatment, Leqembi., Headline: NEW YORK MARKET CLOSE: Stocks rise on growing optimism of rate pause, source:Alliance News, summary: No summary, Headline: Here's what the FDA's endorsement of the Alzheimer's drug Leqembi means for Biogen, source:CNBC, summary: Matt Herper, Stat News senior writer, joins 'Closing Bell: Overtime' to discuss the FDA advisers' unanimous vote to recommend Biogen Alzheimer's drug., Headline: FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease, source:PR Newswire, summary: No summary, Headline: Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval, source:MarketWatch, summary: Biogen Inc. shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation from a Food and..., Headline: US FDA panel back traditional approval for Eisai-Biogen's Alzheimer's drug Leqembi, source:Reuters, summary: A panel of expert advisers on Friday unanimously agreed that a late-stage clinical trial of Eisai and Biogen's Leqembi verified the benefit of the treatment for Alzheimer's disease, clearing the way for traditional U.S. regulatory approval., Headline: Biogen Remains Halted After Panelists Vote Unanimously In Favor Of Its Alzheimer's Drug, source:Yahoo, summary: Biogen stock remained halted Friday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment., Headline: Biogen Halted After Panelists Vote Unanimously In Favor Of Its Alzheimer's Drug, source:Yahoo, summary: Biogen stock remained halted Friday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment., Headline: FDA Advisory Committee Votes in Favor of Biogen Alzheimer’s Drug, Clears Path to Full Approval, source:Yahoo, summary: The vote came two and a half years after the same panel dealt a decisive blow to Aduhelm, another drug from Biogen and Eisai., Headline: US FDA panel backs approval for Eisai-Biogen Alzheimer's drug Leqembi, source:Reuters, summary: A panel of expert advisers on Friday unanimously agreed that a late-stage trial of Eisai and Biogen's Alzheimer's drug Leqembi verified the benefit of the treatment for those at an early stage of the disease, clearing the way for traditional U.S. approval., Headline: FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease, source:Yahoo, summary: Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease The PDUFA action date for traditional approval of LEQEMBI has been set for July 6, 2023, with designation of priority review LEQEMBI received accelerated approval from the FDA for the treatment of early Alzheimer’s disease on January 6, 2023 TOKYO and CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -",BIIB
224,2023-06-11,"Headline: FDA AdComm votes to confirm clinical benefit of LEQEMBI in Alzheimer's disease, source:Thefly.com, summary: No summary, Headline: Alzheimer’s disease market expected to reach $14B globally in 2030, source:Seeking Alpha, summary: No summary, Headline: Eisai, Biogen Clinch FDA Advisers’ Support for Alzheimer’s Drug, source:Yahoo, summary: (Bloomberg) -- Eisai Co.’s Alzheimer’s disease drug developed with Biogen Inc. gained support from advisers to US regulators, paving the way for a likely full regulatory approval that could lead to broader insurance coverage. Most Read from BloombergOil Traders Are Daring to Defy Market Kingpin Saudi ArabiaAs Fed Signals Rate Pause, Powell Will Have to Placate HawksUBS Completes Credit Suisse Takeover to Create Bank TitanJeff Bezos Has Gained $10 on Mystery Purchase of One Amazon ShareUK Politic, Headline: Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote, source:Benzinga, summary: No summary, Headline: Tech Sector Powers S&P 500 To 10-Month High, While Oil Stocks Struggle: What's Driving Markets Today, source:Benzinga, summary: No summary, Headline: Tech Sector Powers S&P 500 To 10-Month High While Oil Stocks Struggle: What's Driving Markets Today, source:Benzinga, summary: No summary, Headline: Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground, source:TalkMarkets, summary: No summary, Headline: US FDA confirms clinical benefit of Biogen's leqembi for Alzheimer's, source:Alliance News, summary: No summary, Headline: What You Missed On Wall Street On Monday, source:Thefly.com, summary: No summary",BIIB
225,2023-06-12,"Headline: These Stocks Are Moving the Most Today: Tesla, Carnival, Nasdaq, SoFi, and More, source:MarketWatch, summary: Tesla is rising for a 12th consecutive day, Carnival trades higher after Wall Street upgrades the stock, and Nasdaq falls after agreeing to acquire software..., Headline: Biogen price target raised to $360 from $350 at Oppenheimer, source:Thefly.com, summary: No summary, Headline: Biogen announces board changes, new date for annual meeting, source:Seeking Alpha, summary: No summary, Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Biogen, Carnival and Oracle post solid gains, while Nasdaq and KeyCorp slump, source:MarketWatch, summary: Here are some of the biggest movers on Monday., Headline: Here’s Why Biogen Stock (NASDAQ:BIIB) is Trending Higher, source:TipRanks, summary: No summary, Headline: Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low, source:Benzinga, summary: No summary, Headline: Biogen price target raised to $350 from $330 at Canaccord, source:Thefly.com, summary: No summary, Headline: Biogen shares jump after FDA advisory panel backs Alzheimer's drug, source:Yahoo, summary: Investing.com -- Shares in Biogen Inc (NASDAQ:BIIB) surged in premarket trading on Monday after an advisory panel to U.S. regulators gave their support to the early-stage usage of an Alzheimer's drug co-developed by the biotech group., Headline: Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Biogen (BIIB), source:TipRanks, summary: No summary, Headline: S&P 500 Futures Rise in Premarket Trading; Nasdaq, Globant Lag, source:MarketWatch, summary: With U.S. stock markets set to open in two hours, (CCL) was up 5.4% in pre-market trading, and (ZBH) was up 5.1%. (ORCL), (PLNT), and (BIIB) were all posting..., Headline: Analysts Offer Insights on Healthcare Companies: ImmunoGen (IMGN), Humacyte (HUMA) and Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: No summary, Headline: Stocks Higher, Fed Decision, Inflation In Focus, Biogen Surges, Oracle Earnings, Silvio Berlusconi Dies - 5 Things To Know, source:Yahoo, summary: Stock futures higher ahead of key market tests; Week Ahead: Fed, inflation, retail sales in focus; Biogen surges as FDA panel gives final nod to Alzheimer's treatment; Oracle set for new record high ahead of Q4 earnings and Silvio Berlusconi, billionaire media mogul and former prime minister of Italy, dies at 86., Headline: BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing, source:InvestorPlace, summary: No summary, Headline: Biogen stock doesn't see big boost from FDA panel endorsement of Leqembi, source:Seeking Alpha, summary: No summary, Headline: Why Are Cruise Stocks CCL, RCL, NCLH Up Today?, source:InvestorPlace, summary: No summary, Headline: Global company events calendar - next 7 days, source:Alliance News, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: HC Wainwright & Co. Reiterates Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: 5 Things to Know Before Markets Open, source:Yahoo, summary: UBS completes its takeover of Credit Suisse and Biogen wins key FDA support for its Alzheimer's disease treatment. Here’s what investors need to know today., Headline: Stocks to Watch Monday: Biogen, Illumina, Oracle, source:Yahoo, summary: **↗️** [**Biogen (BIIB)**](https://www.wsj.com/market-data/quotes/BIIB): The biotech company's shares rose 1.3% after an advisory committee [recommended the Food and Drug Administration approve Leqembi](https://investors., Headline: Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement, source:Yahoo, summary: An FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's disease antibody. NASDAQ halts BIIB's common stock trading on Jun 9., Headline: Biogen Jumps After Panelists Vote Unanimously In Favor Of Its Alzheimer's Drug, source:Yahoo, summary: Biogen stock jumped Monday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment., Headline: FDA recommends Biogen's Alzheimer's drug for approval, source:Yahoo, summary: Shares of biotech company Biogen are rising this morning after an FDA panel recommended its Alzheimer's treatment drug for approval. Yahoo Finance Live takes a look at the stock action., Headline: CORRECTED-Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns , source:Reuters, summary: Shares of Biogen Inc rose 4% in premarket trade on Monday as an unanimous backing of the company's Alzheimer's drug Leqembi by the U.S. regulator's advisers eased concerns that a traditional approval for the treatment will come with major new safety warnings., Headline: Trading the Alzheimer's Space: Here's My Plan as Companies Try to Slay the Beast, source:Yahoo, summary: This will obviously be a huge market. It's time for me to diversify my exposure after positive news on Biogen and Eisai's Leqembi., Headline: These Stocks Are Moving the Most Today: Tesla, Carnival, Nasdaq, NIO, and More, source:Yahoo, summary: Tesla is rising for a 12th consecutive day, Carnival trades higher after Wall Street upgrades the stock, and Nasdaq falls after agreeing to acquire software company Adenza for $10.5 billion in cash and shares., Headline: Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns, source:Reuters, summary: Biogen's shares rose 2% on Monday as a unanimous backing of its Alzheimer's drug by the U.S. health regulator's advisers strengthened the case for a traditional approval with no major new safety warnings., Headline: 3-Stock Lunch: Oracle, Biogen and SentinelOne, source:CNBC, summary: Eva Ados, ERShares chief operations officer, joins ‘Power Lunch’ to discuss three stocks: Oracle, Biogen and SentinelOne., Headline: Biogen Rises After 'Drama-Free' Panel Votes Unanimously In Support Of Alzheimer's Drug, source:Yahoo, summary: Biogen stock rose Monday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment., Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. rose 1.47% to $313.41 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Biogen's Charts So Far Appear Free of Major Side Effects, source:Yahoo, summary: Biotechnology firm Biogen  has pushed up to a new 52-week high Monday on the heels of a Food and Drug Administration panel voting unanimously in favor of its newest Alzheimer's treatment.  The daily On-Balance-Volume (OBV) line shows a rise for the past twelve months.  The 40-week moving average line is rising, The weekly OBV line is bullish and so is the MACD oscillator., Headline: Oppenheimer Maintains Biogen (BIIB) Outperform Recommendation, source:Fintel, summary: nan, Headline: Canaccord Genuity Maintains Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Needham Reiterates Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Biogen Makes Board Changes Ahead of Shareholder Meeting, source:MarketWatch, summary: By Denny Jacob Biogen on Monday made several changes to its board, part of its efforts to achieve sustainable growth. The biopharmaceutical company said..., Headline: Biogen Announces Changes to Its Board of Directors, source:Yahoo, summary: Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023, to Give All Stockholders Sufficient Time to Review and Vote on Proposed Slate CAMBRIDGE, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced several changes to its Board of Directors today. The changes will refresh the composition of the Board and follow the Board’s continual interaction with company stockholders to solicit their perspective on a range of issues around the company’s performance",BIIB
226,2023-06-13,"Headline: Biogen's Leqembi may not be widely used for Alzheimer's in Europe - report, source:Seeking Alpha, summary: No summary, Headline: FOCUS-European Alzheimer's experts unconvinced by new Eisai, Biogen drug, source:Yahoo, summary: Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources.  Lecanemab, branded Leqembi in the U.S., is under regulatory review in Europe and likely poised for traditional U.S. approval next month based on trial data showing it slowed cognitive decline by 27% in patients with early Alzheimer's.  In Europe, where cost-conscious countries rigorously weigh new drugs before adopting their use, nine neurologists and researchers across six countries told Reuters lecanemab is unlikely to be widely used if approved., Headline: European Alzheimer's experts unconvinced by new Eisai, Biogen drug, source:Reuters, summary: Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources., Headline: Biogen in pact with NeuroSense for ALS biomarker study, source:Seeking Alpha, summary: No summary, Headline: FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, European Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories, source:Benzinga, summary: No summary, Headline: FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories, source:Benzinga, summary: No summary, Headline: Methode Electronics, Brookfield Renewable Partners And Other Big Stocks Moving Lower On Tuesday, source:Benzinga, summary: No summary, Headline: Top 20 Most Profitable Pharmaceutical Companies In The World, source:Yahoo, summary: In this article, we will be covering the top 20 most profitable pharmaceutical companies in the world. If you wish to see the top ones, head straight to the Top 5 Most Profitable Pharmaceutical Companies In The World. Undoubtedly, the pharmaceutical industry stands as one of the most financially rewarding and essential sectors worldwide, leading […], Headline: Video: Nasdaq 100 Movers: BIIB, JD, source:Market News Video, summary: No summary, Headline: SVB Securities Sticks to Its Buy Rating for Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Stocks making the biggest moves midday: JD.com, Biogen, Oracle and more, source:CNBC, summary: These are some of the stocks posting the largest moves in midday trading. , Headline: Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources, source:Yahoo, summary: Experts in Europe considering the potential use of a new Alzheimer's disease drug developed by Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) say Leqembi (lecanemab)'s ability to slow cognitive decline may not outweigh its health risks or justify the strain it would place on limited healthcare resources. The drug is currently undergoing regulatory review in Europe and is likely to receive traditional approval in the U.S. next month after the FDA adcomm unanimously voted to favor the dru, Headline: Markets Rise Midday as Inflation News Raises Expectations of a Rate Hike Pause, source:Yahoo, summary: U.S. equities gained at midday on Tuesday, June 13, 2023 as lower inflation raised optimism the Fed could pause its rate hike cycle., Headline: Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes, source:Yahoo, summary: Activist investor Sarissa Capital may have cleared a stumbling block in its push for board seats at Alkermes when one of its candidates resigned from the board of a company that has a commercial relationship with the drugmaker.  The hedge fund's founder, Alex Denner, one of three Sarissa candidates running for seats on Alkermes' 11-member board, said this week that he will give up his board seat at biotech Biogen., Headline: Biogen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slipped 2.81% to $304.60 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: Biogen has been an 'uninvestable' stock for awhile, says Mizuho's Jared Holz, source:CNBC, summary: Jared Holz, Mizuho Securities healthcare sector specialist, joins 'Fast Money' to talk controversy brewing at Biogen, Alzheimer's drug approval roadblocks in Europe, and more., Headline: UPDATE 1-Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes, source:Yahoo, summary: Activist investor Sarissa Capital may have cleared a stumbling block in its push for board seats at Alkermes when one of its candidates resigned from the board of a company that has a commercial relationship with the drugmaker.  The hedge fund's founder, Alex Denner, 53, one of three Sarissa candidates running for seats on Alkermes' 11-member board, on Monday said he would give up his board seat at biotech company Biogen., Headline: GLOBAL BRIEFING: US judge temporarily blocks Microsoft-Activision deal, source:Alliance News, summary: No summary",BIIB
227,2023-06-14,"Headline: Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed, source:Benzinga, summary: No summary, Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 1.51% to $299.99 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index..., Headline: Notable Thursday Option Activity: BIIB, UA, MET, source:Stock Options Channel, summary: No summary",BIIB
228,2023-06-15,"Headline: Sage Therapeutics price target raised to $66 from $61 at BofA, source:Thefly.com, summary: No summary, Headline: 7 Undervalued S&P 500 Stocks to Buy in June, source:InvestorPlace, summary: No summary, Headline: Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More, source:Yahoo, summary: Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector., Headline: Biogen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. dropped 0.72% to $297.83 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: UPDATE 1-ISS backs election of Langer to replace former Biogen director Denner, source:Yahoo, summary: Proxy advisory firm Institutional Shareholder Services on Thursday recommended that Biogen shareholders elect Susan Langer to replace long-standing director Alex Denner, who abruptly left the board earlier this week.  Biogen said Langer, a former corporate strategy chief at the biotech company, would stand for election to replace Denner.  ISS issued its recommendation after the unexpected announcement on Monday that three directors -- Denner, William Jones and Richard Mulligan -- would not stand for reelection., Headline: ISS backs election of Langer to replace former Biogen director Denner, source:Yahoo, summary: Proxy advisory firm Institutional Shareholder Services on Thursday recommended that Biogen  shareholders elect Susan Langer to replace long-standing director Alex Denner, who abruptly left the board earlier this week.  Biogen said Langer, a former corporate strategy chief at the biotech company, would stand for election to replace Denner.  ISS issued its recommendation after the unexpected announcement on Monday that three directors -- Denner, William Jones and Richard Mulligan -- would not stand for reelection., Headline: Clene's ALS drug shows reduction in disease indicator levels in trial, source:Reuters, summary: Clene said on Thursday its experimental amyotrophic lateral sclerosis (ALS) drug showed reduction in levels of an indicator believed to be tied with the disease progression in a mid-stage trial., Headline: 7 Undervalued S&P 500 Stocks to Buy in June, source:Yahoo, summary: When attempting to build a portfolio of reliable entities, you probably can’t go wrong with undervalued S&P 500 stocks. Featuring the market performance of 500 of the largest companies listed on stock exchanges in the U.S., you’re dealing with proven winners. To be fair, you might not receive a blistering performance. At the same time, these ideas are less likely to leave you stranded on the road. In addition, ChatGPT points out that the best S&P 500 stocks to buy offer diversification. Specific",BIIB
229,2023-06-16,"Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Grifols SA (GRFS), source:TipRanks, summary: No summary, Headline: Biogen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. slipped 0.12% to $297.48 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: A Schwab Wealth Survey Reveals a Paradox, source:MarketWatch, summary: Nearly half of the respondents averaging $560,000 in net worth said they were wealthy, when including nonfinancial factors like health and family. But when...",BIIB
230,2023-06-17,"Headline: Biogen Inc. (NASDAQ:BIIB) Shares Could Be 24% Below Their Intrinsic Value Estimate, source:Yahoo, summary: Key Insights Biogen's estimated fair value is US$392 based on 2 Stage Free Cash Flow to Equity Current share price of..., Headline: 2 Market-Beating Stocks With Major Catalysts on the Way, source:Yahoo, summary: For those seeking stocks that have trounced the market over the past year, the biotech sector might be an excellent place to start.  Two drugmakers that have done particularly well for themselves are Vertex Pharmaceuticals (NASDAQ: VRTX) and Biogen (NASDAQ: BIIB).  Vertex Pharmaceuticals has a rich portfolio of cystic fibrosis (CF) drugs that generates growing revenue.",BIIB
231,2023-06-18,"Headline: How to Retire Rich: Biotech Stocks Edition, source:Yahoo, summary: Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector – which falls under the broad healthcare industry – is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement",BIIB
232,2023-06-19,"Headline: PBE: Healthcare Dashboard For June, source:SeekingAlpha, summary: Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Click here for the June edition of the Healthcare Dashboard., Headline: Does This Signal Trouble for Biogen's New Alzheimer's Drug?, source:Yahoo, summary: Biogen (NASDAQ: BIIB) recently got some good news in the U.S. An advisory committee for the Food and Drug Administration (FDA) unanimously confirmed the clinical benefit of its Alzheimer's drug, Leqembi.  The FDA earlier granted Leqembi accelerated approval and now is considering it for traditional approval., Headline: Alzheimer’s Blockbuster Is Coming, but Slowly, source:Yahoo, summary: As any patient or family member dealing with cognitive impairment knows, getting diagnosed with Alzheimer’s disease isn’t simple.  With  Eisai  and  Biogen  anti-amyloid treatment Leqembi likely to receive full Food and Drug Administration approval and subsequent Medicare coverage next month, the focus will shift to tackling the hurdles to patient access.  For Eisai and Biogen, the challenge isn’t just convincing patients and doctors that the drug provides real clinical benefits.",BIIB
233,2023-06-20,"Headline: 5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies, source:Benzinga, summary: No summary, Headline: Ionis: Potential Advancement Into HAE Space Makes This A Must Watch, source:SeekingAlpha, summary: Ionis Pharmaceuticals should be watched closely because it is advancing a drug for the prevention of hereditary angioedema attacks. Find out why IONS stock is a Buy., Headline: ISS recommends one of Sarissa's three nominees for Alkermes board, source:Yahoo, summary: Proxy advisory firm Institutional Investor Services urged Alkermes shareholders to elect one of three director candidates proposed by activist hedge fund Sarissa Capital, arguing more outside pressure on management is needed right now.  ISS said Sarah Schlesinger, a physician with experience serving on public company boards, should be elected to Alkermes' 11-member board at next week's annual meeting., Headline: Biogen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. shed 1.24% to $293.79 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: $1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today, source:Benzinga, summary: No summary",BIIB
234,2023-06-21,"Headline: Wednesday’s Top Analyst Upgrades and Downgrades: ADM, Baidu, Melco Resorts, Palantir, Peabody Energy, Philip Morris, Shopify and More, source:247WallSt, summary: No summary, Headline: Top pharma lobby sues U.S. govt. over Medicare drug pricing negotiations, source:Seeking Alpha, summary: No summary, Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.19% higher to $294.36 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...",BIIB
235,2023-06-22,"Headline: Biogen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. sank 0.14% to $293.95 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",BIIB
236,2023-06-23,"Headline: Mizuho Securities Remains a Buy on Biogen (BIIB), source:TipRanks, summary: No summary, Headline: CMS update 'incremental positive' for Biogen, says William Blair, source:Thefly.com, summary: No summary, Headline: Bank of America Securities Keeps Their Hold Rating on Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?, source:Yahoo, summary: It was two years ago that Biogen's (NASDAQ: BIIB) stock soared to more than $400 on news that its Alzheimer's treatment, Aduhelm (aducanumab), had obtained accelerated approval from the Food and Drug Administration (FDA).  Today, however, the company has given up on Aduhelm and is instead focusing on a potentially more promising Alzheimer's drug, Leqembi.  It has already obtained accelerated approval and next month it could hit a much more important milestone: full, traditional approval., Headline: Biogen Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slid 3.21% to $284.52 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",BIIB
237,2023-06-24,"Headline: 10 Personalized Medicine Stocks Billionaires Are Loading Up On, source:Yahoo, summary: In this article, we will take a look at the 10 personalized medicine stocks billionaires are purchasing. If you want to skip our detailed analysis of the industry and its growth prospects, go to the 5 Personalized Medicine Stocks Billionaires Are Loading Up On. According to Allied Market Research, the global personalized medicine industry is set […]",BIIB
238,2023-06-25,"Headline: GLOBAL BRIEFING: Vladimir Putin weakened by attempted Wagner revolt, source:Alliance News, summary: No summary, Headline: Biogen (BIIB) Receives a Buy from Robert W. Baird, source:TipRanks, summary: No summary",BIIB
239,2023-06-26,"Headline: Biogen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. slipped 1.03% to $281.58 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: UPDATE 1-Biogen shareholders back Susan Langer as director, source:Yahoo, summary: Biogen shareholders elected former company executive Susan Langer as a director on Monday, weeks after her romantic partner, Alex Denner, vacated the seat and the board nominated her to replace him.  Langer, 32, had served in various roles at the biotech company from 2013 to 2019.  Denner was a hedge fund manager, who had been a Biogen director since 2009 and headed the company's nominating and governance committee., Headline: Biogen shareholders back Susan Langer as director, source:Yahoo, summary: Langer, 32, had served in various roles at the biotech company from 2013 to 2019.  Denner was a hedge fund manager, who had been a Biogen director since 2009 and headed the company's nominating and governance committee., Headline: A Look Into Biogen Inc's Price Over Earnings, source:Benzinga, summary: No summary",BIIB
240,2023-06-27,"Headline: Biogen: Highs, Lows, And Mounting Expectations Ahead Of Leqembi Decision, source:SeekingAlpha, summary: Biogen's problem has always been that its products target very difficult-to-treat diseases where signs of success are difficult to establish. Find out why BIIB stock is a Hold., Headline: Biogen: Mounting Expectations Ahead Of Leqembi Decision, source:Seeking Alpha, summary: No summary, Headline: Alcyone Therapeutics gets FDA IDE to initiate study of ThecaFlex DRx System, source:Thefly.com, summary: No summary, Headline: Alcyone Therapeutics Receives FDA IDE Approval to Initiate Clinical Study of the ThecaFlex DRxTM System for Administration of SPINRAZA® (nusinersen), source:PR Newswire, summary: No summary, Headline: Tuesday’s Top Analyst Upgrades and Downgrades: Advance Auto Parts, Alphabet, Micron Technology, Ross Stores, Tesla and More, source:247WallSt, summary: No summary, Headline: Biogen Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.49% higher to $282.95 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",BIIB
241,2023-06-28,"Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.38% higher to $284.02 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P..., Headline: A Drug for Itchy Dogs Costs $1,200. Why Is the Human Equivalent $43,000?, source:MarketWatch, summary: What a shot that treats pet eczema reveals about how pharma companies actually price their drugs., Headline: Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call, source:Thefly.com, summary: No summary",BIIB
242,2023-06-29,"Headline: How Is The Market Feeling About Biogen?, source:Benzinga, summary: No summary, Headline: Biogen's (NASDAQ:BIIB) underlying earnings growth outpaced the favorable return generated for shareholders over the past year, source:Yahoo, summary: The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you..., Headline: Biogen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slid 0.67% to $282.13 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: Catalyst Watch: BorgWarner, Biogen, iRobot and Coty are in the spotlight during holiday-shortened week, source:Seeking Alpha, summary: No summary, Headline: Biogen announces new SPINRAZA data, source:Thefly.com, summary: No summary",BIIB
243,2023-06-30,"Headline: Amgen Inc. Dividend Stock Analysis, source:TalkMarkets, summary: No summary, Headline: Medicare revises guidance on drug price negotiations amid lawsuits, source:Seeking Alpha, summary: No summary, Headline: 10 Health Care Stocks With Whale Alerts In Today's Session, source:Benzinga, summary: No summary, Headline: Sage Therapeutics: Zuranolone August Approval Likely, Opportunity Uncertain, source:SeekingAlpha, summary: Sage Therapeutics should find out in August whether its drug, zuranolone, will be approved. Click here to see our take on SAGE stock., Headline: Biogen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.96% higher to $284.85 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy, source:Yahoo, summary: Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® (onasemnogene abeparvovec)Biogen also reported new real-world evidence and progress on the development of a novel device to enhance the patient treatment experience CAMBRIDGE, Mass., June 30, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new SPINRAZA® (nusinersen) data aimed at answering critical questions for the spinal muscular atrophy (SMA) community., Headline: Lilly, Vertex top pharma performers in H1; Moderna, Pfizer the worst, source:Seeking Alpha, summary: No summary",BIIB
244,2023-07-03,"Headline: Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment, source:Benzinga, summary: No summary, Headline: FDA set to make decisions on several drug applications in July, source:Seeking Alpha, summary: No summary",BIIB
245,2023-07-04,"Headline: Biogen Inc. (NASDAQ:BIIB) is largely controlled by institutional shareholders who own 88% of the company, source:Yahoo, summary: Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...",BIIB
246,2023-07-05,"Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.16% higher to $285.89 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P..., Headline: Biogen trading halted, news pending, source:Thefly.com, summary: No summary, Headline: 3 Biotech Stocks to Make Your ‘Get Rich’ Dreams Come True, source:InvestorPlace, summary: No summary, Headline: FDA converts Biogen Alzheimer's treatment to full approval, source:Thefly.com, summary: No summary",BIIB
247,2023-07-06,"Headline: Biogen, Eisai win full FDA approval for Alzheimer's drug Leqembi, source:Seeking Alpha, summary: No summary, Headline: FDA approves Alzheimer’s treatment Leqembi, clearing the way for Medicare coverage, source:MarketWatch, summary: No summary, Headline: Quanterix launches LucentAD biomarker test for early Alzheimer's disease, source:Seeking Alpha, summary: No summary, Headline: Mizuho Securities Sticks to Their Buy Rating for Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Top 5 Trending Stocks: Prestige Wealth's IPO, Rivian's Lawsuit, Meta's New Platform, Tesla's Dip, And Biogen's FDA Approval, source:Benzinga, summary: No summary, Headline: U.S. Wide-Moat Stocks On Sale - The July 2023 Heat Map, source:SeekingAlpha, summary: Our 3-step process focuses on wide-moat stocks. We're only interested in targets attractively valued in historical comparison. Read what investors need to know., Headline: Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment, source:Yahoo, summary: The FDA could fully approve Biogen's Alzheimer's treatment, Leqembi, on Thursday. The decision could give a lift to Biogen stock., Headline: FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage, source:CNBC, summary: Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding., Headline: Biogen Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. sank 0.31% to $284.99 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: US FDA grants standard approval of Eisai/Biogen Alzheimer's drug, source:Finnhub, summary: The U.S. Food and Drug
Administration on Thursday granted standard approval to Eisai
and Biogen's Leqembi for patients with
Alzheimer's disease, clearing the way for wider insurance
coverage of the..., Headline: FDA approves Biogen and Eisai Alzheimer’s treatment Leqembi, source:MarketWatch, summary: The U.S. Food and Drug Administration on Thursday granted full approval to the Biogen and Eisai Co. Ltd. Alzheimer’s treatment Leqembi, a step that secures..., Headline: FDA approves Alzheimer's drug Leqembi, paving way for broader Medicare coverage, source:CNBC, summary: 'Closing Bell Overtime' breaks latest from the FDA concerning Biogen's Alzheimer's drug., Headline: Who is eligible for the new FDA-approved Alzheimer's drug?, source:Finnhub, summary: July 6 - The U.S. Food and Drug Administration on
Thursday granted standard approval to Eisai and
Biogen's Leqembi for patients with Alzheimer's disease.
             ..., Headline: Many health systems are already ready for 'Leqembi' roll out, says Eisai CEO Ivan Cheung, source:CNBC, summary: Ivan Cheung, Eisai U.S. CEO, joins 'Fast Money' to discuss the FDA approving Biogen's 'Leqembi' Alzheimer's drug., Headline: FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease, source:GlobeNewswire, summary: No summary, Headline: Eisai-Biogen Alzheimer's drug gets standard approval in US, source:Yahoo, summary: The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai and Biogen's Leqembi that has slowed cognitive decline in Alzheimer's patients at an early stage of the memory-robbing disease.  It is the first traditional approval for a drug shown to modify the course of Alzheimer's and is expected to increase use among U.S. patients who have had limited access to the treatment since it received accelerated FDA approval in January., Headline: UPDATE 5-US FDA grants standard approval of Eisai/Biogen Alzheimer's drug, source:Yahoo, summary: Eisai and Biogen's Leqembi won a coveted standard approval nod from the U.S. Food and Drug Administration on Thursday, the first Alzheimer's treatment to achieve that goal, clearing the way for wider insurance coverage of the drug.  The FDA decision marks a new milestone for a fatal disease that has eluded drugmakers' efforts for decades.  Trial data showed that the treatment slows progression of the brain-wasting disease by 27% for patients in the earliest stages of Alzheimer's., Headline: Biogen Snags Full Approval For Alzheimer's Treatment; Shares Halted, source:Yahoo, summary: The FDA fully approved Biogen's Alzheimer's treatment, Leqembi, on Thursday. Biogen stock was halted in late trading., Headline: Levi Strauss & Co., Costco, Biogen: After-hours movers, source:Yahoo, summary: Levi Strauss & Co. shares drop as the company slashes 2023 guidance. Costco reports a 0.4% increase in net sales for June. The FDA approves Eisai and Biogen's Alzheimer's drug Leqembi. Yahoo Finance Live's Seana Smith breaks down the after-hours movers., Headline: US regulators approve first drug to slow progression of Alzheimer’s, source:Yahoo, summary: The US Food and Drug Administration has approved the first Alzheimer’s drug to slow the progression of the neurodegenerative disease, paving the way for millions of American patients to access the treatment.  The regulator said on Thursday it would grant full approval to lecanemab, now known by the brand name Leqembi, which was developed by Japanese drugmaker Eisai and US biotech Biogen.  Teresa Buracchio, acting director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, said a confirmatory study had shown that Leqembi was a “safe and effective treatment” for patients with Alzheimer’s., Headline: Dow Jones Futures: Jobs Report On Tap; Threads Off To Record Start As Elon Musk Rips 'Cheating', source:Yahoo, summary: Stocks retreated as Treasury yields jumped on hot economic data ahead of Friday's jobs report. Meta's Threads had record first-day downloads as Elon Musk decried ""cheating."", Headline: FDA Gives Full Approval to Alzheimer’s Drug, source:Yahoo, summary: Federal approval for the treatment marks a major step forward in making the drug accessible. The Centers for Medicare and Medicaid Services said in January it would cover much of the cost., Headline: FDA Approves Leqembi, Extending Alzheimer’s Treatment to More Patients, source:Yahoo, summary: A treatment for Alzheimer’s disease is on its way to many more patients across the U.S.  The Food and Drug Administration on Thursday granted full approval to Leqembi, allowing Medicare enrollees to get fully covered treatment with the drug if they qualify and agree to report data to a registry.  Most of the six million people in the U.S. with Alzheimer’s are eligible for Medicare., Headline: FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease, source:Yahoo, summary: Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous use, making LEQEMBI the first and only approved treatment shown to reduce the r, Headline: Trending : Eisai, Biogen's Alzheimer's Treatment Gets Full FDA Approval, source:Finnhub, summary: 0408 GMT - Eisai is one of the most mentioned companies in the news over the past 12 hours, according to Factiva data, after its Alzheimer's drug Leqembi secured traditional approval from the U.S...., Headline: TOP NEWS: US FDA approves Biogen's Alzheimer's treatment Leqembi, source:Alliance News, summary: No summary, Headline: If You Invested $1000 In This Stock 15 Years Ago, You Would Have $4,900 Today, source:Benzinga, summary: No summary, Headline: Notable Two Hundred Day Moving Average Cross - BIIB, source:Market News Video, summary: No summary, Headline: Noteworthy Friday Option Activity: BIIB, LLY, AVGO, source:Stock Options Channel, summary: No summary, Headline: Biogen, Eisai’s Alzheimer’s Drug Scores Big With FDA’s Full Approval, source:TipRanks, summary: No summary, Headline: Mixed Jobs Data; Fed Governors Want More Interest Rate Hikes; US, China Spat Rattles Semiconductor Sector: The Week In The Markets, source:Benzinga, summary: No summary, Headline: What You Missed On Wall Street On Friday, source:Thefly.com, summary: No summary, Headline: Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call, source:Thefly.com, summary: No summary",BIIB
248,2023-07-07,"Headline: Analysts’ Opinions Are Mixed on These Healthcare Stocks: Thermo Fisher (TMO), Biogen (BIIB) and Boston Scientific (BSX), source:TipRanks, summary: No summary, Headline: Biogen set up nicely to generate upside, says Canaccord, source:Thefly.com, summary: No summary, Headline: H.C. Wainwright Remains a Buy on Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Black box warning on Leqembi  'bit if a surprise,' says Piper Sandler, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Biogen (BIIB) and Crinetics Pharmaceuticals (CRNX), source:TipRanks, summary: No summary, Headline: Label for Biogen's Leqembi generally as expected, says Mizuho, source:Thefly.com, summary: No summary, Headline: Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move, source:Benzinga, summary: No summary, Headline: Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug, source:CNBC, summary: Leqembi is the first Alzheimer's antibody treatment to receive full FDA approval., Headline: BMO Capital Sticks to Their Buy Rating for Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Label for Biogen's Leqembi not barrier to treatment, says William Blair, source:Thefly.com, summary: No summary, Headline: Biogen shares little changed after resumption of trade, source:Thefly.com, summary: No summary, Headline: Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Simulations Plus (SLP), source:TipRanks, summary: No summary, Headline: Jefferies Remains a Buy on Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Biogen’s stock slides premarket as analysts take mixed view of Alzheimer’s disease drug approval, source:MarketWatch, summary: Biogen Inc.’s stock rose about 2% before paring those gains premarket Friday, after the U.S. Food and Drug Administration on Thursday granted full approval..., Headline: What 29 Analyst Ratings Have To Say About Biogen, source:Benzinga, summary: No summary, Headline: Stocks making the biggest premarket moves: Levi Strauss, Biogen, Alibaba and more, source:CNBC, summary: These are the stocks posting the largest moves in the premarket., Headline: BIIB Stock Alert: What to Know as FDA Approves Biogen’s Alzheimer’s Drug, source:InvestorPlace, summary: No summary, Headline: Why Is Alibaba (BABA) Stock Up Today?, source:InvestorPlace, summary: No summary, Headline: EISAI - FDA GRANTS TRADITIONAL APPROVAL FOR LEQEMBI FOR THE TREATMENT OF ALZHEIMER'S DISEASE, source:Finnhub, summary: TOKYO - Eisai Co., Ltd.  and Biogen Inc.  announced today that the U.S. Food and Drug Administration  has approved the supplemental Biologics License Application  supporting the traditional approval..., Headline: FSLR Stock Alert: The $1 Billion Reason First Solar Is Up Today, source:InvestorPlace, summary: No summary, Headline: Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher?, source:SeekingAlpha, summary: Esai and Biogen's Alzheimer's Disease therapeutic, Leqembi, received full FDA approval on July 6th. Read more here., Headline: Demand for Biogen's new Alzheimer's drug will surprise to the upside, says Piper Sandler analyst, source:CNBC, summary: Christopher Raymond, Piper Sandler, joins 'Squawk on the Street' to discuss the market's reaction to Biogen's FDA approval, what demand will look like for Biogen's new drug and the serious side effects of the Alzheimer's drug., Headline: Biogen’s big Alzheimer’s drug win fails to boost the stock as analysts see slow Leqembi rollout, source:MarketWatch, summary: Milestone Leqembi approval is “a mixed bag,” analysts say, given drug label's risk warnings and infusion-center bottlenecks., Headline: Why The Market Is Likely Wrong About Cassava Sciences, Again, source:SeekingAlpha, summary: Cassava Sciences stock crashed in reaction to top-line data from a Phase 2 trial. Click here to find out why SAVA stock is rated a strong buy., Headline: These Stocks Are Moving the Most Today: Rivian, Tesla, Levi Strauss, Paramount, and More, source:Yahoo, summary: Analysts boost their price targets on Rivian and Tesla, Levi Strauss cuts its revenue outlook for the fiscal year, and Paramount shares are downgraded., Headline: Needham Reiterates Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: HC Wainwright & Co. Reiterates Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Dow Jones Futures Fall With Jobs Report Due; Meta Leads 7 Resilient Stocks, source:Yahoo, summary: The jobs report looms with Treasury yields soaring. Meta is among stocks holding up as Threads had record first-day downloads., Headline: Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts, source:Benzinga, summary: No summary, Headline: Stocks Rebound, Dollar Tumbles As June Jobs Data Eases Fed Hike Wagers: What's Driving Markets Friday?, source:Benzinga, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Biogen (BIIB), Eisai Get Full FDA Nod for Leqembi in Alzheimer's, source:Yahoo, summary: Following the full approval, Biogen (BIIB)/Eisai's Leqembi is the first approved treatment to slow progression of Alzheimer's disease. This also paves the way for a broader Medicare coverage., Headline: Eisai-Biogen's Alzheimer's treatment drug receives FDA approval, source:Yahoo, summary: Shares of Biogen and Eisai are lower amid news of label updates to the FDA officially approved the Alzheimer's treatment drug Leqembi. Yahoo Finance Live breaks down the story., Headline: Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024, source:CNBC, summary: Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term. , Headline: Three-Stock Lunch: Meta, Biogen and Levi Strauss, source:CNBC, summary: Gina Sanchez, chief market strategist at Lido Advisors, joins ‘Power Lunch’ to discuss her thoughts on three stocks: Meta, Biogen and Levi Strauss., Headline: Biogen Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 3.48% to $275.07 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index..., Headline: More Eisai/Biogen Alzheimer's drug approvals seen likely despite safety warning, source:Yahoo, summary: With U.S. approval of Eisai's and Biogen's Alzheimer's drug Leqembi secured, Wall Street analysts said they expect other region's health regulators to follow suit even if they share similar concerns about a potentially severe side effect.  Leqembi won standard approval from the U.S. Food and Drug Administration (FDA) on Thursday, but the FDA placed its strongest ""boxed"" safety warning on the drug's label, flagging the risk of potentially dangerous brain swelling in it and similar drugs.  Outside the United States, Eisai and Biogen are seeking approval for Leqembi, whose chemical name is lecanemab, in Japan, the European Union, China, Canada, Great Britain and South Korea., Headline: These Stocks Are Moving the Most Today: Rivian, Tesla, Alibaba, Levi Strauss, and More, source:Yahoo, summary: Analysts boost their price targets on Rivian and Tesla, Alibaba stock rises after Chinese authorities fine Ant Group—a fintech company of which Alibaba owns a third—almost $1 billion, and Levi Strauss cuts its fiscal-year outlook., Headline: Biogen’s Alzheimer’s Drug Rollout Could Be Slow, source:Yahoo, summary: Biogen has said it doesn't expect to clear a profit on Alzheimer's treatment Leqembi, which was approved by the FDA Thursday, until late 2024., Headline: New Alzheimer's drug from Biogen, Eisai gets government approval, but faces long road ahead, source:Yahoo, summary: Biogen and Eisai's second attempt at a new class of Alzheimer's treatments faces pressure despite regulatory and CMS greenlight., Headline: Biogen Skids As Analysts Debate Uptake For Newly Approved Alzheimer's Drug, source:Yahoo, summary: Biogen stock skidded Friday after the Food and Drug Administration fully approved its Alzheimer's treatment, Leqembi., Headline: Rivian, Tesla, Alibaba, Levi Strauss, First Solar, and More Stock Market Movers, source:Yahoo, summary: Analysts boosted their price targets on Rivian and Tesla, Alibaba stock rose after Chinese authorities fine Ant Group—a fintech company of which Alibaba owns a third—almost $1 billion, and Levi Strauss cut its fiscal-year outlook., Headline: Biogen, Eisai stocks fall despite receiving FDA approval for Alzheimer's drug, source:Yahoo, summary: Shares of pharmaceutical developers Biogen and Eisai are falling in the after-hours session. This comes following the companies received official FDA approval for their Alzheimer's treatment drug, Leqembi. Yahoo Finance Healthcare Reporter Anjalee Khemlani joins the Live show to detail the treatment plan., Headline: Biogen/Eisai's Leqembi set to become Medicare's single highest drug spend, source:Seeking Alpha, summary: No summary, Headline: Needham Reaffirms Their Buy Rating on Biogen (BIIB), source:TipRanks, summary: No summary",BIIB
249,2023-07-08,"Headline: Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know, source:CNBC, summary: Patients with early Alzheimer's disease could still pay more than $5,000 in out-of-pocket costs for Leqembi even with Medicare coverage.",BIIB
250,2023-07-09,"Headline: Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising?, source:Yahoo, summary: Biogen (NASDAQ: BIIB) once stood out as one of the most successful biotech companies.  Biogen turned its attention to Alzheimer's disease.  Along with partner Eisai, Biogen advanced Leqembi -- and the companies just reached a major milestone., Headline: Eisai: Looking To Upside Targets Following Leqembi Full Approval, source:SeekingAlpha, summary: FDA approved Eisai's Leqembi label last week, developed with Biogen, for treatment of adult patients with Alzheimer's Disease. Find out why ESALF stock is a Buy., Headline: Goldman Sachs sees rays of hope in underperforming health sector, source:Seeking Alpha, summary: No summary, Headline: Biogen And Alzheimer's Disease: Too Early To Celebrate, source:SeekingAlpha, summary: The FDA granted full approval to Biogen and Eisaiâs anti-amyloid antibody drug Leqembi. Click here to read why BIIB stock is a Hold., Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary",BIIB
251,2023-07-10,"Headline: Icahn Enterprises shares jump on loan agreement and other stocks on the move, source:MarketWatch, summary: Icahn Enterprises, Alibaba and Northern Trust are stocks on the move., Headline: Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Galapagos (GLPG) and Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Monday’s Top Analyst Upgrades and Downgrades: Biogen, Bloom Energy, ConocoPhillips, DraftKings, Humana, IBM, JP Morgan Chase, Newmont, Playtika, Williams-Sonoma and More, source:247WallSt, summary: No summary, Headline: Biogen shares ‘an under-owned turnaround story,’ Jefferies analysts say, source:MarketWatch, summary: Shares of Biogen Inc. which last week received a milestone U.S. Food and Drug Administration approval for Alzheimer’s treatment Leqembi, “remain an..., Headline: Biogen (BIIB) Stock Down Despite FDA Nod to Alzheimer's Drug, source:Yahoo, summary: Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimer's Disease., Headline: BIOGEN : TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS JULY 25, 2023, source:Finnhub, summary: Cambridge, Mass.- Biogen Inc.  today announced it will report second quarter 2023 financial results Tuesday, July 25, 2023, before the financial markets open.
      
      
       ..., Headline: Biogen Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. rose 2.37% to $281.58 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index..., Headline: Why Biotech Stocks Keep Falling on Good News, source:Yahoo, summary: It’s a sign that investors are increasingly wary of the biopharma sector.  It happened in late June, when  Sarepta Therapeutics  (ticker: SRPT) dropped 16% over the course of a few days after the FDA approved its new gene therapy for Duchenne muscular dystrophy.  On June 29, the FDA approved another gene therapy, this one a hemophilia A treatment from  BioMarin Pharmaceutical  (BMRN); BioMarin shares fell 3.6% that day and 2.5% the following day.",BIIB
252,2023-07-11,"Headline: ADC Therapeutics falls after pausing mid-stage trial for lead asset, source:Seeking Alpha, summary: No summary, Headline: Biogen price target raised to $341 from $332 at RBC Capital, source:Thefly.com, summary: No summary, Headline: Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study, source:Yahoo, summary: Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)., Headline: RBC Capital Maintains Biogen (BIIB) Outperform Recommendation, source:Fintel, summary: nan, Headline: Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation, source:Fintel, summary: nan, Headline: Biogen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. dropped 0.62% to $279.84 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: We've only seen the beginning of Moderna's story, says Goldman Sachs' Salveen Richter, source:CNBC, summary: Salveen Richter, Goldman Sachs lead biotech analyst, joins 'Closing Bell Overtime' to discuss the biotech sector and how investors should play in the space.",BIIB
253,2023-07-12,"Headline: Biogen Inc. (NASDAQ:BIIB) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?, source:Yahoo, summary: With its stock down 11% over the past month, it is easy to disregard Biogen (NASDAQ:BIIB). But if you pay close..., Headline: P/E Ratio Insights for Biogen, source:Benzinga, summary: No summary, Headline: Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again, source:Yahoo, summary: Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report., Headline: Biogen Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. sank 0.79% to $277.62 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index..., Headline: Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed the most recent trading day at $277.41, moving -0.87% from the previous trading session.",BIIB
254,2023-07-13,"Headline: Acumen Pharmaceuticals: A Risky Bet Through Upcoming Data Readout, source:SeekingAlpha, summary: Acumen will present Phase 1 topline data on its Alzheimerâs therapeutic candidate, ACU193, at the annual AAIC. Check out our recommendation on ABOS stock., Headline: Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Silence Therapeutics (SLN) and Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Why Isn't Biogen Stock Soaring After This Major FDA Approval?, source:Yahoo, summary: Investors in Biogen (NASDAQ: BIIB) got some great news last week as the Food and Drug Administration (FDA) approved the company's Alzheimer's drug Leqembi.  Here's why investors might still be hesitant about buying the stock despite the approval.  The FDA previously approved Leqembi on an accelerated basis., Headline: 7 Stocks That AI Says Will Make You a Millionaire by 2025, source:InvestorPlace, summary: No summary, Headline: Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment, source:Yahoo, summary: Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector., Headline: Biogen Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.13% higher to $277.97 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P...",BIIB
255,2023-07-14,"Headline: Biogen Inc. stock underperforms Friday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.35% higher to $278.93 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...",BIIB
256,2023-07-16,"Headline: Eli Lilly, Merck among top pharma picks in Barclays Q2 preview, source:Seeking Alpha, summary: No summary, Headline: These 2 Numbers Should Scare Every Biogen Shareholder, source:Yahoo, summary: Most Biogen (NASDAQ: BIIB) shareholders are probably excited about the company's newly approved Alzheimer's drug Leqembi right about now, and it's no surprise why.  As a pharma company, Biogen needs to consistently use its research and development (R&D) capabilities to discover, test, and commercialize new medicines over time.  For the business to grow, and for shareholders to earn a return, it needs to make more money from selling its medicines than it costs to develop them., Headline: Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?, source:Yahoo, summary: Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...",BIIB
257,2023-07-17,"Headline: Acumen stock rallies over 60% on Alzheimer's drug data, source:Seeking Alpha, summary: No summary, Headline: Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year, source:CNBC, summary: Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month., Headline: Eli Lilly full phase 3 data confirms benefit of Alzheimer's asset donanemab, source:Seeking Alpha, summary: No summary, Headline: Should You Buy the Dip With Biogen Stock Right Now?, source:Yahoo, summary: With shares of Biogen (NASDAQ: BIIB) falling by 11% in the last 30 days, and by 20% in the last five years, could there be an opportunity for enterprising investors to buy the dip on this struggling biotech stock?  On the positive side, the company's new Alzheimer's drug Leqembi secured full approval from the Food and Drug Administration (FDA) on July 6.  For people with early-stage Alzheimer's disease, Leqembi slows the rate of progression by around 27%, such that their cognitive capabilities remain relatively more intact for longer than they would otherwise., Headline: Biogen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. slumped 0.19% to $278.40 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",BIIB
258,2023-07-18,"Headline: Eli Lilly’s (NYSE:LLY) Alzheimer’s Drug Inches Closer to FDA Approval, source:TipRanks, summary: No summary, Headline: Biogen price target lowered to $357 from $380 at BMO Capital, source:Thefly.com, summary: No summary, Headline: The Tech Stock Rally Has Reached a Critical Moment. Watch Tesla, Netflix Earnings., source:MarketWatch, summary: AT&T hit by report about lead on cables, Eli Lilly’s Alzheimer’s drug shows promise in latest trial, and other news to start your day., Headline: 5 things to know before the stock market opens Tuesday, source:CNBC, summary: Here are the most important news items that investors need to start their trading day., Headline: Acumen: A First In Targeting, May Lead To Improvement For Early AD Patients, source:SeekingAlpha, summary: Acumen reported positive topline results from its phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early Alzheimer's Disease. Read more here., Headline: Biogen, Eli Lilly likely to split the Alzheimer’s drug market, analysts say, source:MarketWatch, summary: Eli Lilly and Co. and Biogen Inc. are likely to reach an “equitable split” of the Alzheimer’s drug market after Lilly on Monday released more details on its..., Headline: Sanofi expands collaboration with Scribe on CRISPR genome editing, source:Seeking Alpha, summary: No summary, Headline: Earnings Preview: Biogen Inc. (BIIB) Q2 Earnings Expected to Decline, source:Yahoo, summary: Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: New Alzheimer's drug success 'was built on failures': Eisai exec, source:Yahoo, summary: Eisai just reached the finish line with its long-fought battle to gain Medicare approval for Alzheimer's drug Leqembi. But the company says more work remains., Headline: Lilly's (LLY) Donanemab Slows Alzheimer's Disease Progression, source:Yahoo, summary: Data from a phase III study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and functional decline by 60% in study participants at the earliest stage of Alzheimer's disease., Headline: Biogen Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 0.80% to $276.17 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: IBD Stock Of The Day Eli Lilly: How Alzheimer's And Weight Loss Are Driving A New Breakout, source:Yahoo, summary: Eli Lilly stock is Tuesday's IBD Stock Of The Day. Shares are rising as Lilly's Alzheimer's treatment appears ""very competitive"" with Biogen's., Headline: Alzheimer’s Drugs May Be a Big-Pharma Payday. Lilly and Biogen Are Facing Off., source:Yahoo, summary: Two similar Alzheimer’s drugs are likely to be on the market and accessible for Medicare patients sometime in 2024., Headline: The Fight Against Alzheimer Goes Beyond Plaque. Tangles Are a Target Too., source:Yahoo, summary: Several companies at an Amsterdam conference reported progress in going after tau protein tangles. Prothena probably has the most at stake., Headline: The Fight Against Alzheimer’s Goes Beyond Plaque. Tangles Are a Target, Too., source:Yahoo, summary: Several companies at an Amsterdam conference reported progress in going after tau protein tangles. Prothena probably has the most at stake., Headline: Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Biogen Inc. (BIIB) closed at $276.17, marking a -0.8% move from the previous day.",BIIB
259,2023-07-19,"Headline: At-home Alzheimer’s testing is on the horizon, researchers say, source:MarketWatch, summary: No summary, Headline: Prediction: This Beaten-Down Stock Will Be a Biotech Giant by 2030, source:Yahoo, summary: When you think of biotech giants, you may think of Amgen or Biogen. These companies have brought significant treatments to market over time -- and have generated billions of dollars in earnings, too. Most investors would be happy to find the next company set to follow in their footsteps., Headline: Is Biogen Stock a Buy Now?, source:Yahoo, summary: Over the past few years, Biogen (NASDAQ: BIIB) has been engaged in a much-talked-about journey to develop an effective Alzheimer's disease (AD) medicine.  On July 6, the company announced that along with its longtime partner, Japan-based Esai, it had earned traditional approval for Leqembi, a therapy that targets patients with early AD.  Leqembi had previously earned accelerated approval in January., Headline: GSK (GSK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release, source:Yahoo, summary: Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Biogen (BIIB) to Report Q2 Earnings: Here's What to Expect, source:Yahoo, summary: Biogen's sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved., Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.26% higher to $276.89 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P..., Headline: Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023, source:GlobeNewswire, summary: No summary, Headline: Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023, source:Yahoo, summary: Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI®) treatment showed reductions in amyloid-beta (Aβ) pathology and downstream biomarker changes. This analysis, and the latest findings on the lecanemab",BIIB
260,2023-07-20,"Headline: EISAI PRESENTS LATEST ANALYSIS OF LECANEMAB'S EFFECT ON BIOMARKER CHANGES AND SUBCUTANEOUS DOSING AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2023, source:Finnhub, summary: TOKYO - Eisai Co., Ltd. and Biogen Inc.  announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb  treatment showed reductions in..., Headline: (BIIB) - Analyzing Biogen's Short Interest, source:Benzinga, summary: No summary, Headline: Robert W. Baird Sticks to Their Buy Rating for Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Are Investors Undervaluing Biogen Inc. (NASDAQ:BIIB) By 31%?, source:Yahoo, summary: Key Insights Using the 2 Stage Free Cash Flow to Equity, Biogen fair value estimate is US$402 Biogen is estimated to be..., Headline: Biogen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slid 0.79% to $274.70 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Final Trades: Charles Schwab, Biogen & more, source:CNBC, summary: The ""Halftime Report"" traders give their top picks to watch for the second half., Headline: Eisai hopes to start new Alzheimer's drug trials in 2024, Nikkei Asia says, source:Thefly.com, summary: No summary, Headline: Earnings week ahead: Microsoft, Google, Meta, Boeing, Coca-Cola and more, source:Seeking Alpha, summary: No summary, Headline: Biogen Inc. stock underperforms Friday when compared to competitors despite daily gains, source:MarketWatch, summary: No summary",BIIB
261,2023-07-21,"Headline: Biogen Unusual Options Activity, source:Benzinga, summary: No summary",BIIB
262,2023-07-23,"Headline: 4 Ideal Barron's Mid-Year 2023 Dividend Dog Buys, source:SeekingAlpha, summary: Barronâs Mid-Year Roundtable, Published July 17, listed 40 stocks of note for 2023; 38 of those were unduplicated US publicly-listed companies. Read more here., Headline: Analyst Favorites With Strong Buyback Activity: Biogen Ranks As a Top Pick, source:The Online Investor, summary: No summary, Headline: Biogen Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: No summary",BIIB
263,2023-07-24,"Headline: Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Biogen (BIIB) and Johnson & Johnson (JNJ), source:TipRanks, summary: No summary, Headline: Editas Medicine appoints Burkly as Chief Scientific Officer, source:Thefly.com, summary: No summary, Headline: Notable companies reporting before tomorrow's open, source:Thefly.com, summary: No summary, Headline: Notable earnings before Tuesday's open, source:Seeking Alpha, summary: No summary, Headline: Biogen Q2 2023 Earnings Preview, source:Seeking Alpha, summary: No summary, Headline: Better Big Biotech Buy: Vertex vs. Biogen, source:Yahoo, summary: When you think of biotech companies, you may think of up-and-coming players with exciting pipelines, but zero marketed products.  Two top examples are Vertex Pharmaceuticals (NASDAQ: VRTX) and Biogen (NASDAQ: BIIB).  Vertex brings in billions of dollars in earnings annually thanks to its cystic fibrosis (CF) portfolio., Headline: Eli Lilly: Does 'Miracle' Weight Loss Franchise Justify Rising Price Tag?, source:SeekingAlpha, summary: Eli Lilly's share price won't stop climbing on the promise of its miracle diabetes and weight loss drug, tirzepatide. Learn more about LLY stock here., Headline: All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings, source:Yahoo, summary: Biogen stock is trading flat in 2023 ahead of earnings as analysts await news from biotechnology firm about its Alzheimer's drug, Leqembi., Headline: GLOBAL BRIEFING: Beijing pledges support for faltering economy, source:Alliance News, summary: No summary, Headline: Biogen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary",BIIB
264,2023-07-25,"Headline: Biogen reports Q2 EPS $4.02, consensus $3.77, source:Thefly.com, summary: No summary, Headline: Biogen backs FY23 EPS view of $15.00-$16.00, consensus $15.43, source:Thefly.com, summary: No summary, Headline: Biogen Non-GAAP EPS of $4.02 beats by $0.26, revenue of $2.46B beats by $100M, source:Seeking Alpha, summary: No summary, Headline: Biogen tops earnings estimates and says it will shift resources to higher value areas, source:MarketWatch, summary: No summary, Headline: Nasdaq Futures Rise Ahead Of Microsoft, Alphabet Earnings: Analyst Warns Of Volatility From Fed's Message 'Crafting', source:Benzinga, summary: No summary, Headline: Biogen : Reports Q2 2023 Earnings, source:Finnhub, summary: Press Release
      
      
        Cambridge, Mass. - July 25, 2023
      
      
        Biogen reports second quarter 2023 results and reaffirms full year 2023 guidance;
      
    ..., Headline: Biogen : Q2 2023 Biogen Earnings Presentation, source:Finnhub, summary: Second Quarter 2023
        
        
          Financial Results and Business Update
        
      
      
        
          
            
              
               ..., Headline: Biogen (NASDAQ:BIIB) Gains On Q2 Beat, source:TipRanks, summary: No summary, Headline: Biogen : Reports Second Quarter 2023 Results, source:Finnhub, summary: Press Release
      
      
        Cambridge, Mass. - July 25, 2023
      
      
        Biogen reports second quarter 2023 results and reaffirms full year 2023 guidance;
      
    ..., Headline: Biogen : reports second quarter 2023 results and reaffirms full year 2023 guidance; LEQEMBI launched in the U.S - Form 8-K, source:Finnhub, summary: Biogen reports second quarter 2023 results and reaffirms full year 2023 guidance;
    
    
      LEQEMBI launched in the U.S.
    
    
      
    
    
      Second quarter revenue $2,456..., Headline: Biogen sees saving about $1B in gross operating expenses from 'Fit for Growth', source:Thefly.com, summary: No summary, Headline: GE, General Motors, Verizon rise premarket; Goldman Sachs, Dow fall, source:Yahoo, summary: Investing.com -- U.S. futures edged higher Tuesday, as investors digest a deluge of corporate earnings ahead of a key Federal Reserve meeting., Headline: Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Biogen announces layoffs as focus turns to new products, source:Seeking Alpha, summary: No summary, Headline: Biogen Q2 Earnings Tops Expectations, Shift Resources To Higher Value Area(s), Layoff 1K Staff, source:Benzinga, summary: No summary, Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: No summary, Headline: Tuesday’s Top Analyst Upgrades and Downgrades: American Express, Apple, Conagra, Estee Lauder, Livent, Microsoft, Netflix, Nvidia, Shopify, Tesla and More, source:247WallSt, summary: No summary, Headline: Biogen backs yearly guidance after second-quarter revenue fall, source:Alliance News, summary: No summary, Headline: Biogen Layoffs 2023: What to Know About the Latest BIIB Job Cuts, source:InvestorPlace, summary: No summary, Headline: Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch , source:CNBC, summary: Biogen, in its second-quarter earnings report, said the plan will result in $700 million in net operating expense savings by 2025. , Headline: MBLY Stock Alert: Morgan Stanley Restarts Mobileye Coverage, source:InvestorPlace, summary: No summary, Headline: Biogen Inc. Tops Q2 Earnings And Revenue Estimates, source:TalkMarkets, summary: No summary, Headline: WMT Stock Alert: Is Walmart Really Worth $210?, source:InvestorPlace, summary: No summary, Headline: Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event, TikTok Takes On Twitter, Analysts Expect Nvidia's AI Revenues To Reach $300B In Five Years: Today's Top Stories, source:Benzinga, summary: No summary, Headline: Biogen to slash 1,000 jobs as it looks to save $700 million, source:MarketWatch, summary: No summary, Headline: Biogen price target lowered to $320 from $324 at Stifel, source:Thefly.com, summary: No summary, Headline: Biogen, Eisai, And Eli Lilly: Goldilocks-Like Treatments For Alzheimer's May Hurt, source:SeekingAlpha, summary: Biogen, Eisai, and Eli Lilly's Alzheimer's drugs have shown little efficacy, particularly in non-APOE4 carriers. Read more here., Headline: Wolfe says Biogen 'struck a more cautious tone' on possible Tysabri biosimilar, source:Thefly.com, summary: No summary, Headline: Biogen to cut 1,000 jobs to save costs as Alzheimer's drug launch gathers pace, source:Yahoo, summary: Biogen Inc said on Tuesday it expects to slash about 1,000 jobs, or about 11% of its workforce, to save costs as the company ramps up the launch of a new Alzheimer's disease drug in efforts to return to growth.  Investors have pinned their hopes on Leqembi, which Biogen sells with Eisai, to power growth as money spinner multiple sclerosis and spinal muscular atrophy (SMA) treatments face fierce competition from cheaper versions and rival drugs.  ""Biogen's business is in transition,"" CEO Christopher Viehbacher said in a statement., Headline: Biogen announces job cuts, turns focus to Alzheimer's drug launch, source:Yahoo, summary: (Reuters) -Biogen Inc said on Tuesday it expects to slash about 1,000 jobs, or 11% of its workforce, in a fresh round of cost-cutting as it looks to the launch of a new Alzheimer's drug to help it return to growth.  The company said its costs are elevated compared to rivals and that it would focus on higher-growth products such as the recently approved Alzheimer's drug Leqembi, which it sells with partner Eisai.  ""I don't think we as a company have really made the changes in our ... cost base to really reflect that transition,"" Viehbacher said after the job cuts were announced., Headline: Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Stocks making the biggest moves midday: Spotify, RTX, General Electric and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Biogen Inc. (BIIB) Tops Q2 Earnings and Revenue Estimates, source:Yahoo, summary: Biogen Inc. (BIIB) delivered earnings and revenue surprises of 6.63% and 3.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?, Headline: Biogen Inc. (BIIB) Q2 2023 Earnings Call Transcript, source:SeekingAlpha, summary: Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q2 2023 Earnings Conference Call July 25, 2023 8:00 AM ETCompany ParticipantsChuck Triano - Head of Investor RelationsChristopher Viehbacher - President and..., Headline: US Stocks Climb Before Big Tech Earnings, Fed Meeting As China Stimulus Boosts Excitement: What's Driving Markets Tuesday?, source:Benzinga, summary: No summary, Headline: Compared to Estimates, Biogen Inc. (BIIB) Q2 Earnings: A Look at Key Metrics, source:Yahoo, summary: While the top- and bottom-line numbers for Biogen Inc. (BIIB) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values., Headline: Biogen to cut another 1,000 jobs in 'complete redesign', source:Yahoo, summary: Biogen Inc. is making sweeping cuts again as it works to offset declining revenue due to competition from generic drugs.  The Cambridge drugmaker (Nasdaq: BIIB) said in its second-quarter earnings report Tuesday morning that it would cut another 1,000 jobs, part of an overhaul that also includes the elimination of some early-stage R&D programs.  Biogen shares were down 2.4% at market close, giving the company a market capitalization of $39.1 billion., Headline: Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates, source:Yahoo, summary: Biogen stock dropped Tuesday after the biotechnology firm said it's eliminating 1,000 jobs as part of a strategy to cut operating expenses., Headline: Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts, source:Yahoo, summary: Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market., Headline: A Surprising Beneficiary of New Alzheimer’s Drugs: GE HealthCare, source:Yahoo, summary: With a new drug for Alzheimer’s disease set to unleash a massive new market, attention is now shifting to the imaging needs likely to be created by this patient group.  For patients to be put on Eisai and  Biogen  Leqembi, they will likely need to undergo at least one PET scan to confirm they have the disease and then repeated MRI scans to assess them for safety.  While those requirements might create a bottleneck for the drugmakers given the limited number of PET machines in the country, they represent a growth opportunity for developers of imaging equipment such as  GE HealthCare Siemens Healthineers  and Philips., Headline: Biogen to cut 1,000 jobs as focus turns to Alzheimer's drug Leqembi launch, source:Yahoo, summary: Biogen said on Tuesday it expects to eliminate roughly 1,000 positions in the U.S. to save money ahead of launching a new drug to treat Alzheimer's disease., Headline: Biogen Stock Drops Despite News of Layoffs as Company Rolls Out Alzheimer’s Drug, source:Yahoo, summary: The company is reducing its staff by about 11%, in a cost-cutting effort it expects it will save $1 billion a year in gross operating expenses., Headline: Biogen to Lay Off Roughly 11% of Workforce to Focus on Big-Return Drugs, source:Yahoo, summary: The biotech company cited the launch of Alzheimer’s drug Leqembi as part of its new focus on big-return products., Headline: Biogen (BIIB) Q2 2023 Earnings Call Transcript, source:Yahoo, summary: BIIB earnings call for the period ending June 30, 2023., Headline: Why Biogen Stock Got Sick Today, source:Yahoo, summary: While the company has won approval for a promising drug, it's cutting costs in the wake of that regulatory green light., Headline: Stifel Maintains Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Needham Reiterates Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Analysts’ Opinions Are Mixed on These Healthcare Stocks: ImmunoGen (IMGN) and Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: No summary",BIIB
265,2023-07-26,"Headline: Q2 2023 Biogen Inc Earnings Call, source:Yahoo, summary: Q2 2023 Biogen Inc Earnings Call, Headline: Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Abbott Labs (ABT), source:TipRanks, summary: No summary, Headline: Biogen price target lowered to $310 from $320 at BofA, source:Thefly.com, summary: No summary, Headline: Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Terns Pharmaceuticals (TERN), source:TipRanks, summary: No summary, Headline: Biogen price target raised to $323 from $320 at Needham, source:Thefly.com, summary: No summary, Headline: GLOBAL BROKER RATINGS: HSBC cuts Glencore; LBBW likes Adidas, source:Alliance News, summary: No summary, Headline: Biogen price target raised to $379 from $341 at RBC Capital, source:Thefly.com, summary: No summary, Headline: Truist Financial Reaffirms Their Buy Rating on Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Sage hits eight-month low as FDA decision on depression therapy nears, source:Seeking Alpha, summary: No summary, Headline: Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More, source:Yahoo, summary: Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector., Headline: Biogen’s CEO Didn’t Mention an Impending FDA Decision. Investors Got Spooked., source:Yahoo, summary: Despite generally positive earnings and a cost-savings plan that will reduce the company’s head count by 1,000, shares of Biogen have traded down sharply since Tuesday's earnings call., Headline: 12 Out of Favor Stocks That Hedge Funds Love, source:Yahoo, summary: In this article, we will be taking a look at 12 out of favor stocks that hedge funds love. To skip our detailed analysis of investing moves today, you can go directly to see the 5 Out of Favor Stocks That Hedge Funds Love. Investing in stocks will always be a tricky exercise. The market […], Headline: Why Sage Therapeutics Stock Is Tumbling Today, source:Yahoo, summary: A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today., Headline: RBC Capital Maintains Biogen (BIIB) Outperform Recommendation, source:Fintel, summary: nan, Headline: Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation, source:Fintel, summary: nan, Headline: Wedbush Maintains Biogen (BIIB) Neutral Recommendation, source:Fintel, summary: nan, Headline: BMO Capital Maintains Biogen (BIIB) Outperform Recommendation, source:Fintel, summary: nan, Headline: HC Wainwright & Co. Reiterates Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Needham Maintains Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Biogen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: No summary",BIIB
266,2023-07-27,"Headline: Biogen initiated with an Outperform at Scotiabank, source:Thefly.com, summary: No summary, Headline: Thursday’s Top Analyst Upgrades and Downgrades: Alphabet, Disney, Eli Lilly, Etsy, Microsoft, Mosaic, NetApp, RTX, Spotify and More, source:247WallSt, summary: No summary, Headline: I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO, source:Yahoo, summary: When you think about biotech leaders, the name Biogen (NASDAQ: BIIB) may come to mind.  As a result, revenue has been on the decline, and the share price has stagnated.  Biogen prepared for the loss of exclusivity by developing new products, most specifically one to treat Alzheimer's disease., Headline: Meta Platforms upgraded, Estee Lauder downgraded: Wall Street's top analyst call, source:Yahoo, summary: Meta Platforms upgraded, Estee Lauder downgraded: Wall Street's top analyst call, Headline: Scotiabank Initiates Coverage of Biogen (BIIB) with Sector Outperform Recommendation, source:Fintel, summary: nan, Headline: Buy/Sell: Wall Street's top 10 stock calls this week, source:Thefly.com, summary: No summary, Headline: Reata Pharmaceuticals downgraded to Hold from Buy at Jefferies, source:Thefly.com, summary: No summary, Headline: What You Missed On Wall Street On Friday, source:Thefly.com, summary: No summary, Headline: Biogen Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: No summary",BIIB
267,2023-07-28,"Headline: Intel is chipper, Boston Beer fizzes, and other movers, source:MarketWatch, summary: Roku shares rally after the streamer's results beat expectations, Headline: Reata downgraded to Market Perform from Outperform at SVB Securities, source:Thefly.com, summary: No summary, Headline: Biogen to acquire Reata Pharmaceuticals for $172.50 per share in cash, source:Thefly.com, summary: No summary, Headline: Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion in cash, source:MarketWatch, summary: No summary, Headline: Biogen agrees to buy Reata Pharmaceuticals for $172.50 a share in cash, source:Seeking Alpha, summary: No summary, Headline: Biogen agrees to buy Reata Pharmaceuticals in deal valued at $7.3B, source:Seeking Alpha, summary: No summary, Headline: Biogen considering takeover of biotech Reata - Bloomberg Law, source:Finnhub, summary: Biogen is exploring an
acquisition of biotech firm Reata Pharmaceuticals,
Bloomberg Law reported on Friday, citing people familiar with
the matter.
              Shares of Reata surged about 13% in..., Headline: Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering, source:MarketWatch, summary: Biogen's all-cash deal is a rare-disease play., Headline: Biogen : Business Update, source:Finnhub, summary: Reata acquisition expected to meaningfully advance Biogen's
        
        
          return to growth objective
        
      
      
        
          
           ..., Headline: Stocks making the biggest moves premarket: Intel, Roku, Procter & Gamble and more , source:CNBC, summary: These are the stocks posting the largest moves in premarket trading. , Headline: Friday’s Top Analyst Upgrades and Downgrades: Apple, Boeing, Carvana, Coty, Meta, RTX, Southwest Airlines, SunPower and More, source:247WallSt, summary: No summary, Headline: Biogen Snaps Up Reata Pharma In $7.3B Deal, source:TipRanks, summary: No summary, Headline: Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?, source:InvestorPlace, summary: No summary, Headline: Intel, Reata Pharma and Roku rally, and other movers, source:MarketWatch, summary: No summary, Headline: Reata Pharmaceuticals Shares Soar on Takeover by Biogen >RETA, source:MarketWatch, summary: By Colin Kellaher Reata Pharmaceuticals shares surged to a multi-year high Friday after the biopharmaceutical company struck a $7.3 billion deal to be..., Headline: Health Care Company Biogen Announces Acquisition of Reata Pharmaceuticals, source:Benzinga, summary: No summary, Headline: Biogen bolsters rare disease treatments with USD7 billion Reata buy, source:Alliance News, summary: No summary, Headline: Reata Pharmaceuticals downgraded to Hold from Buy at Stifel, source:Thefly.com, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Biogen to Acquire Reata Pharmaceuticals, source:Yahoo, summary: SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical needExpected to be significantly accretive to Biogen’s Non-GAAP diluted EPS beginning in 2025Biogen to host investor conference call today at 9:00 a.m. ET. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE, Headline: UPDATE 4-Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio, source:Yahoo, summary: Biogen agreed to buy biotech firm Reata Pharmaceuticals for nearly $6.5 billion to bolster its position in the rare disease drugs market while its older multiple sclerosis drugs face intense competition.  Through the deal, Biogen said it will gain Plano, Texas-based Reata's recently approved drug Skyclarys to treat a rare genetic disorder that causes progressive damage to the nervous system.  Biogen has said it has been hunting for deals, especially in areas such as rare diseases and immunology, to expand beyond its multiple sclerosis drugs portfolio that is under pressure from competition., Headline: Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio, source:Yahoo, summary: (Reuters) -Biogen agreed to buy rare disease drugmaker Reata Pharmaceuticals for nearly $6.5 billion, the first large acquisition under new CEO Christopher Viehbacher as he seeks to return the drugmaker to growth.  Viehbacher was hired in November to put Biogen back on a growth path after a series of missteps around the controversial Alzheimer's drug Aduhelm hurt the company, which was already grappling with intense competition to its top-selling drugs.  Through the deal, Biogen said it will gain Texas-based Reata's recently approved drug Skyclarys to treat a rare genetic disorder that causes progressive damage to the nervous system., Headline: Biogen to bulk up rare disease treatments with $7 billion Reata acquisition, source:Yahoo, summary: Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments.  The Alzheimer’s treatment developer said Friday it will pay $172.50 in cash for each share of Reata in a deal it expects to close by the end of this year.  Plano, Texas-based Reata focuses on developing treatments that regulate cellular metabolism and deal with inflammation in serious neurologic diseases., Headline: Larimar, Design higher as they benefit from Biogen deal for Reata, source:Seeking Alpha, summary: No summary, Headline: Will Biogen's Deal Splash Give Biotech a Lift?, source:Yahoo, summary: It’s a merger Friday, and that means payday for shareholders of Reata Pharmaceuticals. Shares of Reata, which specializes in developing drugs to treat rare neurologic diseases, are up 51% in premarket trading., Headline: Biogen to buy a Texas-based rare disease firm for $7.2B, source:Yahoo, summary: Biogen is paying $7.2 billion to buy a Texas-based biotech as new CEO makes good on his promise to expand into the rare disease space., Headline: Biogen to Buy Reata for $7.3 Billion in Rare-Disease Deal, source:Yahoo, summary: (Bloomberg) -- Biogen Inc. agreed to acquire Reata Pharmaceuticals Inc. for $7.3 billion, including debt, to expand its rare disease treatments in one of its biggest-ever acquisitions. Most Read from BloombergLargest US Grid Declares Emergency Alert For July 27BOJ Sends Yields Soaring With Surprise Change to Rate LimitSubway Offers Free Sandwiches That Come With a Lifetime CommitmentChina’s Push to Expand BRICS Membership FaltersS&P 500 Up 1% as ‘Goldilocks’ Data Embolden Bulls: Markets WrapThe, Headline: Reata Stock Surges. Biogen Is Buying It for $7.3 Billion in Cash., source:Yahoo, summary: Biogen will acquire Reata for $172.50 a share in cash, expanding its portfolio of neuromuscular disease treatments., Headline: Biogen Announces $7.3 Billion Acquisition After Outlining Plans To Cut 11% Of Workforce, source:Yahoo, summary: Biogen announced Friday it has agreed to acquire Reata Pharmaceuticals for about $7.3 billion, boosting biopharmaceutical company Biogen's drug offerings for serious neurological diseases.  Reata stock surged early as Biogen stock slid.  RETA stock skyrocketed 52.4% to 165.24 early Friday during market trade after Biogen reported it plans to pay $172.50 per share in cash for Reata., Headline: Enphase Energy outlook, Biogen-Reata deal, Boston Beer stock: Top stocks, source:Yahoo, summary: Enphase Energy shares slide on a cloudy outlook stemming from an elevated interest rate environment. Biogen is set to acquire Reata Pharmaceuticals in a $7.3 billion deal. Boston Beer Company stock soars on increased demand for its Twisted Tea. Yahoo Finance Live's Brad Smith, Julie Hyman, and Rachelle Akuffo take a look at several stocks trending in the morning session., Headline: Biogen's Alzheimer's drug is the biggest growth catalyst for the stock, says Jefferies' Yee, source:CNBC, summary: Michael Yee, Jefferies biotech analyst, joins 'Power Lunch' to discuss what Biogen's purchase of Reata means for the former, the biggest catalyst for Biogen stock, and more., Headline: Eli Lilly: There Is No Logic To This Over Optimism, source:SeekingAlpha, summary: Mounjaro may rake in $25B of annualized sales by 2026, exceeding ABBV's Humira. This naturally explains Mr. Market's optimism surrounding the LLY's stock thus far., Headline: NEW YORK MARKET CLOSE: Tech stars as stocks end winning week on high, source:Alliance News, summary: No summary, Headline: Biogen Buying Rare-Disease Drugmaker In $7.3 Billion Deal, source:Yahoo, summary: The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases., Headline: Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On Investors, source:SeekingAlpha, summary: Biogen Inc. now plans to acquire Reata Pharmaceuticals, Inc. for $7.3 billion, validating the potential of Skyclarys. Click for my updated take on RETA shares., Headline: Why Biogen Agreed to Acquire Reata for $7.3 Billion, source:Yahoo, summary: Biogen agreed to acquire Reata Pharmaceuticals for $7.3 billion, including debt, to expand its rare disease treatments. Michelle Davis reports on ""Bloomberg Markets."" Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com Connect with us on... Twitter: https://twitter.com/business Facebook: https://www.facebook.com/bloombergbusiness/ Instagram: https://www.instagram.com/quicktake/?hl=en, Headline: Biogen to buy rare-disease drugmaker Reata in $7.3B deal, source:Yahoo, summary: Biogen will pay $7.3 billion to buy Reata Pharmaceuticals, company that makes a drug for a rare neurological condition. Analysts have been generally positive on the deal, with one calling it ""low-risk."" Yahoo Finance Health Care Reporter Anjalee Khemlani recaps some of the biggest stories from the health industry., Headline: Biogen Buys Reata Pharmaceuticals, Expanding Its Lineup of Rare Disease Drugs, source:Yahoo, summary: Biogen said it was buying Reata Pharmaceuticals for $7.3 billion, expanding its rare disease treatment portfolio., Headline: S&P 500 Gains and Losses Today: Stocks Jump as Inflation Cools, source:Yahoo, summary: U.S. equities rallied on Friday, July 28, 2023 after a report showing inflation cooled in June, and the S&P 500 rose 1%.",BIIB
268,2023-07-29,"Headline: Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil, source:Yahoo, summary: As biotech stock prices have fallen, Wall Street and biotech boards have grown increasingly unfriendly. Amid the turmoil, key biotech stocks have become the targets of activist investors demanding new executives, new boards and new strategies. The specifics of each case vary, but the biotech stocks in sharpest focus have been those whose earnings and revenue have disappointed investors. Of course, it’s no accident this happens. Investors want to protect their investments. And if the company isn’, Headline: 3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes, source:InvestorPlace, summary: No summary",BIIB
269,2023-07-30,"Headline: Biogen's (NASDAQ:BIIB) underlying earnings growth outpaced the return generated for shareholders over the past year, source:Yahoo, summary: It hasn't been the best quarter for Biogen Inc. ( NASDAQ:BIIB ) shareholders, since the share price has fallen 15% in..., Headline: TOP NEWS: Biogen to acquire Reata Pharmaceuticals in USD7 billion deal, source:Alliance News, summary: No summary",BIIB
270,2023-07-31,"Headline: Promising new Alzheimer's drugs may benefit whites more than Blacks, source:Finnhub, summary: Groundbreaking treatments
for Alzheimer's disease that work by removing a toxic protein
called beta amyloid from the brain may benefit whites more than
Black Americans, whose disease may be driven by..., Headline: Reata Pharmaceuticals downgraded to Neutral from Buy at Ladenburg, source:Thefly.com, summary: No summary, Headline: Reata Pharmaceuticals price target raised to $173 from $85 at Baird, source:Thefly.com, summary: No summary, Headline: Quest Diagnostics launches first at-home blood test to assess risk of developing Alzheimer’s disease, source:DowJones, summary: Quest Diagnostics Inc. said Monday it has brought the first blood-based biomarker test to assess the risk of developing Alzheimer’s disease to market and..., Headline: US announces trial payment program for care providers of dementia patients, source:Finnhub, summary: The U.S. government said on Monday
it would trial a new payment program for people who provide
dementia care coordination services for patients covered by the
Medicare health plan.
              The..., Headline: Biotech Alert: Searches spiking for these stocks today, source:Thefly.com, summary: No summary, Headline: Rising Stars, Falling Trends: July's Industry ETF Winners And Losers, source:Benzinga, summary: No summary, Headline: Biogen’s New Boss Is Delivering, but Stock Isn’t Pricing It in Yet, source:Yahoo, summary: The decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street’s skepticism presents an opportunity., Headline: Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen, source:Yahoo, summary: Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) will soon likely be going head to head in the market for therapies that treat Alzheimer's disease.  Both drug developers see the market for such medicines as being a major one in the coming years, and their candidates are set up to duel for the first leg of growth.  Let's dive in and evaluate the case for each on the basis of how their medicines seem to perform so far., Headline: 10 Most Oversold S&P 500 Stocks Right Now, source:Yahoo, summary: In this article, we will take a look at 10 most oversold S&P 500 stocks right now. To skip our analysis of the recent market activity, you can go directly to see the 5 Most Oversold S&P 500 Stocks Right Now. The stock markets have been through the wringer in the recent past especially since […], Headline: Needham Reiterates Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: RBC Capital Maintains Biogen (BIIB) Outperform Recommendation, source:Fintel, summary: nan, Headline: Biogen Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary",BIIB
271,2023-08-01,"Headline: Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know., source:Yahoo, summary: Biogen's (NASDAQ: BIIB) biggest problem in recent times has been growth.  The biotech giant's multiple sclerosis (MS) portfolio is facing more and more generic competition, and that's resulted in declining sales.  All this has weighed on share performance too, as investors wonder about what the company and its earnings will look like in the future., Headline: For Dementia Patients and Their Caregivers, Help Could Be Coming Next Year, source:MarketWatch, summary: A voluntary nationwide program starting next year aims to improve care for the more than 6.7 million Americans living with dementia and their unpaid caregivers., Headline: Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points, source:Yahoo, summary: The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%. Despite the massive amount of revenue being generated, most biotech companies remain small and medium-sized enterprises. Many of the companies operating in the space are start-ups. Yet they are performing cutting-edge research and developing life-saving innovations that are in high demand. This presents an opportunity fo, Headline: Biogen Unusual Options Activity For August 02, source:Benzinga, summary: No summary, Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: No summary",BIIB
272,2023-08-02,"Headline: Larimar: Friedreich's Ataxia Drug With Significant Potential, source:SeekingAlpha, summary: Larimar therapeutics has been making significant progress in advancing its drug known as CTI-1601. Read more about LRMR here., Headline: Earnings Insight: Analysts Raising Full-Year 2023 Estimates For U.S. And European Equities, source:SeekingAlpha, summary: Weâve seen a shift in analyst sentiment over the last two weeks when looking at data in This Week in Earnings and STOXX 600 Earnings Outlook report., Headline: 3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now, source:Yahoo, summary: Medical stocks, in general, aren’t enjoying the market-wide reversal we’re seeing in the back half of 2023. The Morningstar US Healthcare Index, which measures a range of biotech, pharma, medical device and healthcare facility companies, has returned less than 1% since January. Compare that performance to the S&P 500’s rapid mid-March reversal and 20% jump since then, and healthcare stockholders’ woes are understandable. Despite strained supply chains and an industry-wide inability to readapt to, Headline: Biogen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: No summary",BIIB
273,2023-08-03,"Headline: Goldman in, Microsoft out of BofA Alpha Surprise Portfolio, source:Seeking Alpha, summary: No summary, Headline: Biogen Inc. (NASDAQ:BIIB) is a favorite amongst institutional investors who own 88%, source:Yahoo, summary: Key Insights Institutions' substantial holdings in Biogen implies that they have significant influence over the..., Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: No summary",BIIB
274,2023-08-04,"Headline: Biogen trading halted, news pending, source:Thefly.com, summary: No summary, Headline: FDA approves Zurzuvae for postpartum depression, source:Thefly.com, summary: No summary, Headline: Sage, Biogen postpartum depression pill zuranolone wins FDA approval, source:Seeking Alpha, summary: No summary, Headline: Eli Lilly Stock Is on a Tear. Expect More Gains After Earnings., source:MarketWatch, summary: Despite its strong start to the year, the drugmaker’s report on Tuesday should lift shares even further., Headline: 5 Healthcare Stocks to Buy Now, According to Analysts – August 2023, source:TipRanks, summary: No summary, Headline: FDA approves first-ever pill for postpartum depression in new mothers, source:MarketWatch, summary: Biogen and Sage Therapeutics are behind the first FDA-approved pill for treating postpartum depression., Headline: The Biotech Game Is Changing. Watch for Disruptions, Says RBC., source:Yahoo, summary: SECTORFOCUS BLOG  The rules of the biotech game could change dramatically if several trends play out in science and regulation. Investors should be on alert, say analysts from RBC Capital Markets. Government programs could command deep discounts., Headline: FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder, source:Finnhub, summary: Postpartum depression  approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with..., Headline: US FDA approves Biogen-Sage Therapeutics pill for postpartum depression, source:Yahoo, summary: The companies had sought the FDA's approval for the drug, Zurzuvae, to treat major depressive disorder (MDD), or clinical depression, as well as postpartum depression, which affect millions of people.  PPD severely affects a woman's ability to return to normal functioning, while also potentially affecting the mother's relationship with her child., Headline: First Pill for Postpartum Depression Is Approved by FDA, source:Yahoo, summary: The pill, to be taken daily for at least two weeks, significantly reduced postpartum depression among new mothers in a recent trial., Headline: UPDATE 1-US FDA approves Biogen-Sage Therapeutics pill for postpartum depression, source:Yahoo, summary: The U.S. Food and Drug Administration on Friday approved Biogen and Sage Therapeutics' oral pill to treat postpartum depression (PPD) in adults.  The companies had sought the FDA's approval for the drug, Zurzuvae, to treat major depressive disorder), or clinical depression, as well as postpartum depression (PPD), which affect millions of people.  Analysts were anticipating the stocks of both companies to fall if the drug was approved only for postpartum depression due to the smaller patient population., Headline: Postpartum depression drug developed by Sage, Biogen approved by FDA, source:Yahoo, summary: A new depression drug has received the green light from the U.S. Food and Drug Administration after years of development by two Cambridge drugmakers. Zuranolone, a new drug co-developed by Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics Inc. (Nasdaq: SAGE), scored an FDA approval late Friday — but the approval was only for postpartum depression, not major depressive disorder. The companies had applied to market the drug as a treatment for both., Headline: FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder, source:Yahoo, summary: CAMBRIDGE, Mass., August 05, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAETM (zuranolone) 50 mg for adults with postpartum depression (PPD). ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD. ZURZUVAE is expected to launch and be commercially available in the fourth quarter of 2023 shortly following sch",BIIB
275,2023-08-05,"Headline: 2023 shaping up to be biggest year for biopharma M&A since pandemic, source:Seeking Alpha, summary: No summary",BIIB
276,2023-08-06,"Headline: DiaMedica Therapeutics: Risk-Reward Favors Following Insider Optimism, source:SeekingAlpha, summary: DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on recombinant proteins to treat life-threatening diseases. Read more here., Headline: Biogens, Sage Therapeutics postpartum depression treatment approved, source:Alliance News, summary: No summary, Headline: CORRECT: Biogens, Sage Therapeutics postpartum depression drug okayed, source:Alliance News, summary: No summary, Headline: Sage, Biogen receive CRL for zuranolone in major depressive disorder, source:Thefly.com, summary: No summary, Headline: Biogen Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: No summary",BIIB
277,2023-08-07,"Headline: Biogen (BIIB) Receives a Hold from Barclays, source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Becton Dickinson (BDX) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Wedbush cuts Sage to neutral, questions Biogen's future funding of zuranolone, source:Seeking Alpha, summary: No summary, Headline: J.P. Morgan Sticks to Its Hold Rating for Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX), Aurinia Pharmaceuticals (AUPH) and Biogen (BIIB), source:TipRanks, summary: No summary, Headline: RBC Capital cuts Sage to sector perform, calls FDA decision ""major setback"", source:Seeking Alpha, summary: No summary, Headline: Sage sees cash and equivalentes enough to support operations into 2025, source:Thefly.com, summary: No summary, Headline: Biogen price target lowered to $333 from $340 at Baird, source:Thefly.com, summary: No summary, Headline: Sage plummets 46% after FDA declines zuranolone in major depression, source:Seeking Alpha, summary: No summary, Headline: Wedbush downgrades Sage Therapeutics to Neutral, lowers price target to $22, source:Thefly.com, summary: No summary, Headline: Biogen price target lowered to $269 from $276 at Wedbush, source:Thefly.com, summary: No summary, Headline: Biogen price target lowered to $290 from $310 at BofA, source:Thefly.com, summary: No summary, Headline: Sage Therapeutics’ stock craters 49% after FDA approves zuranolone for postpartum depression, but not major depressive disorder, source:MarketWatch, summary: No summary, Headline: Biogen price target lowered to $290 from $360 at Oppenheimer, source:Thefly.com, summary: No summary, Headline: Biogen price target lowered to $350 from $380 at Piper Sandler, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Horizon Therapeutics (HZNP) and Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Biogen, Sage face uphill battle with postpartum depression pill, source:Finnhub, summary: The U.S. drug regulator's approval of
Biogen and Sage Therapeutics'
first-of-its-kind postpartum depression  pill is unlikely
to allay the drugmakers' growth concerns, analysts said on
Monday.
       ..., Headline: Sage Therapeutics Shares Slide Premarket After Zurzuvae MDD Setback >SAGE, source:MarketWatch, summary: By Colin Kellaher Shares of Sage Therapeutics tumbled more than 45% in premarket trading Monday after the U.S. Food and Drug Administration rejected a key..., Headline: Biogen price target lowered to $343 from $350 at Wells Fargo, source:Thefly.com, summary: No summary, Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: No summary, Headline: Biogen price target lowered to $294 from $311 at Barclays, source:Thefly.com, summary: No summary, Headline: Biogen price target lowered to $354 from $374 at RBC Capital, source:Thefly.com, summary: No summary, Headline: PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories, source:Benzinga, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Pharvaris (PHVS), source:TipRanks, summary: No summary, Headline: Biogen, Sage face challenges as FDA rejects pill for clinical depression, source:Finnhub, summary: The approval of Biogen and
Sage Therapeutics' depression pill for a
smaller-than-expected patient cohort has fueled concerns over
its growth prospects, analysts said on Monday.
              The U.S...., Headline: Retirees' Biggest Social Security News of the Year Is Less Than 10 Weeks Away, source:Yahoo, summary: Retirees don't only have cooler temperatures to look forward to.  The Social Security Administration (SSA) hasn't officially announced when it will reveal the cost-of-living adjustment (COLA) for 2024.  SSA provided its update for the 2022 COLA on Oct. 13, 2021., Headline: Major US health systems expect to offer Alzheimer's drug Leqembi in a few months, source:Yahoo, summary: Five major U.S. health systems said they would offer Eisai and Biogen's promising new Alzheimer's drug Leqembi after working out payment and administrative policies, and how to assess and monitor patients, most likely in the next month or two.  Leqembi, which won full U.S. regulatory approval last month, is the first treatment proven to slow progression of the mind-robbing disease for people in the earliest stages of Alzheimer's.  The disease affects an estimated 6.5 million people, most of whom are part of the U.S. government’s Medicare plan for people 65 and older., Headline: Sage Therapeutics' Zuranolone Is A Lost Cause In Depression Market, source:SeekingAlpha, summary: Sage Therapeutics faces challenges with declining cash, rising expenses, and limited market potential despite FDA approval for Zurzuvae in PPD treatment., Headline: Sage Therapeutics stock plunges more than 50% after FDA denies wider use of postpartum depression drug, source:CNBC, summary: The FDA approved the pill zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for major depressive disorder. , Headline: FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says, source:Benzinga, summary: No summary, Headline: Dow Rises Over 300 Points To Start The Week, source:TalkMarkets, summary: No summary, Headline: Sage Therapeutics downgraded to Neutral at BofA after MDD CRL, source:Thefly.com, summary: No summary, Headline: Sage Tumbles as Depression Pill Approval Omits Major Disorder, source:Yahoo, summary: (Bloomberg) -- Sage Therapeutics Inc. slumped in early trading after regulators granted approval to its fast-acting pill only for postpartum depression, denying the drug clearance for major depressive disorder.Most Read from BloombergMusk Says He May Need Surgery, Will Get MRI on Back and NeckTexas Power Prices to Surge 800% on Sunday Amid Searing HeatPayPal Launches a Stablecoin in Latest Crypto Payments PushUkraine Black Sea Drone Attacks Signal Rapidly Expanding WarHSBC Executive Slams ‘Weak’, Headline: Sage Stock Tumbles After FDA Decision on Depression Drug, source:Yahoo, summary: Sage Therapeutics says it's 'evaluating resource allocation, including pipeline prioritization and a workforce reorganization with a goal of extending our cash runway.', Headline: Sage tumbles to record low on clinical depression pill setback, source:Finnhub, summary: Shares of Sage Therapeutics slumped to a record low on Monday after the U.S. health regulator approved the company and partner Biogen's pill for postpartum depression, but rejected it as a..., Headline: What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead, source:Benzinga, summary: No summary, Headline: Split FDA Call on Depression Drug Upsets Strategies for Biogen, Sage, source:Yahoo, summary: Sage Therapeutics says it is 'evaluating resource allocation, including pipeline prioritization and a workforce reorganization with a goal of extending our cash runway.', Headline: FDA approves first postpartum depression pill from Biogen, Sage, source:Yahoo, summary: The U.S. Food and Drug Administration has approved the first pill to help treat postpartum depression. The pill was co-developed by Biogen (BIIB) and Sage Therapeutics (SAGE). The approval was a mixed bag for the companies. It was not approved to treat for major depressive disorder, which would have been made the pill marketable to more patients. Also, there was a surprise warning from the FDA about not driving for 12 hours after taking the pill. The drugmakers say the pill should be ready for launch in the fourth quarter of 2023. Yahoo Finance Health Care Reporter Anjalee Khemlani explains the pill's approval., Headline: Sage shares cut in half after postpartum drug approval. Here's what happened., source:Yahoo, summary: The Cambridge drugmaker saw its market value drop by about $1 billion in the first minutes of trading Monday, following a partial approval of a new depression drug late Friday. Cambridge-based Sage had applied to market the depression drug, zuranolone, as a treatment for both major depressive disorder (MDD) and postpartum depression (PPD). The U.S. Food and Drug Administration approved zuranolone, now marketed under the name Zurzuvae, for PPD but rejected it as a treatment for MDD, citing a lack, Headline: Why Sage Therapeutics Stock Is Crashing Today, source:Yahoo, summary: The huge sell-off came after the company and its partner, Biogen, announced following the market close on Friday that the U.S. Food and Drug Administration (FDA) didn't approve Zurzuvae (zuranolone) for major depressive disorder (MDD).  The FDA did approve Zurzuvae for treating postpartum depression (PPD).  The big problem for Sage -- and the main reason the biotech stock is plunging -- is that Zurzuvae will have a much smaller market size to target now., Headline: Future Prospects For Johnson & Johnson Following Strong Q2 Performance, source:SeekingAlpha, summary: Johnson & Johnson, the mastodon of the healthcare sector, released its financial results for the 2nd quarter of 2023. Read why JNJ stock is a hold., Headline: Sage Therapeutics Shares Plummet Following FDA Decision on Depression Drug, source:Yahoo, summary: Sage Therapeutic shares fell to an all-time low after the FDA rejected use of its treatment for major depressive disorder., Headline: Eli Lilly to Report Earnings as Hope Soars for Weight-Loss Drug Mounjaro, source:Yahoo, summary: Things couldn't be going much better for the drugmaker. The stock is up about 50% over the past 12 months and nearly 25% so far this year., Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: No summary",BIIB
278,2023-08-08,"Headline: BofA upgrades Axome to neutral, cites improved outlook for MDD drug, source:Seeking Alpha, summary: No summary, Headline: DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday, source:Benzinga, summary: No summary, Headline: Biogen price target lowered to $336 from $347 at BMO Capital, source:Thefly.com, summary: No summary, Headline: Looking Into Biogen's Recent Short Interest, source:Benzinga, summary: No summary, Headline: Needham cuts Sage Therapeutics to Hold on reduced zuranalone opportunity, source:Thefly.com, summary: No summary, Headline: Biogen price target lowered to $340 from $3500 at Truist, source:Thefly.com, summary: No summary, Headline: Wells Fargo Maintains Biogen (BIIB) Overweight Recommendation, source:Fintel, summary: nan, Headline: RBC Capital Maintains Biogen (BIIB) Outperform Recommendation, source:Fintel, summary: nan, Headline: Oppenheimer Maintains Biogen (BIIB) Outperform Recommendation, source:Fintel, summary: nan, Headline: Lilly reaches all-time high on Q2 results, 2023 guidance boost, source:Seeking Alpha, summary: No summary, Headline: Is Sage Therapeutics a Contrarian Buy?, source:Yahoo, summary: Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE), a company that focuses on developing therapies for brain disorders.  The stock plummeted by more than 53% after the company revealed that its blockbuster drug candidate, zuranolone, failed to win approval from the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD).  Zuranolone, which Sage Therapeutics developed in collaboration with Biogen (NASDAQ: BIIB), is a novel antidepressant designed to offer fast and durable relief from depressive symptoms, with a short course of treatment and minimal side effects., Headline: Eli Lilly Stock Is Flying After Strong Results. Obesity Drugs Delivered the Goods., source:Yahoo, summary: Things couldn't be going much better for the drugmaker. The stock is up about 50% over the past 12 months and nearly 25% so far this year., Headline: Is Biogen Inc (BIIB) Modestly Overvalued? A Comprehensive Valuation Analysis, source:Yahoo, summary: Exploring the intrinsic value and financial health of Biogen Inc (BIIB), Headline: Regional Bank U.S. Bancorp Tops Moat Stocks In July, source:SeekingAlpha, summary: While U.S. equities extended their rally, Morningstarâs Moat Index extended its year-to-date lead over the S&P 500 to nearly 800 basis points. U.S. Bancorp stood out as the top contributor., Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: No summary",BIIB
279,2023-08-09,"Headline: Denali Therapeutics price target lowered to $31 from $37 at Wedbush, source:Thefly.com, summary: No summary, Headline: Truist Securities Maintains Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Needham Maintains Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Atlantic Equities Maintains Biogen (BIIB) Neutral Recommendation, source:Fintel, summary: nan, Headline: Barclays Maintains Biogen (BIIB) Equal-Weight Recommendation, source:Fintel, summary: nan, Headline: Biotech Alert: Searches spiking for these stocks today, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Caliber Imaging & Diagnostic (OtherLCDX), source:TipRanks, summary: No summary, Headline: Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy?, source:Yahoo, summary: Eli Lilly surged 15% in one day on enthusiasm for weight-loss and Alzheimer’s drugs. But is LLY stock a buy now? Here's what you should know., Headline: With an Acquisition on the Way, Is Biogen Stock a Buy?, source:Yahoo, summary: Biotech giant Biogen (NASDAQ: BIIB) can't seem to keep its name out of the news.  After a recent major approval for its Alzheimer's disease (AD) medicine Leqembi, the company just announced that it would acquire Reata Pharmaceuticals, a company that focuses on developing treatments for serious and life-threatening diseases.  Biogen has been a relatively volatile stock to own over the past few years, but could this new acquisition move help the company turn things around?, Headline: More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection, source:Yahoo, summary: Alzheimer's patients could soon have more treatment options available.  Biogen's Leqembi obtained approval from the U.S. Food and Drug Administration earlier this year, and another treatment from Eli Lilly, donanemab, may not be far behind.  The one drawback, however, is that those drugs treat Alzheimer's when the disease is in its early stages, and thus, many people won't be able to benefit from them., Headline: U.S. Wide-Moat Stocks On Sale - The August 2023 Heat Map, source:SeekingAlpha, summary: Discover our 3-step process for identifying undervalued wide-moat stocks, including a heat map of top investable candidates. Click here to read our picks., Headline: Biogen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: No summary",BIIB
280,2023-08-10,"Headline: Wall Street Analysts Trim Price Targets for These 10 Stocks, source:Yahoo, summary: In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts Trim Price Targets for These 5 Stocks. A series of daily 1% changes in the S&P 500, whether it goes up […], Headline: Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?, source:Yahoo, summary: Biogen (NASDAQ: BIIB) is an intriguing stock right now.  For starters, the company's Alzheimer's treatment, Leqembi, obtained approval from the Food and Drug Administration (FDA) earlier this year.  Plus, it announced a significant $6.5 billion acquisition last month that could bolster its portfolio of drugs., Headline: Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates, source:Yahoo, summary: Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023., Headline: Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues, source:Yahoo, summary: Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen., Headline: Biotech Duo Sage (NASDAQ:SAGE) and BioGen (NASDAQ:BIIB) Jump on Pricing Data, source:TipRanks, summary: No summary, Headline: Biogen Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: No summary",BIIB
281,2023-08-11,"Headline: Insurers won't cover new Alzheimer's treatment for some customers, source:Associated Press, The, summary: No summary, Headline: Biogen/ Sage expected to hike price for new depression drug after narrow label, source:Seeking Alpha, summary: No summary, Headline: Should Weakness in Biogen Inc.'s (NASDAQ:BIIB) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?, source:Yahoo, summary: It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined 13..., Headline: Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects, source:SeekingAlpha, summary: Biogen focuses on neurological therapies, recently acquired Reata Pharmaceuticals, and shows mixed financial performance. Click here to read more., Headline: 15 Most Important Medical Discoveries in History, source:Yahoo, summary: In this article, we take a look at the 15 most important medical discoveries in history. You can skip our detailed analysis of the global medicine industry and go directly to the 5 Most Important Medical Discoveries in History. Medical discoveries have done wonders for civilizations and helped humans to thrive. Since the evolution of […]",BIIB
282,2023-08-12,"Headline: INSIGHT-What happens when a $2 million gene therapy is not enough, source:Yahoo, summary: Baby Ben Kutschke was diagnosed at three months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally.  It leaves children too weak to walk, talk, swallow or even breathe.  So when in 2021 his parents heard about Zolgensma – a one-time therapy costing millions of dollars that promises to replace genes needed for the body to control muscles – they had high hopes.",BIIB
283,2023-08-13,"Headline: 13 Best Wide Moat Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this piece, we will take a look at the 13 best wide moat stocks to buy according to hedge funds. If you want to skip our primer on wide moat investing, then head on over to 5 Best Wide Moat Stocks To Buy According To Hedge Funds. Among the countless ways in which companies […], Headline: Biogen Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: No summary",BIIB
284,2023-08-14,"Headline: Capitalizing On Inflammation's Role In Neurological Disease Part 1: Coya Therapeutics, source:SeekingAlpha, summary: Coya Therapeutics aims to target inflammation-related diseases, like ALS, with Treg-enhancing therapeutics. Click here to read my analysis of COYA stock., Headline: Biogen price target lowered to $335 from $340 at Mizuho, source:Thefly.com, summary: No summary, Headline: Second Half Outlook For Biotech Stocks, source:SeekingAlpha, summary: Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%. Click here to read my thoughts., Headline: Mizuho Maintains Biogen (BIIB) Buy Recommendation, source:Fintel, summary: nan, Headline: Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity, source:SeekingAlpha, summary: Sage Therapeutics, Inc. is revolutionizing the treatment of postpartum depression, while also tackling CNS disorders. Click here to read more on SAGE stock., Headline: Sanofi was second bidder for Reata, Bloombreg reports, source:Thefly.com, summary: No summary, Headline: Sanofi was second bidder for Reata, Bloomberg reports, source:Thefly.com, summary: No summary, Headline: Sanofi was mystery bidder in Reata Pharma bidding war - report, source:Seeking Alpha, summary: No summary, Headline: Sanofi was mystery suitor in Reata Pharma bidding war - report, source:Seeking Alpha, summary: No summary, Headline: Biogen Inc. stock falls Tuesday, still outperforms market, source:MarketWatch, summary: No summary",BIIB
285,2023-08-15,"Headline: Is Biogen (NASDAQ:BIIB) A Risky Investment?, source:Yahoo, summary: Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that..., Headline: BofA upgrades Axsome to neutral, cites improved outlook for MDD drug, source:Seeking Alpha, summary: No summary, Headline: Biogen Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: No summary",BIIB
286,2023-08-16,"Headline: Wells Fargo starts GE HealthCare at overweight, sees increased imaging demand, source:Seeking Alpha, summary: No summary, Headline: CORRECTED-INSIGHT-What happens when a $2 million gene therapy is not enough, source:Yahoo, summary: Baby Ben Kutschke was diagnosed at three months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally.  It leaves children too weak to walk, talk, swallow or even breathe.  So when in 2021 his parents heard about Zolgensma – a one-time therapy costing millions of dollars that promises to replace genes needed for the body to control muscles – they had high hopes., Headline: Biogen Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: No summary",BIIB
287,2023-08-17,"Headline: Biogen's 1,000-person layoff begins in Cambridge, source:Yahoo, summary: Cambridge-based Biogen (Nasdaq: BIIB) employees began posting about the changes on LinkedIn on Thursday. Some offered help to departing colleagues, while others announced that they were open to work.",BIIB
288,2023-08-18,"Headline: Biogen Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. slumped 0.13% to $261.15 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",BIIB
289,2023-08-19,"Headline: Is There An Opportunity With Biogen Inc.'s (NASDAQ:BIIB) 47% Undervaluation?, source:Yahoo, summary: Key Insights Biogen's estimated fair value is US$496 based on 2 Stage Free Cash Flow to Equity Current share price of...",BIIB
290,2023-08-21,"Headline: Biogen Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Biogen Inc. rallied 1.50% to $265.07 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",BIIB
291,2023-08-22,"Headline: Biogen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. slumped 0.79% to $262.98 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index..., Headline: Biogen's Leqembi set for strong uptake based on Baird physician survey, source:Seeking Alpha, summary: No summary",BIIB
292,2023-08-23,"Headline: Biogen Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.69% higher to $264.80 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: Bristol-Myers Squibb: Top Defensive Pick During Recessions With A Value Proposition, source:SeekingAlpha, summary: Discover why Bristol-Myers is a strong investment, undervalued with a promising dividend yield. After a slow start, expect a bullish turnaround.",BIIB
293,2023-08-24,"Headline: FDA approves Sandoz's biosimilar of Biogen's blockbuster MS drug Tysabri, source:Seeking Alpha, summary: No summary, Headline: Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock, source:InvestorPlace, summary: No summary, Headline: Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico, source:Seeking Alpha, summary: No summary, Headline: October 6th Options Now Available For Biogen (BIIB), source:Stock Options Channel, summary: No summary, Headline: Biogen Inc. (BIIB) Down 0.2% Since Last Earnings Report: Can It Rebound?, source:Yahoo, summary: Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues., Headline: Biogen Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Biogen Inc. slid 0.90% to $262.43 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index..., Headline: Biogen stock slips after FDA approves first biosimilar to Tysabri MS treatment, source:MarketWatch, summary: Biogen Inc. shares slipped in the extended session Thursday after the Food and Drug Administration granted a soon-to-be Novartis AG spinoff approval for the...",BIIB
294,2023-08-25,"Headline: Analysts Offer Insights on Healthcare Companies: Stericycle (SRCL), Biogen (BIIB) and Cooper Co (COO), source:TipRanks, summary: No summary, Headline: Novartis’ (NYSE:NVS) Sandoz Bags FDA Approval for Tyruko in Multiple Sclerosis, source:TipRanks, summary: No summary, Headline: Novartis comes for a Biogen MS drug with new biosimilar, source:Yahoo, summary: On Thursday, the U.S. Food and Drug Administration approved a new biosimilar designed to mimic Tysabri, one of Biogen's (Nasdaq: BIIB) MS products. Biosimilars, like generics, are typically more affordable versions of brand-name drugs., Headline: Biogen Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.76% higher to $264.43 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: Crohn's disease drugmakers set to benefit from expected rise in cases, source:Seeking Alpha, summary: No summary",BIIB
295,2023-08-28,"Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: 12 Undervalued Wide Moat Stocks To Invest In, source:Yahoo, summary: In this piece, we will take a look at 12 undervalued wide moat stocks to invest in. If you want to skip our primer on wide moat investing, then check out 5 Undervalued Wide Moat Stocks To Invest In. The strategy of wide moat investing has gained a lot of traction over the past few […], Headline: Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar, source:Yahoo, summary: Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri., Headline: Biogen Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.23% higher to $265.05 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: RBC Capital sees Biogen stock undervaluing Leqembi prospects, source:Seeking Alpha, summary: No summary, Headline: Gingko Bioworks (NASDAQ:DNA) Blasts Up on New Alphabet (NASDAQ:GOOG) Partnership, source:TipRanks, summary: No summary, Headline: Ginkgo Bioworks (NASDAQ:DNA) Blasts Up on New Alphabet (NASDAQ:GOOG) Partnership, source:TipRanks, summary: No summary, Headline: Ginkgo Bioworks (NASDAQ:DNA) Blasts Up on New Alphabet Partnership, source:TipRanks, summary: No summary",BIIB
296,2023-08-29,"Headline: Biogen price target raised to $357 from $354 at RBC Capital, source:Thefly.com, summary: No summary, Headline: RBC Capital Remains a Buy on Biogen (BIIB), source:TipRanks, summary: No summary, Headline: Better Buy: Biogen vs. Eli Lilly, source:Yahoo, summary: Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) have a lot in common. Both companies are among the leaders in the biotech industry. Both have deep lineups and pipelines. And both are looking to dominate an area with a severe and growing need for new therapies: Alzheimer's disease (AD)., Headline: Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns, source:Yahoo, summary: Following the label expansion, Roche's (RHHBY) Evrysdi is now approved to treat people of all ages with SMA in the European Union., Headline: Biogen Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Biogen Inc. rose 1.11% to $268.00 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500..., Headline: RBC Capital Maintains Biogen (BIIB) Outperform Recommendation, source:Fintel, summary: nan",BIIB
297,2023-08-30,"Headline: The 3 Most Promising Pharma Stocks to Own Now, source:InvestorPlace, summary: No summary, Headline: Biogen : to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference, source:Finnhub, summary: Cambridge, MA, - - Biogen Inc. announced today that Christopher Viehbacher, CEO, will participate in the Morgan Stanley 21st Annual Global Healthcare Conference. The webcast will be..., Headline: Biogen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. shed 0.31% to $267.18 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed the most recent trading day at $267.18, moving -0.31% from the previous trading session.",BIIB
298,2023-08-31,"Headline: Sage cuts 40% of staff in portfolio shake-up ahead of Zurzuvae launch, source:Seeking Alpha, summary: No summary, Headline: The 7 Most Promising Momentum Stocks to Own Now, source:InvestorPlace, summary: No summary, Headline: Sage Therapeutics to lay off 40% of staff as it gears up for launch of postpartum-depression treatment, source:DowJones, summary: Sage Therapeutics Inc. said Thursday it is reorganizing its business operations and workforce as it gears up for the launch of its postpartum-depression..., Headline: Sage Therapeutics (NASDAQ:SAGE) Slashes 40% Positions with Zurzuvae Launch in Mind, source:TipRanks, summary: No summary, Headline: Sage Therapeutics (NASDAQ:SAGE) Slashes 40% of Positions with Zurzuvae Launch in Mind, source:TipRanks, summary: No summary, Headline: UPDATE 1-Sage Therapeutics to cut about 188 jobs after depression drug setback, source:Yahoo, summary: Sage Therapeutics said on Thursday it plans to lay off about 188 people, or about 40% of its workforce, weeks after the U.S. health regulator declined to approve its drug to treat major depressive disorder.  The U.S. Food and Drug Administration (FDA) in early August approved the company and partner Biogen's pill for postpartum depression (PDD), but rejected it as a treatment for clinical depression, which is a much larger market.  Sage said the job cuts, which are part of a reorganization plan, will help it launch the drug for women with PDD and also position the company for long-term growth., Headline: Sage cuts nearly half its staff in wake of partial FDA rejection, source:Yahoo, summary: Sage Therapeutics is letting go of around 276 workers following some mixed news from the U.S. Food and Drug Administration., Headline: Biogen Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Biogen Inc. inched 0.07% higher to $267.36 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P..., Headline: FDA Documents Suggest Sage's Battle In Depression Drugs Will Be Trickier Than Expected, source:Yahoo, summary: Sage said Thursday it will cut about 40% of its workforce following a setback for depression treatment Zurzuvae. Sage stock edged higher., Headline: Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Biogen Inc. (BIIB) closed the most recent trading day at $267.36, moving +0.07% from the previous trading session.",BIIB
299,2023-09-01,"Headline: Biogen in $1.5B unsecured loan facility for Reata acquisition, source:Seeking Alpha, summary: No summary, Headline: (BIIB) - Analyzing Biogen's Short Interest, source:Benzinga, summary: No summary, Headline: Biogen Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Biogen Inc. slipped 0.07% to $267.17 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",BIIB
